



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference X15876	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/PEA/416)	
International application No. PCT/US 03/26300	International filing date (day/month/year) 17.09.2003	Priority date (day/month/year) 19.09.2002
International Patent Classification (IPC) or both national classification and IPC A61K31/4412		
Applicant ELI LILLY AND COMPANY et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 8 sheets, including this cover sheet.  
  
☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).  
  
 These annexes consist of a total of 80 sheets.

3. This report contains indications relating to the following items:
  - I ☒ Basis of the opinion
  - II ☐ Priority
  - III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
  - IV ☐ Lack of unity of invention
  - V ☒ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
  - VI ☐ Certain documents cited
  - VII ☐ Certain defects in the international application
  - VIII ☐ Certain observations on the international application

Date of submission of the demand  06.04.2004	Date of completion of this report  22.11.2004
Name and mailing address of the international preliminary examining authority:   European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized Officer  Gavriliu, D  Telephone No. +49 89 2399-8274  

# PATENT COOPERATION TREATY

REC'D 24 NOV 2004

WIPO

PCT

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

**The International Bureau of WIPO**  
34, chemin des Colombettes  
CH - 1211 Geneva 20  
Switzerland

**PCT**

NOTIFICATION CONCERNING  
DOCUMENTS TRANSMITTED

Date of mailing  
(day/month/year)

22.11.2004

International application No: PCT/US 03/26300

This International Preliminary Examining Authority transmits herewith the following documents:

1. ☐ demand (Rule 61.1(a)).
2. ☒ copy of the international preliminary examination report and its annexes (Rule 71.1).
3. ☐ \_\_\_\_\_ other documents (*specify*):

Name and mailing address of the international  
preliminary examining authority:



European Patent Office  
D-80298 Munich  
Tel. +49 89 2399 - 0 Tx: 523656 epmu d  
Fax: +49 89 2399 - 4465

Authorized Officer

Ambroa, J.R.

Tel. +49 89 2399-8012



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. **PCT/US 03/26300**

**I. Basis of the report**

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17):*

**Description, Pages**

1-3, 9-538 as originally filed  
4-8, 8a-8j filed with telefax on 24.09.2004

**Claims, Numbers**

1-41 filed with telefax on 24.09.2004

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).  
☐ the language of publication of the international application (under Rule 48.3(b)).  
☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.  
☐ filed together with the international application in computer readable form.  
☐ furnished subsequently to this Authority in written form.  
☐ furnished subsequently to this Authority in computer readable form.  
☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.  
☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:  
☐ the claims, Nos.:  
☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)).

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. **PCT/US 03/26300**

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application,

☒ claims Nos. 1(part), 3-18(part), 26-27(part), 28-31,32(part), 33-38

because:

☒ the said international application, or the said claims Nos. 28-31,33-38 relate to the following subject matter which does not require an international preliminary examination (specify):

**see separate sheet**

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☒ no international search report has been established for the said claims Nos. 1(part), 3-18(part), 26-27(part), 29-39(part)

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the Standard.

☐ the computer readable form has not been furnished or does not comply with the Standard.

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)	Yes: Claims	19-25
	No: Claims	
Inventive step (IS)	Yes: Claims	19-25
	No: Claims	
Industrial applicability (IA)	Yes: Claims	1-27, 32, 33-38
	No: Claims	

2. Citations and explanations

**see separate sheet**



**Re Item III**

**Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

For reasoning with regards to unsearched subject-matter, see Form PCT/ISA/210 of the International Search Report. No International Preliminary Examination will be carried out with respect to subject-matter which is not covered by the search report (Rule 66.1(e)PCT).

Present Claim 1 relates to an extremely large number of possible compounds. In fact, Claim 1 contains so many options, variables, possible permutations that a lack of clarity (and conciseness) within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT arises to such an extent as to render a meaningful search of the Claim 1 impossible. The Claim 1 can in no way be considered to be a reasonable generalisation of the actual examples since it includes numerous possibilities which cannot be considered as equivalents, homologues or analogues of the examples. Consequently, the search was carried out for those parts of the application which do appear to be clear (concise and supported by the tested examples), namely for the compounds of formula Ib. It should be noted that if the incomplete search objection were not made there would be a much greater objection to be made re lack of unity. The structural element shared by all compounds falling under the general structure (I) is diaryl ether core-structure substituted with the carboxamido and amino functions. A further unifying feature conferring a technical relationship between the said alternatives is the use of the above-mentioned compound as medicaments to treat obesity. However, according to Rule 13.2 PCT the special technical features providing a link between the several alternatives must make contribution over the prior art. Since D1-D4 already disclose diaryl ethers substituted with the above-mentioned moieties and having the same uses as the present compounds, the above-mentioned requirement is not fulfilled.

Claims 28-31, 33-38 relate to subject-matter considered by this Authority to be covered by the provision of Rule 67.1(iv)PCT. Consequently, no opinion will be formulated with respect to the novelty, inventive step and industrial applicability of the subject-matter of these claims(Article 34(4)(a)(I)PCT).

**Re Item V**

**Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/US 03/26300

1. The opinion expressed below with regard to novelty, inventive step and industrial applicability refers only to subject-matter for which an international search report has been drawn up (i.e. compounds of formula Ib-Claim 2- as well as for the compounds claimed by the present Claims 19-25)
2. **Amendments (Article 19(2)PCT)**

The amendments filed with the last set of claims (24.09.2004) relate to the deletion of definitions C2-C8alkylCH(OH)aryl, C2-C8alkylCH(OH)cycloalkyl, or C2-C8 alkylCH(OH)heterocyclyl C2-C8alkylCH(OH)aryl. Since the above-mentioned amendments relate to deletion of some terms from a list of possible definitions, these amendments fulfil the requirements of article 19(2)PCT. Claim 1 has been also amended to specify that one of R1 or R2 cannot be C1-C8 alkyl when the other one is hydrogen and that the group NR1R2 is not NHCH2phenyl. The above-mentioned amendments seem not to be disclosed in the application as originally filled, therefore they do not fulfill the requirements of article 19(2)PCT (the possibility that R1 and R2 are not simultaneously hydrogen was disclosed but this does not mean that the other one should be C1-C8 alkyl; the -NR1R2 cannot be -NHCH2phenyl was disclosed only for specific compounds-see description page 4-lines15-16 and not for all possible compounds claimed by Claim 1). Claim 1 was also amended by the introduction of a list of specific compounds which appears already to be disclosed in the description, as originally filed, examples section. New Claims 2, 40 and 41 were introduced with the last set of claims (24.09.2004). The current Claim 2, claims compounds of formula Ib, as disclosed in page 15 of the description, together with specific compounds, list of compounds which appears to be already disclosed in the description(examples section). The above-mentioned amendments seem thus to fulfil the requirements of Article 19(2)PCT. The Claims 3-39 are the same as Claims 2-38 as originally filed. Claims 40 and 41 relate to pharmaceutical compositions containing specific compounds. Support for the new claims 40 and 41 is provided in description (pages 22-38)

2. **Reference is made to the following documents:**

D1: EP-A-0827746  
D2: WO-A-9710825  
D3: WO-A-0206276  
D4: EP-A-0921120

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US 03/26300

D5: US-A-4891379  
D6: US-B1-6436959  
D7: WO-A-9967204  
D8: WO-A-0040560

**3. Novelty (Article 33(1) and 33(2) PCT).**

The subject-matter of the present application relates to compounds of formula (I) (see present Claim 1) as opioid receptor antagonists, useful to treat or prevent obesity and related diseases.

The present compounds differ from the compounds disclosed by D5-D7 through the ether linkage between the 2 aryl moieties and from the compounds disclosed by D8 through the substituents R3 and R3' (see the present Claim 1 as well the Claims 1 of D5-D8).

The present compounds of formula (Ib) are novel over the D2 compounds on the account that R1 and R2 cannot be simultaneously hydrogen.

D1, discloses also in page 16, compounds of formula XXIII which are present overlapping range with the present compounds, when R4 is a phenyl substituted with an OR10 moiety, X2 is a direct bond or a C2 alkylene, R10 being a phenyl or pyridyl moiety substituted with a CONR11R12 function (R11 and R12 are not hydrogen)(since only compounds for which v=2 and NR1R2 is not NHCH2phenyl were excluded by the proviso of the original Claim 1 and the corresponding amendment filed with the letter of 24.09.2004 was not allowable). Moreover, 4-(4-(N-benzyl-2-aminoethyl)phenoxy)nicotinamide, disclosed by D1 as preparation 93 (see the preparation description wherein 6-chloronicotinamide is used as reagent-D1-page 37-lines 35-41), is a novelty-destroying embodiment for the subject-matter of the present Claim 1.

The Markush intermediate structure III, disclosed by D3 (page 13, lines 1-7, 15-20), presents an overlap with the present claimed compounds, when X2 is oxygen(D3-page 11, line 29), X3 is a phenyl or pyridyl, substituted with a carboxamido function (see page 11 of D3-lines 1-7 and R2 is an alkyl moiety(see e.g. page 11, line 15)) (the provision that when one of R1 or R2 is hydrogen the other one cannot be a C1-C8 alkyl moiety filled with the letter of telefax of 24.09.2004, is not allowable since was not originally disclosed).

The intermediate compounds of formula (XXIII), disclosed by D4 present an overlap with the present compounds, when R4 is a phenyl substituted with OR10 and R10 is a pyridiyl substituted with a CONR11R12 moiety(see D4 pages 4-8 and 14) (the proviso that -NR1R2 cannot be -NHCH2Phenyl for all the compounds of formula (Ib) filed with the telefax of 24.09.2004 is not allowable).

Since, the documents D1, D3 and D4 disclose general structures which present overlapping regions with the present formula (I), the novelty for the present subject-matter cannot be acknowledged either for the compounds of formula (I) or for the compounds of formula (Ib). However, the specific compounds claimed by the present Claims 19-25 are novel over the prior art.

**4. Inventive step (Article 33(1) and 33(3)PCT)**

Since D1-D4 and D8 disclose structurally similar compounds, useful for the treatment of the same diseases(namely obesity and diabetes), it should be equally considered the closest prior art.

The end-products of D1-D4 are 4-carboxamid-diaryl ethers, which differ from the present compounds through the definitions of R1 and R2 (when X1 of D1, D2, D4 and X of D3 are a direct bond) and on the other hand through the definitions of the present R3, R3'. Moreover the compounds disclosed by D1-D4, D8 are beta-amino alcohol derivatives.

Since the compounds disclosed by D1-D4, D8 known as being useful to treat obesity and diabetes via beta-3 adrenergic receptor contain all a beta-aminoalcohol functionality (which cannot be the case for the present compounds since R3 and R3' are not a HO moiety) and the compounds disclosed by D5-D7 known as opioid ligands contain other core-structures as the present compounds (are not diaryl ethers), an inventive step can be acknowledged for the novel compounds claimed by the Claims 19-25 as well as for the corresponding pharmaceutical compositions and uses.

**5. Industrial applicability (Article 33(4)PCT).**

For the assessment of the present Claims 28-31, 33-38 on the question whether they are industrial applicable, no unified criteria exist in the PCT Contracting

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---


International application No. PCT/US 03/26300

States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may also allow, however, claims to a known compound for the manufacture of a medicament for a new medical treatment.

## Replacement Sheet 4

## Summary of the Invention

The present invention provides a compound of the formula (I)



wherein

each of  $X_1, X_2, X_3, X_4, X_5, X_6, X_7, X_8, X_9$  and  $X_{10}$  is C, CH, or N; provided that each of rings A or B has no more than 2 nitrogen atoms;

E is O or NH;

v is 1, 2, or 3;

$R^1$  and  $R^2$  are independently selected from hydrogen,  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_8$  alkenyl,  $C_2$ - $C_8$  alkynyl, aryl,  $C_3$ - $C_8$  cycloalkyl,  $-C_1$ - $C_{10}$  alkylaryl, heterocyclyl,  $-C_1$ - $C_{10}$  alkylheterocyclic, -arylheterocyclyl,  $-C_3$ - $C_8$  cycloalkylheterocyclyl,  $-C_1$ - $C_8$  alkylC(O) $C_1$ - $C_8$  alkyl, aryl C(O) $C_1$ - $C_8$  alkyl-,  $C_3$ - $C_8$  cycloalkylC(O)( $CH_2$ ) $_n$ -,  $-C_1$ - $C_8$  alkylC(O)heterocyclic,  $-C_1$ - $C_8$  alkylC(O)aryl, aryloxy $C_1$ - $C_8$  alkyl-, benzhydryl, fused bicyclic,  $C_1$ - $C_8$  alkylfused bicyclic, phenylC(O)-, phenylC(O)  $C_1$ - $C_8$  alkyl-,  $C_1$ - $C_8$  alkoxy $C_1$ - $C_8$  alkyl-, CO(O) $C_1$ - $C_8$ alkyl,  $-SO_2C_1$ - $C_8$ alkyl,  $-SO_2C_1$ - $C_{10}$  alkylaryl,  $-SO_2C_1$ - $C_8$  alkylheterocyclic,  $-C_1$ - $C_8$  alkylcycloalkyl,  $-(CH_2)_nC(O)OR^8$ ,  $-(CH_2)_mC(O)NR^6R^7$ , and  $-(CH_2)_mNSO_2R^8$ ; wherein each of the alkyl, alkenyl, cycloalkyl, heterocyclic, and aryl groups are optionally substituted with one to five groups independently selected from halo,  $C_1$ - $C_8$  haloalkyl,  $C_1$ - $C_8$  thioalkyl,  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_8$  alkenyl, aryl,  $-C_1$ - $C_8$  alkylaryl,  $-C(O)C_1$ - $C_8$  alkyl,  $-SO_2C_1$ - $C_8$  alkyl,  $-SO_2C_1$ - $C_8$  alkylaryl,  $-SO_2C_1$ - $C_8$  alkylheterocyclic,  $-C_1$ - $C_8$  alkylcycloalkyl,  $-(CH_2)_nC(O)OR^8$ ,  $-(CH_2)_mC(O)R^8$ ; and wherein  $R^1$  and  $R^2$  may optionally combine with each other, or with 1, or 2 atoms adjacent to the nitrogen atom to form a 4, 5, 6, or 7-membered nitrogen-containing heterocycle which nitrogen - containing heterocycle may further have substituents selected from the group consisting of amino,  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_8$  alkenyl,  $C_2$ - $C_8$  alkynyl, aryl,  $C_1$ - $C_8$  alkylaryl,  $-C(O)C_1$ - $C_8$  alkyl,  $-CO(O)C_1$ - $C_8$  alkyl, halo, oxo,  $C_1$ - $C_8$  haloalkyl; and wherein  $R^1$  and  $R^2$  may

## Replacement Sheet 5

independently attach to the A ring to form a 4, 5, 6, or 7-member nitrogen-containing bicyclic heterocycle which nitrogen-containing bicyclic heterocycle may further have substituents selected from the group consisting of oxo, amino, -C<sub>1</sub>-C<sub>8</sub> alkyl, -C<sub>2</sub>-C<sub>8</sub> alkenyl, -C<sub>2</sub>-C<sub>8</sub> alkynyl, aryl, -C<sub>1</sub>-C<sub>8</sub> alkylaryl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, -CO(O)C<sub>1</sub>-C<sub>8</sub> alkyl, halo, and C<sub>1</sub>-C<sub>8</sub> haloalkyl;

and wherein R<sup>1</sup> and R<sup>2</sup> are not simultaneously hydrogen; and provided that when one of R<sup>1</sup> and R<sup>2</sup> is hydrogen the other is not C<sub>1</sub>-C<sub>8</sub> alkyl; and provided that the group NR<sup>1</sup>R<sup>2</sup> is not -NHCH<sub>2</sub>Ph; and further provided that when one of R<sup>1</sup> or R<sup>2</sup> is -CH<sub>2</sub>CH<sub>2</sub>-optionally substituted phenyl or -CH<sub>2</sub>CH<sub>2</sub>-optionally substituted naphthyl, or -CH<sub>2</sub>CH<sub>2</sub>-optionally substituted 5 or 6 member monocyclic heterocyclic aromatic, and v is 1, then R<sup>6</sup> and R<sup>7</sup> are not simultaneously hydrogen;

R<sup>3</sup> and R<sup>3'</sup> are each independently selected from hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, aryl, -C<sub>1</sub>-C<sub>8</sub> alkylcycloalkyl, and -C<sub>1</sub>-C<sub>8</sub> alkylaryl;

R<sup>4</sup> and R<sup>5</sup> are each independently selected from hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, -C<sub>2</sub>-C<sub>8</sub> alkynyl, -C<sub>1</sub>-C<sub>8</sub> alkoxyalkyl, C<sub>1</sub>-C<sub>8</sub> thioalkyl, halo, C<sub>1</sub>-C<sub>8</sub> haloalkyl, -C<sub>1</sub>-C<sub>8</sub> alkoxyhaloalkyl, aryl, -C<sub>1</sub>-C<sub>8</sub> alkylaryl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, or -C(O)OC<sub>1</sub>-C<sub>8</sub> alkyl, -C<sub>1</sub>-C<sub>8</sub> alkylamino, -C<sub>1</sub>-C<sub>8</sub> alkylcycloalkyl, -(CH<sub>2</sub>)<sub>m</sub>C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, and (CH<sub>2</sub>)<sub>n</sub>NR<sup>8</sup>R<sup>8</sup>, wherein each R<sup>4</sup> or R<sup>5</sup> is attached to its respective ring only at carbon atoms, and wherein y is 0, 1, 2, or 3; and wherein z is 0, 1, 2, or 3;

R<sup>6</sup> and R<sup>7</sup> are each independently selected from hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, hydroxy, C<sub>1</sub>-C<sub>8</sub> alkoxy, -SO<sub>2</sub>C<sub>1</sub>-C<sub>8</sub> alkyl, SO<sub>2</sub>C<sub>1</sub>-C<sub>8</sub> alkylaryl, -SO<sub>2</sub>C<sub>1</sub>-C<sub>8</sub> alkylheterocyclic, aryl, -C<sub>1</sub>-C<sub>8</sub> alkylaryl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, -C<sub>1</sub>-C<sub>8</sub> alkylcycloalkyl, -(CH<sub>2</sub>)<sub>n</sub>C(O)R<sup>8</sup>, -(CH<sub>2</sub>)<sub>m</sub>C(O)NR<sup>8</sup>R<sup>8</sup>, and -(CH<sub>2</sub>)<sub>m</sub>NSO<sub>2</sub>R<sup>8</sup>; wherein each of the alkyl, alkenyl, and aryl groups are optionally substituted with one to five groups independently selected from C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, aryl, and C<sub>1</sub>-C<sub>8</sub> alkylaryl; and wherein R<sup>6</sup> and R<sup>7</sup> may independently combine with each other, and with the nitrogen atom to which they are attached or with 1, or 2 atoms adjacent to the nitrogen atom to form a 4, 5, 6, or 7-membered nitrogen containing heterocycle which nitrogen-containing heterocycle may optionally have substituents selected from the group consisting of oxo, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, aryl, -C<sub>1</sub>-C<sub>8</sub> alkylaryl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, -

## Replacement Sheet 6

CO(O)C<sub>1</sub>-C<sub>8</sub> alkyl, hydroxy, C<sub>1</sub>-C<sub>8</sub> alkoxy, -C<sub>1</sub>-C<sub>8</sub> alkylamine, amino, halo, and haloalkyl;

R<sup>8</sup> is hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>1</sub>-C<sub>8</sub> alkylaryl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, or -C(O)OC<sub>1</sub>-C<sub>8</sub> alkyl; and wherein n is 0, 1, 2, 3 or 4 and m is 1, 2, or 3;

or a compound selected from the group consisting of:

6-[4-(3-Pentylamino-propyl)-phenoxy]-nicotinamide,  
6-[4-(1-Methyl-2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
6-[2-Methyl-4-(3-methyl-butylamino-methyl)-phenoxy]nicotinamide,  
6-[2-Fluoro-4-(3-methyl-butylamino-methyl)-phenoxy]nicotinamide,  
6-[2-Chloro-4-(3-methyl-butylamino-methyl)-phenoxy]nicotinamide,  
6-[2-Ethoxy-4-(3-methyl-butylamino-methyl)-phenoxy]nicotinamide,  
6-{4-[(3,3-Dimethyl-butylamino)-methyl]-2-methyl-phenoxy}-nicotinamide,  
6-(4-Butylaminomethyl-2-methyl-phenoxy)-nicotinamide,  
6-(2-Methyl-4-{[methyl-(3-methyl-butyl)-amino]-methyl}-phenoxy)-nicotinamide,  
3-Fluoro-4-{2-methyl-4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
6-(4-Allylaminomethyl-phenoxy)-nicotinamide,  
6-[4-[(3,3-Dimethyl-butylamino)-methyl]-2-ethoxyphenoxy]nicotinamide,  
6-[4-[(3-Methyl-butylamino)-methyl]-2,5-dimethylphenoxy]nicotinamide,  
6-[4-[(3-Methyl-butylamino)-methyl]-2-ethoxyphenoxy]nicotinamide,  
6-[4-[(3,3-Dimethyl-butylamino)-methyl]-2-ethoxyphenoxy]nicotinamide,  
6-[4-(Butylamino-methyl)-2-ethoxyphenoxy]nicotinamide,  
6-[4-[(3-Methyl-butylamino)-methyl]-2,5-dimethylphenoxy]nicotinonamide,  
5-{4-[(3-Methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide, 5-{2-Methyl-4-[(3-methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide, 5-{2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide,  
5-{2-Fluoro-4-[(3-methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide, 5-{2-Methyl-4-[(3-methylbutylamino)methyl]phenoxy}pyrazine-2-carboxamide,  
5-(2-Fluoro-4-pentylaminomethylphenoxy)pyridine-2-carboxamide,  
5-{2-Chloro-4-[(3-methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide,  
5-(2-Chloro-4-(pentylaminomethyl)phenoxy)pyridine-2-carboxamide,  
6-{2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy}nicotinamide,



## Replacement Sheet 7

6-(2-Methoxy-4-pentylaminomethylphenoxy)nicotinamide,  
6-(4-Butylaminomethyl-2-methoxyphenoxy)nicotinamide,  
6-{4-[(2-Ethylbutylamino)methyl]-2-methoxyphenoxy}nicotinamide,  
6-(4-Hexylaminomethyl-2-methoxyphenoxy)nicotinamide,  
6-{2-Methoxy-4-[(4-methylpentylamino)methyl]phenoxy}nicotinamide,  
5-{4-[(3,3-Dimethylbutylamino)methyl]-2-methylphenoxy}pyrazine-2-carboxamide, 5-  
{4-[(3-Methylbutylamino)methyl]phenoxy}pyrazine-2-carboxamide,  
5-{4-[(3,3-Dimethylbutylamino)methyl]phenoxy}pyrazine-2-carboxamide,  
6-(4-Hexylaminomethyl-2-methoxyphenoxy)nicotinamide methanesulfonate, 6-{4-[(2-  
Ethylbutylamino)methyl]-2-methoxyphenoxy}nicotinamide,  
6-{4-[(3,3-Dimethylbutylamino)methyl]-2-methoxyphenoxy}nicotinamide,  
6-{2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy}nicotinamide,  
4-[5-(Isobutylamino-methyl)-pyridin-2-yloxy]-benzamide,  
4-{5-[(3,3-Dimethyl-butylamino)-methyl]-pyridin-2-yloxy}-benzamide  
4-{5-[(3-Methyl-butylamino)-methyl]-pyridin-2-yloxy}-benzamide,  
4-{5-[(3,3-Dimethyl-butylamino)-methyl]-pyridin-2-yloxy}-benzamide,  
4-{5-[(3-Methyl-butylamino)-methyl]-pyridin-2-yloxy}-benzamide,  
6-{2-Chloro-4-[(3,3-dimethylbutylamino)-methyl]-phenoxy}-nicotinamide,  
3-Bromo-4-(5-pentylaminomethyl-pyridin-2-yloxy)-benzamide,  
3-Bromo-4-{5-[(3,3-dimethyl-butylamino)-methyl]-pyridin-2-yloxy}-benzamide,  
3-Methoxy-4-(5-pentylaminomethyl-pyridin-2-yloxy)-benzamide,  
4-{5-[(3,3-Dimethyl-butylamino)-methyl]-pyridin-2-yloxy}-3-methoxy-benzamide,  
4-{2-Methyl-4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
4-{3-Chloro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide, 4-{2-Ethoxy-4-  
[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
6-{2-Methyl-4-[2-(3-methyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{2-Methyl-4-[2-(3,3-dimethyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-[2-Methyl-4-(2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
6-{3-Chloro-4-[2-(3-methyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{3-Chloro-4-[2-(3,3-dimethyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-[3-Chloro-4-(2-pentylamino-ethyl)-phenoxy]-nicotinamide,

## Replacement Sheet 8

6-{2,6-Difluoro-4-[2-(3-methyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3,3-Dimethyl-butylamino)-ethyl]-2,6-difluoro-phenoxy}-nicotinamide,  
6-[2,6-Difluoro-4-(2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
6-{2-Methyl-4-[2-(3-methyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{2-Methyl-4-[2-(3,3-dimethyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-[2-Methyl-4-(2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
6-[3-Chloro-4-(2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
6-{2,6-Difluoro-4-[2-(3-methyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3,3-Dimethyl-butylamino)-ethyl]-2,6-difluoro-phenoxy}-nicotinamide,  
6-[2,6-Difluoro-4-(2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
6-[4-(*tert*-butylamino methyl)-2-fluoro phenoxy] nicotinonamide,  
6-(4-Ethylaminomethyl-2-fluoro-phenoxy)-nicotinamide,  
6-(2-Fluoro-4-propylaminomethyl-phenoxy)-nicotinamide,  
6-(2-Fluoro-4-hexylaminomethyl-phenoxy)-nicotinamide,  
6-[2-Fluoro-4-(isobutylamino-methyl)-phenoxy]-nicotinamide,  
6-[2-Fluoro-4-(isobutylamino-methyl)-phenoxy]-nicotinamide,  
2-Fluoro-4-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
3-Methoxy-4-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
2-Methyl-4-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
3-Methyl-4-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
3-Fluoro-4-{4-[3-methylbutylamino)-methyl]phenoxy}-benzamide,  
3-Fluoro-4-{4-[(3,3-Dimethyl-butylamino)-methy]-phenoxy}-3-fluoro-benzamide,  
3-Fluoro-4-(4-pentylaminomethyl-phenoxy)-benzamide,  
3,5-Difluoro-4-{4-[3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
3-Fluoro-4-(4-{[methyl-(3-methyl-butyl)-amino]-methyl}-phenoxy)-benzamide,  
3,5-Difluoro-4-(4-{[methyl-(3-methyl-butyl)-amino]-methyl}-phenoxy)-benzamide,  
4-{2-Chloro-4-[(3,3-dimethyl-butylamino)-methyl]-phenoxy}-benzamide,  
4-{2-Chloro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
4-(2-Chloro-4-pentylaminomethyl-phenoxy)-benzamide,  
6-[4-(2-Methylamino-ethyl)-phenoxy]-nicotinamide,


## Replacement Sheet 8a

4-{4-[(3,3-Dimethyl-butylamino)-methyl]-2-trifluoromethyl-phenoxy}-benzamide,  
3-Chloro-4-(3-methoxy-4-pentylaminomethyl-phenoxy)-benzamide,  
3-Bromo-4-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
3-Bromo-4-(3-pentylaminomethyl-phenoxy)-benzamide,  
6-(2,3-Difluoro-4-pentylaminomethyl-phenoxy)-nicotinamide,  
6-{4-[(3,3-Dimethyl-butylamino)-methyl]-2-fluoro-6-methoxy-phenoxy}-nicotinamide,  
6-{4-[(3,3-Dimethyl-butylamino)-methyl]-2,6-difluoro-phenoxy}-nicotinamide,  
6-{2,6-Difluoro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide,  
6-{2,3,6-Trifluoro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide,  
6-{3-[(2-Cyclohexyl-ethylamino)-methyl]-2-methyl-phenoxy}-nicotinamide,  
6-[2-Isopropyl-3-(2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
5-(2-Methoxy-4-pentylaminomethylphenoxy)pyrazine-2-carboxamide,  
6-{2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy}pyridazine-3-carboxamide,  
6-(2-Methoxy-4-propylaminomethylphenoxy)nicotinamide,  
6-[4-(Isobutylaminomethyl)-2-methoxyphenoxy]nicotinamide,  
6-{4-[(2,2-Dimethylpropylamino)methyl]-2-methoxyphenoxy}nicotinamide,  
5-{4-[(3,3-Dimethylbutylamino)methyl]-2-fluorophenoxy}pyrazine-2-carboxamide,  
5-{2-Fluoro-4-[(4-methylpentylamino)methyl]phenoxy}pyridine-2-carboxamide,  
5-{4-[(3,3-Dimethylbutylamino)methyl]-2-fluorophenoxy}pyridine-2-carboxamide,  
5-{2-Fluoro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-pyrazine-2-carboxamide,  
5-(2-Fluoro-4-pentylaminomethylphenoxy)pyrazine-2-carboxamide,  
5-(2-Fluoro-4-hexylaminomethylphenoxy)pyrazine-2-carboxamide,  
6-{4-[(3,3-Dimethylbutylamino)methyl]-2-methoxyphenoxy}pyridazine-3-carboxamide,  
5-(2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy)pyrazine-2-carboxamide,  
5-(2-Methoxy-4-[(4-methylpentylamino)methyl]phenoxy)pyrazine-2-carboxamide,  
5-{4-[(3,3-Dimethylbutylamino)methyl]-2-methoxyphenoxy}pyrazine-2-carboxamide,  
(6-{4-[(3-Methyl-butylamino)-methyl]-phenoxy}-pyridin-3-yl)-piperidin-1-yl-  
methanone,  
N-Methyl-6-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide,  
N-Ethyl-6-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide,  
N-Isopropyl-6-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide,

## Replacement Sheet 8a

5-{4-[(4,4-Dimethylpentylamino)methyl]-2-fluorophenoxy}pyridine-2-carboxamide,  
 5-{4-[(3-Ethylpentylamino)methyl]-2-fluorophenoxy}pyridine-2-carboxamide,  
 5-{4-[(4,4-Dimethylpentylamino)methyl]-2-fluorophenoxy}pyrazine-2-carboxamide,  
 5-{4-[(3-Ethylpentylamino)methyl]-2-fluorophenoxy}pyrazine-2-carboxamide,  
 5-{4-[(4,4-Dimethylpentylamino)methyl]-2-methoxyphenoxy}pyrazine-2-carboxamide,  
 and  
 5-{4-[(3-Ethylpentylamino)methyl]-2-methoxyphenoxy}pyrazine-2-carboxamide;  
 or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or  
 mixture of diastereomers thereof.

The present invention also relates to a compound of formula Ib



wherein

each X is independently C, CH, or N; provided that ring B has no more than 2 nitrogen atoms;

v is 1, 2, or 3;

R<sup>1</sup> and R<sup>2</sup> are independently selected from hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, aryl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, -C<sub>1</sub>-C<sub>10</sub> alkylaryl, heterocyclyl, -C<sub>1</sub>-C<sub>10</sub> alkylheterocyclic, -arylheterocyclyl, -C<sub>3</sub>-C<sub>8</sub> cycloalkylheterocyclyl, -C<sub>1</sub>-C<sub>8</sub> alkylC(O)C<sub>1</sub>-C<sub>8</sub> alkyl, aryl C(O)C<sub>1</sub>-C<sub>8</sub> alkyl-, C<sub>3</sub>-C<sub>8</sub> cycloalkylC(O)(CH<sub>2</sub>)<sub>n</sub>-, -C<sub>1</sub>-C<sub>8</sub> alkylC(O)heterocyclic, -C<sub>1</sub>-C<sub>8</sub> alkylC(O)aryl, aryloxyC<sub>1</sub>-C<sub>8</sub> alkyl-, benzhydryl, fused bicyclic, C<sub>1</sub>-C<sub>8</sub> alkylfused bicyclic, phenylC(O)-, phenylC(O)C<sub>1</sub>-C<sub>8</sub> alkyl-, C<sub>1</sub>-C<sub>8</sub> alkoxyC<sub>1</sub>-C<sub>8</sub> alkyl-, -CO(O)C<sub>1</sub>-C<sub>8</sub> alkyl, -SO<sub>2</sub>C<sub>1</sub>-C<sub>8</sub> alkyl, -SO<sub>2</sub>C<sub>1</sub>-C<sub>10</sub> alkylaryl, -SO<sub>2</sub>C<sub>1</sub>-C<sub>8</sub> alkylheterocyclic, -C<sub>1</sub>-C<sub>8</sub> alkylcycloalkyl, -(CH<sub>2</sub>)<sub>n</sub>C(O)OR<sup>8</sup>, -(CH<sub>2</sub>)<sub>m</sub>C(O)NR<sup>8</sup>R<sup>8</sup>, and -(CH<sub>2</sub>)<sub>m</sub>NSO<sub>2</sub>R<sup>8</sup>; wherein each of the alkyl, alkenyl, cycloalkyl, heterocyclic, and aryl groups are optionally

## Replacement Sheet 8b

substituted with one to five groups independently selected from halo, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> thioalkyl, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, aryl, -C<sub>1</sub>-C<sub>8</sub> alkylaryl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, -SO<sub>2</sub>C<sub>1</sub>-C<sub>8</sub> alkyl, -SO<sub>2</sub>C<sub>1</sub>-C<sub>8</sub> alkylaryl, -SO<sub>2</sub>C<sub>1</sub>-C<sub>8</sub> alkylheterocyclic, -C<sub>1</sub>-C<sub>8</sub> alkylcycloalkyl, -(CH<sub>2</sub>)<sub>n</sub>C(O)OR<sup>8</sup>, -(CH<sub>2</sub>)<sub>n</sub>C(O)R<sup>8</sup>; and wherein R<sup>1</sup> and R<sup>2</sup> may optionally combine with each other, or with 1, or 2 atoms adjacent to the nitrogen atom to form a 4, 5, 6, or 7-membered nitrogen-containing heterocycle which nitrogen-containing heterocycle may further have substituents selected from the group consisting of amino, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, aryl, C<sub>1</sub>-C<sub>8</sub> alkylaryl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, -CO(O)C<sub>1</sub>-C<sub>8</sub> alkyl, halo, oxo, C<sub>1</sub>-C<sub>8</sub> haloalkyl; and wherein R<sup>1</sup> and R<sup>2</sup> may independently attach to the A ring to form a 4, 5, 6, or 7-member nitrogen-containing bicyclic heterocycle which nitrogen-containing bicyclic heterocycle may further have substituents selected from the group consisting of oxo, amino, -C<sub>1</sub>-C<sub>8</sub> alkyl, -C<sub>2</sub>-C<sub>8</sub> alkenyl, -C<sub>2</sub>-C<sub>8</sub> alkynyl, aryl, -C<sub>1</sub>-C<sub>8</sub> alkylaryl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, -CO(O)C<sub>1</sub>-C<sub>8</sub> alkyl, halo, and C<sub>1</sub>-C<sub>8</sub> haloalkyl;

and wherein R<sup>1</sup> and R<sup>2</sup> are not simultaneously hydrogen; and provided that when one of R<sup>1</sup> and R<sup>2</sup> is hydrogen the other is not C<sub>1</sub>-C<sub>8</sub> alkyl; and provided that the group NR<sup>1</sup>R<sup>2</sup> is not -NHCH<sub>2</sub>Ph; and further provided that when one of R<sup>1</sup> or R<sup>2</sup> is -CH<sub>2</sub>CH<sub>2</sub>-optionally substituted phenyl or -CH<sub>2</sub>CH<sub>2</sub>-optionally substituted naphthyl, or -CH<sub>2</sub>CH<sub>2</sub>-optionally substituted 5 or 6 member monocyclic heterocyclic aromatic, and v is 1, then R<sup>6</sup> and R<sup>7</sup> are not simultaneously hydrogen;

R<sup>3</sup> and R<sup>3'</sup> are each independently selected from hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, aryl, -C<sub>1</sub>-C<sub>8</sub> alkylcycloalkyl, and -C<sub>1</sub>-C<sub>8</sub> alkylaryl;

R<sup>4</sup> and R<sup>5</sup> are each independently selected from hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, -C<sub>2</sub>-C<sub>8</sub> alkynyl, -C<sub>1</sub>-C<sub>8</sub> alkoxyalkyl, C<sub>1</sub>-C<sub>8</sub> thioalkyl, halo, C<sub>1</sub>-C<sub>8</sub> haloalkyl, -C<sub>1</sub>-C<sub>8</sub> alkoxyhaloalkyl, aryl, -C<sub>1</sub>-C<sub>8</sub> alkylaryl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, or -C(O)OC<sub>1</sub>-C<sub>8</sub> alkyl, -C<sub>1</sub>-C<sub>8</sub> alkylamino, -C<sub>1</sub>-C<sub>8</sub> alkylcycloalkyl, -(CH<sub>2</sub>)<sub>m</sub>C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, and (CH<sub>2</sub>)<sub>n</sub>NR<sup>8</sup>R<sup>8</sup>, wherein each R<sup>4</sup> or R<sup>5</sup> is attached to its respective ring only at carbon atoms, and wherein y is 0, 1, 2, or 3; and wherein z is 0, 1, 2, or 3;

R<sup>6</sup> and R<sup>7</sup> are each independently selected from hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, hydroxy, C<sub>1</sub>-C<sub>8</sub> alkoxy, -SO<sub>2</sub>C<sub>1</sub>-C<sub>8</sub> alkyl, SO<sub>2</sub>C<sub>1</sub>-C<sub>8</sub>

## Replacement Sheet 8c

alkylaryl,  $-\text{SO}_2\text{C}_1-\text{C}_8$  alkylheterocyclic, aryl,  $-\text{C}_1-\text{C}_8$  alkylaryl,  $\text{C}_3-\text{C}_7$  cycloalkyl,  $-\text{C}_1-\text{C}_6$  alkylcycloalkyl,  $-(\text{CH}_2)_n\text{C}(\text{O})\text{R}^8$ ,  $-(\text{CH}_2)_m\text{C}(\text{O})\text{NR}^8\text{R}^8$ , and  $-(\text{CH}_2)_m\text{NSO}_2\text{R}^8$ ; wherein each of the alkyl, alkenyl, and aryl groups are optionally substituted with one to five groups independently selected from  $\text{C}_1-\text{C}_8$  alkyl,  $\text{C}_2-\text{C}_8$  alkenyl, aryl, and  $\text{C}_1-\text{C}_8$  alkylaryl; and wherein  $\text{R}^6$  and  $\text{R}^7$  may independently combine with each other, and with the nitrogen atom to which they are attached or with 1, or 2 atoms adjacent to the nitrogen atom to form a 4, 5, 6, or 7-membered nitrogen containing heterocycle which nitrogen-containing heterocycle may optionally have substituents selected from the group consisting of oxo,  $\text{C}_1-\text{C}_8$  alkyl,  $\text{C}_2-\text{C}_8$  alkenyl,  $\text{C}_2-\text{C}_8$  alkynyl, aryl,  $-\text{C}_1-\text{C}_8$  alkylaryl,  $-\text{C}(\text{O})\text{C}_1-\text{C}_8$  alkyl,  $-\text{CO}(\text{O})\text{C}_1-\text{C}_8$  alkyl, hydroxy,  $\text{C}_1-\text{C}_8$  alkoxy,  $-\text{C}_1-\text{C}_8$  alkylamine, amino, halo, and haloalkyl;

$\text{R}^8$  is hydrogen,  $\text{C}_1-\text{C}_8$  alkyl,  $\text{C}_2-\text{C}_8$  alkenyl,  $\text{C}_1-\text{C}_8$  alkylaryl,  $-\text{C}(\text{O})\text{C}_1-\text{C}_8$  alkyl, or  $-\text{C}(\text{O})\text{OC}_1-\text{C}_8$  alkyl; and wherein n is 0, 1, 2, 3 or 4 and m is 1, 2, or 3;

or a compound selected from the group consisting of:

- 6-[4-(3-Pentylamino-propyl)-phenoxy]-nicotinamide,
- 6-[4-(1-Methyl-2-pentylamino-ethyl)-phenoxy]-nicotinamide,
- 6-[2-Methyl-4-(3-methyl-butylamino-methyl)-phenoxy]nicotinamide,
- 6-[2-Fluoro-4-(3-methyl-butylamino-methyl)-phenoxy]nicotinamide,
- 6-[2-Chloro-4-(3-methyl-butylamino-methyl)-phenoxy]nicotinamide,
- 6-[2-Ethoxy-4-(3-methyl-butylamino-methyl)-phenoxy]nicotinamide,
- 6-{4-[(3,3-Dimethyl-butylamino)-methyl]-2-methyl-phenoxy}-nicotinamide,
- 6-(4-Butylaminomethyl-2-methyl-phenoxy)-nicotinamide,
- 6-(2-Methyl-4-[[methyl-(3-methyl-butyl)-amino]-methyl]-phenoxy)-nicotinamide,
- 3-Fluoro-4-{2-methyl-4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,
- 6-(4-Allylaminomethyl-phenoxy)-nicotinamide,
- 6-[4-((3,3-Dimethyl-butylamino)-methyl)-2-ethoxyphenoxy]nicotinamide,
- 6-[4-((3-Methyl-butylamino)-methyl)-2,5-dimethylphenoxy]nicotinamide,
- 6-[4-((3-Methyl-butylamino)-methyl)-2-ethoxyphenoxy]nicotinamide,
- 6-[4-((3,3-Dimethyl-butylamino)-methyl)-2-ethoxyphenoxy]nicotinamide,
- 6-[4-(Butylamino-methyl)-2-ethoxyphenoxy]nicotinamide,

## Replacement Sheet 8d

6-[4-((3-Methyl-butylamino)-methyl)-2,5-dimethylphenoxy]nicotinamide,  
5-{4-[(3-Methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide, 5-{2-Methyl-4-  
[(3-methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide, 5-{2-Methoxy-4-[(3-  
methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide,  
5-{2-Fluoro-4-[(3-methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide, 5-{2-  
Methyl-4-[(3-methylbutylamino)methyl]phenoxy}pyrazine-2-carboxamide,  
5-(2-Fluoro-4-pentylaminomethylphenoxy)pyridine-2-carboxamide,  
5-{2-Chloro-4-[(3-methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide,  
5-(2-Chloro-4-(pentylaminomethyl)phenoxy)pyridine-2-carboxamide,  
6-{2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy}nicotinamide,  
6-(2-Methoxy-4-pentylaminomethylphenoxy)nicotinamide,  
6-(4-Butylaminomethyl-2-methoxyphenoxy)nicotinamide,  
6-{4-[(2-Ethylbutylamino)methyl]-2-methoxyphenoxy}nicotinamide,  
6-(4-Hexylaminomethyl-2-methoxyphenoxy)nicotinamide,  
6-{2-Methoxy-4-[(4-methylpentylamino)methyl]phenoxy}nicotinamide,  
5-{4-[(3,3-Dimethylbutylamino)methyl]-2-methylphenoxy}pyrazine-2-carboxamide, 5-  
{4-[(3-Methylbutylamino)methyl]phenoxy}pyrazine-2-carboxamide,  
5-{4-[(3,3-Dimethylbutylamino)methyl]phenoxy}pyrazine-2-carboxamide,  
6-(4-Hexylaminomethyl-2-methoxyphenoxy)nicotinamide methanesulfonate, 6-{4-[(2-  
Ethylbutylamino)methyl]-2-methoxyphenoxy}nicotinamide,  
6-{4-[(3,3-Dimethylbutylamino)methyl]-2-methoxyphenoxy}nicotinamide,  
6-{2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy}nicotinamide,  
6-{2-Chloro-4-[(3,3-dimethylbutylamino)-methyl]-phenoxy}-nicotinamide,  
4-{2-Methyl-4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
4-{3-Chloro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide, 4-{2-Ethoxy-4-  
[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
6-{2-Methyl-4-[2-(3-methyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{2-Methyl-4-[2-(3,3-dimethyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-[2-Methyl-4-(2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
6-{3-Chloro-4-[2-(3-methyl-butylamino)-ethyl]-phenoxy}-nicotinamide,

## Replacement Sheet 8e

6-{3-Chloro-4-[2-(3,3-dimethyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-[3-Chloro-4-(2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
6-{2,6-Difluoro-4-[2-(3-methyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3,3-Dimethyl-butylamino)-ethyl]-2,6-difluoro-phenoxy}-nicotinamide,  
6-[2,6-Difluoro-4-(2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
6-{2-Methyl-4-[2-(3-methyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{2-Methyl-4-[2-(3,3-dimethyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-[2-Methyl-4-(2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
6-[3-Chloro-4-(2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
6-{2,6-Difluoro-4-[2-(3-methyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3,3-Dimethyl-butylamino)-ethyl]-2,6-difluoro-phenoxy}-nicotinamide,  
6-[2,6-Difluoro-4-(2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
6-[4-(*tert*-butylamino methyl)-2-fluoro phenoxy] nicotinonamide,  
6-(4-Ethylaminomethyl-2-fluoro-phenoxy)-nicotinamide,  
6-(2-Fluoro-4-propylaminomethyl-phenoxy)-nicotinamide,  
6-(2-Fluoro-4-hexylaminomethyl-phenoxy)-nicotinamide,  
6-[2-Fluoro-4-(isobutylamino-methyl)-phenoxy]-nicotinamide,  
6-[2-Fluoro-4-(isobutylamino-methyl)-phenoxy]-nicotinamide,  
2-Fluoro-4-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
3-Methoxy-4-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
2-Methyl-4-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
3-Methyl-4-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
3-Fluoro-4-{4-[3-methylbutylamino)-methyl]phenoxy}-benzamide,  
3-Fluoro-4-{4-[(3,3-Dimethyl-butylamino)-methyl]-phenoxy}-3-fluoro-benzamide,  
3-Fluoro-4-(4-pentylaminomethyl-phenoxy)-benzamide,  
3,5-Difluoro-4-{4-[3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
3-Fluoro-4-(4-{[methyl-(3-methyl-butyl)-amino]-methyl}-phenoxy)-benzamide,  
3,5-Difluoro-4-(4-{[methyl-(3-methyl-butyl)-amino]-methyl}-phenoxy)-benzamide,  
4-{2-Chloro-4-[(3,3-dimethyl-butylamino)-methyl]-phenoxy}-benzamide,




## Replacement Sheet 8f

4-{2-Chloro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
4-(2-Chloro-4-pentylaminomethyl-phenoxy)-benzamide,  
6-[4-(2-Methylamino-ethyl)-phenoxy]-nicotinamide,  
4-{4-[(3,3-Dimethyl-butylamino)-methyl]-2-trifluoromethyl-phenoxy}-benzamide,  
3-Chloro-4-(3-methoxy-4-pentylaminomethyl-phenoxy)-benzamide,  
3-Bromo-4-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
3-Bromo-4-(3-pentylaminomethyl-phenoxy)-benzamide,  
6-(2,3-Difluoro-4-pentylaminomethyl-phenoxy)-nicotinamide,  
6-{4-[(3,3-Dimethyl-butylamino)-methyl]-2-fluoro-6-methoxy-phenoxy}-nicotinamide,  
6-{4-[(3,3-Dimethyl-butylamino)-methyl]-2,6-difluoro-phenoxy}-nicotinamide,  
6-{2,6-Difluoro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide,  
6-{2,3,6-Trifluoro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide,  
6-{3-[(2-Cyclohexyl-ethylamino)-methyl]-2-methyl-phenoxy}-nicotinamide,  
6-[2-Isopropyl-3-(2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
5-(2-Methoxy-4-pentylaminomethylphenoxy)pyrazine-2-carboxamide,  
6-{2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy}pyridazine-3-carboxamide,  
6-(2-Methoxy-4-propylaminomethylphenoxy)nicotinamide,  
6-[4-(Isobutylaminomethyl)-2-methoxyphenoxy]nicotinamide,  
6-{4-[(2,2-Dimethylpropylamino)methyl]-2-methoxyphenoxy}nicotinamide,  
5-{4-[(3,3-Dimethylbutylamino)methyl]-2-fluorophenoxy}pyrazine-2-carboxamide,  
5-{2-Fluoro-4-[(4-methylpentylamino)methyl]phenoxy}pyridine-2-carboxamide,  
5-{4-[(3,3-Dimethylbutylamino)methyl]-2-fluorophenoxy}pyridine-2-carboxamide,  
5-{2-Fluoro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-pyrazine-2-carboxamide,  
5-(2-Fluoro-4-pentylaminomethylphenoxy)pyrazine-2-carboxamide,  
5-(2-Fluoro-4-hexylaminomethylphenoxy)pyrazine-2-carboxamide,  
6-{4-[(3,3-Dimethylbutylamino)methyl]-2-methoxyphenoxy}pyridazine-3-carboxamide,  
5-{2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy}pyrazine-2-carboxamide,  
5-{2-Methoxy-4-[(4-methylpentylamino)methyl]phenoxy}pyrazine-2-carboxamide,  
5-{4-[(3,3-Dimethylbutylamino)methyl]-2-methoxyphenoxy}pyrazine-2-carboxamide,

## Replacement Sheet 8g

(6-{4-[(3-Methyl-butylamino)-methyl]-phenoxy}-pyridin-3-yl)-piperidin-1-yl-methanone,  
 N-Methyl-6-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide,  
 N-Ethyl-6-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide,  
 N-Isopropyl-6-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide,  
 5-{4-[(4,4-Dimethylpentylamino)methyl]-2-fluorophenoxy}pyridine-2-carboxamide,  
 5-{4-[(3-Ethylpentylamino)methyl]-2-fluorophenoxy}pyridine-2-carboxamide,  
 5-{4-[(4,4-Dimethylpentylamino)methyl]-2-fluorophenoxy}pyrazine-2-carboxamide,  
 5-{4-[(3-Ethylpentylamino)methyl]-2-fluorophenoxy}pyrazine-2-carboxamide,  
 5-{4-[(4,4-Dimethylpentylamino)methyl]-2-methoxyphenoxy}pyrazine-2-carboxamide,  
 and  
 5-{4-[(3-Ethylpentylamino)methyl]-2-methoxyphenoxy}pyrazine-2-carboxamide;  
 or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixture of diastereomers thereof.

The present invention also provides a method for the prevention, treatment and/or amelioration of the symptoms of obesity and Related Diseases comprising administering a therapeutically effective amount of a compound of formula II to a patient in need thereof wherein formula II is represented by the structure



wherein

each of  $X_1'$ ,  $X_2'$ ,  $X_3'$ ,  $X_4'$ ,  $X_5'$ ,  $X_6'$ ,  $X_7'$ ,  $X_8'$ ,  $X_9'$  and  $X_{10}'$  is C, CH, or N; provided that each of rings A' or B' has no more than 2 nitrogen atoms;

E' is O or NH;

v is 0, 1, 2 or 3;

## Replacement Sheet 8h

$R^{1'}$  and  $R^{2'}$  are independently selected from hydrogen,  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_8$  alkenyl,  $C_2$ - $C_8$  alkynyl, aryl,  $C_3$ - $C_8$  cycloalkyl,  $-C_1$ - $C_{10}$  alkylaryl, heterocyclyl,  $-C_1$ - $C_{10}$  alkylheterocyclic, -arylheterocyclyl,  $-C_3$ - $C_8$  cycloalkylheterocyclyl,  $-C_1$ - $C_8$  alkylC(O) $C_1$ - $C_8$  alkyl, aryl C(O) $C_1$ - $C_8$  alkyl-,  $C_3$ - $C_8$  cycloalkylC(O)( $CH_2$ ) $_n$ -,  $-C_1$ - $C_8$  alkylC(O)heterocyclic,  $-C_1$ - $C_8$  alkylC(O)aryl, aryloxy $C_1$ - $C_8$  alkyl-, benzhydryl, fused bicyclic,  $C_1$ - $C_8$  alkylfused bicyclic, phenylC(O)-, phenylC(O)  $C_1$ - $C_8$  alkyl-,  $C_1$ - $C_8$  alkoxy $C_1$ - $C_8$  alkyl-,  $-CO(O)C_1$ - $C_8$  alkyl,  $-SO_2C_1$ - $C_8$  alkyl,  $-SO_2C_1$ - $C_{10}$  alkylaryl,  $-SO_2C_1$ - $C_8$  alkylheterocyclic,  $-C_1$ - $C_8$  alkylcycloalkyl,  $-(CH_2)_nC(O)OR^8$ ,  $-(CH_2)_nC(O)R^8$ ,  $-(CH_2)_mC(O)NR^8R^8$ , and  $-(CH_2)_mNSO_2R^8$ ; wherein each of the alkyl, alkenyl, cycloalkyl, heterocyclic, and aryl groups are optionally substituted with one to five groups independently selected from halo,  $C_1$ - $C_8$  haloalkyl,  $C_1$ - $C_8$  thioalkyl,  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_8$  alkenyl, aryl,  $-C_1$ - $C_8$  alkylaryl,  $-C(O)C_1$ - $C_8$  alkyl,  $-CO(O)C_1$ - $C_8$  alkyl,  $-SO_2C_1$ - $C_8$  alkyl,  $-SO_2C_1$ - $C_8$  alkylaryl,  $-SO_2C_1$ - $C_8$  alkylheterocyclic,  $-C_1$ - $C_8$  alkylcycloalkyl,  $-(CH_2)_nC(O)OR^8$ ,  $-(CH_2)_nC(O)R^8$ ; and wherein  $R^{1'}$  and  $R^{2'}$  may optionally combine with each other, or with 1, or 2 atoms adjacent to the nitrogen atom to form a 4, 5, 6, or 7-membered nitrogen-containing heterocycle which nitrogen-containing heterocycle may further have substituents selected from the group consisting of amino,  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_8$  alkenyl,  $C_2$ - $C_8$  alkynyl, aryl,  $C_1$ - $C_8$  alkylaryl,  $-C(O)C_1$ - $C_8$  alkyl,  $-CO(O)C_1$ - $C_8$  alkyl, halo, oxo,  $C_1$ - $C_8$  haloalkyl; and wherein  $R^{1'}$  and  $R^{2'}$  may independently attach to the A' ring to form a 4, 5, 6, or 7-member nitrogen-containing bicyclic heterocycle which nitrogen-containing bicyclic heterocycle may further have substituents selected from the group consisting of oxo, amino,  $-C_1$ - $C_8$  alkyl,  $C_2$ - $C_8$  alkenyl,  $-C_2$ - $C_8$  alkynyl, aryl,  $-C_1$ - $C_8$  alkylaryl,  $-C(O)C_1$ - $C_8$  alkyl,  $-CO(O)C_1$ - $C_8$  alkyl, halo, and  $C_1$ - $C_8$  haloalkyl; provided that  $R^{1'}$  and  $R^{2'}$  are not simultaneously hydrogen; and provided that when  $v$  is 2, and  $R^{3a}$  and  $R^{3b}$  are both hydrogen or  $CH_3$ , and both A' and B' rings are phenyl, then the group  $-NR^{1'}R^{2'}$  is not  $-NHCH_2$ Phenyl; and further provided that when one of  $R^{1'}$  or  $R^{2'}$  is  $-CH_2CH_2$ -optionally substituted phenyl or  $-CH_2CH_2$ -optionally substituted naphthyl, or  $-CH_2CH_2$ -optionally substituted 5 or 6 member monocyclic heterocyclic aromatic, and  $v$  is 1, then  $R^{6'}$  and  $R^{7'}$  are not simultaneously hydrogen;

## Replacement Sheet 8j

$R^{3a}$  and  $R^{3b}$  are each independently selected from hydrogen,  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_8$  alkenyl,  $C_2$ - $C_8$  alkynyl, aryl,  $-C_1$ - $C_8$  alkylcycloalkyl, aryl, and  $-C_1$ - $C_8$  alkylaryl;

$R^{4'}$  and  $R^{5'}$  are each independently selected from hydrogen,  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_8$  alkenyl,  $C_2$ - $C_8$  alkynyl,  $-C_1$ - $C_8$  alkoxyalkyl,  $C_1$ - $C_8$  thioalkyl, halo,  $C_1$ - $C_8$  haloalkyl,  $-C_1$ - $C_8$  alkoxyhaloalkyl, aryl,  $-C_1$ - $C_8$  alkylaryl,  $-C(O)C_1$ - $C_8$  alkyl, or  $-C(O)OC_1$ - $C_8$  alkyl,  $-C_1$ - $C_8$  alkylamino,  $-C_1$ - $C_8$  alkylcycloalkyl,  $-(CH_2)_mC(O)C_1$ - $C_8$  alkyl, and  $-(CH_2)_nNR^8R^8$ ,

wherein each  $R^{4'}$  and  $R^{5'}$  is attached to its respective ring only at carbon atoms, and wherein  $y$  is 0, 1, 2, or 3; and wherein  $z$  is 0, 1, 2, or 3;

$R^{6'}$  and  $R^{7'}$  are each independently selected from hydrogen,  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_8$  alkenyl,  $C_2$ - $C_8$  alkynyl,  $-C(O)C_1$ - $C_8$  alkyl, hydroxy,  $C_1$ - $C_8$  alkoxy,  $-SO_2C_1$ - $C_8$  alkyl,  $SO_2C_1$ - $C_8$  alkylaryl,  $-SO_2C_1$ - $C_8$  alkylheterocyclic, aryl,  $-C_1$ - $C_8$  alkylaryl,  $C_3$ - $C_7$  cycloalkyl,  $-C_1$ - $C_6$  alkylcycloalkyl,  $-(CH_2)_nC(O)R^8$ ,  $-(CH_2)_mC(O)NR^8R^8$ , and  $-(CH_2)_mNSO_2R^8$ ; wherein each of the alkyl, alkenyl, and aryl groups are optionally substituted with one to five groups independently selected from  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_8$  alkenyl, aryl, and  $C_1$ - $C_8$  alkylaryl; and wherein  $R^{6'}$  and  $R^{7'}$  may independently combine together, and with the nitrogen atom to which they are attached or with 1, or 2 atoms adjacent to the nitrogen atom to form a 4, 5, 6, or 7-membered nitrogen containing heterocycle which nitrogen containing heterocycle may further have substituents selected from the group consisting of  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_8$  alkenyl,  $C_2$ - $C_8$  alkynyl, phenyl,  $-C_1$ - $C_8$  alkylaryl,  $-C(O)C_1$ - $C_8$  alkyl,  $-CO(O)C_1$ - $C_8$  alkyl, hydroxy,  $-C_1$ - $C_8$  alkoxy, halo, and haloalkyl;

$R^8$  is hydrogen,  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_8$  alkenyl,  $C_1$ - $C_8$  alkylaryl,  $-C(O)C_1$ - $C_8$  alkyl, or  $-C(O)OC_1$ - $C_8$  alkyl; wherein  $n$  is 0, 1, 2, 3 or 4 and wherein  $m$  is 1, 2 or 3;

or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomers or mixtures thereof.

The present invention also provides a pharmaceutical formulation comprising a compound of formula I or II in association with a carrier, diluent and/or excipient.

The present invention also relates to a method for the treatment and/or prophylaxis of obesity and Related Diseases including eating disorders (bulimia, anorexia nervosa, etc.), diabetes, diabetic complications, diabetic retinopathy, sexual/reproductive disorders, depression related to obesity, anxiety related to obesity, epileptic seizure,

## Replacement Sheet 8j

hypertension, cerebral hemorrhage, congestive heart failure, sleeping disorders, atherosclerosis, , stroke, hyperlipidemia, hypertriglyceremia, hyperglycemia, hyperlipoproteinemia, substance abuse, drug overdose, compulsive behavior disorders (such as paw licking in dog), and addictive behaviors such as for example, gambling, and alcoholism, comprising administering a therapeutically effective amount of a compound of formula I or formula II or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixture of diastereomers thereof.

The present invention provides a compound of formula (I) or (II) useful for the manufacture of a medicament for the treatment, prevention and/or amelioration of symptoms associated with obesity and Related Diseases.

In another embodiment, the present invention provides a compound of formula I or II or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful as an appetite suppressant.

In another embodiment, the present invention provides a method of achieving weight loss while maintaining or minimizing the loss of lean muscle mass, comprising administering a compound of formula I or II or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, to a patient in need thereof.


X-15876 PCT

## REPLACEMENT CLAIMS

539

We claim:

1. A compound of formula (I)



wherein

each of  $X_1, X_2, X_3, X_4, X_5, X_6, X_7, X_8, X_9$  and  $X_{10}$  is C, CH, or N; provided that each of rings A or B has no more than 2 nitrogen atoms;

E is O or NH;

v is 1, 2, or 3;

$R^1$  and  $R^2$  are independently selected from hydrogen,  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_8$  alkenyl,  $C_2$ - $C_8$  alkynyl, aryl,  $C_3$ - $C_8$  cycloalkyl,  $-C_1$ - $C_{10}$  alkylaryl, heterocyclyl,  $-C_1$ - $C_{10}$  alkylheterocyclic, -arylheterocyclyl,  $-C_3$ - $C_8$  cycloalkylheterocyclyl,  $-C_1$ - $C_8$  alkylC(O) $C_1$ - $C_8$  alkyl, aryl C(O) $C_1$ - $C_8$  alkyl-,  $C_3$ - $C_8$  cycloalkylC(O)( $CH_2$ ) $_n$ -,  $-C_1$ - $C_8$  alkylC(O)heterocyclic,  $-C_1$ - $C_8$  alkylC(O)aryl, aryloxy $C_1$ - $C_8$  alkyl-, benzhydryl, fused bicyclic,  $C_1$ - $C_8$  alkylfused bicyclic, phenylC(O)-, phenylC(O)  $C_1$ - $C_8$  alkyl-,  $C_1$ - $C_8$  alkoxy $C_1$ - $C_8$  alkyl-,  $-CO(O)C_1$ - $C_8$ alkyl-,  $-SO_2C_1$ - $C_8$ alkyl,  $-SO_2C_1$ - $C_{10}$  alkylaryl,  $-SO_2C_1$ - $C_8$  alkylheterocyclic,  $-C_1$ - $C_8$  alkylcycloalkyl,  $-(CH_2)_nC(O)OR^8$ ,  $-(CH_2)_mC(O)NR^6R^7$ , and  $-(CH_2)_mNSO_2R^8$ ; wherein each of the alkyl, alkenyl, cycloalkyl, heterocyclic, and aryl groups are optionally substituted with one to five groups independently selected from halo,  $C_1$ - $C_8$  haloalkyl,  $C_1$ - $C_8$  thioalkyl,  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_8$  alkenyl, aryl,  $-C_1$ - $C_8$  alkylaryl,  $-C(O)C_1$ - $C_8$  alkyl-,  $-SO_2C_1$ - $C_8$  alkyl,  $-SO_2C_1$ - $C_8$  alkylaryl,  $-SO_2C_1$ - $C_8$  alkylheterocyclic,  $-C_1$ - $C_8$  alkylcycloalkyl,  $-(CH_2)_nC(O)OR^8$ ,  $-(CH_2)_nC(O)R^8$ ; and wherein  $R^1$  and  $R^2$  may optionally combine with each other, or with 1, or 2 atoms adjacent to the nitrogen atom to form a 4, 5, 6, or 7-membered nitrogen-containing heterocycle which nitrogen-containing heterocycle may further have substituents selected from the group consisting of amino,  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_8$  alkenyl,  $C_2$ - $C_8$  alkynyl, aryl,  $C_1$ - $C_8$  alkylaryl,  $-C(O)C_1$ - $C_8$  alkyl-,  $-CO(O)C_1$ - $C_8$  alkyl, halo, oxo,  $C_1$ - $C_8$  haloalkyl; and wherein  $R^1$  and  $R^2$  may independently

X-15876 PCT

## REPLACEMENT CLAIMS

540

attach to the A ring to form a 4, 5, 6, or 7-member nitrogen-containing bicyclic heterocycle which nitrogen-containing bicyclic heterocycle may further have substituents selected from the group consisting of oxo, amino, -C<sub>1</sub>-C<sub>8</sub> alkyl, -C<sub>2</sub>-C<sub>8</sub> alkenyl, -C<sub>2</sub>-C<sub>8</sub> alkynyl, aryl, -C<sub>1</sub>-C<sub>8</sub> alkylaryl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, -CO(O)C<sub>1</sub>-C<sub>8</sub> alkyl, halo, and C<sub>1</sub>-C<sub>8</sub> haloalkyl;

and wherein R<sup>1</sup> and R<sup>2</sup> are not simultaneously hydrogen; and provided that when one of R<sup>1</sup> and R<sup>2</sup> is hydrogen the other is not C<sub>1</sub>-C<sub>8</sub> alkyl; and provided that the group NR<sup>1</sup>R<sup>2</sup> is not -NHCH<sub>2</sub>Ph; and further provided that when one of R<sup>1</sup> or R<sup>2</sup> is -CH<sub>2</sub>CH<sub>2</sub>-optionally substituted phenyl or -CH<sub>2</sub>CH<sub>2</sub>-optionally substituted naphthyl, or -CH<sub>2</sub>CH<sub>2</sub>-optionally substituted 5 or 6 member monocyclic heterocyclic aromatic, and v is 1, then R<sup>6</sup> and R<sup>7</sup> are not simultaneously hydrogen;

R<sup>3</sup> and R<sup>3'</sup> are each independently selected from hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, aryl, -C<sub>1</sub>-C<sub>8</sub> alkylcycloalkyl, and -C<sub>1</sub>-C<sub>8</sub> alkylaryl;

R<sup>4</sup> and R<sup>5</sup> are each independently selected from hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, -C<sub>2</sub>-C<sub>8</sub> alkynyl, -C<sub>1</sub>-C<sub>8</sub> alkoxyalkyl, C<sub>1</sub>-C<sub>8</sub> thioalkyl, halo, C<sub>1</sub>-C<sub>8</sub> haloalkyl, -C<sub>1</sub>-C<sub>8</sub> alkoxyhaloalkyl, aryl, -C<sub>1</sub>-C<sub>8</sub> alkylaryl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, or -C(O)OC<sub>1</sub>-C<sub>8</sub> alkyl, -C<sub>1</sub>-C<sub>8</sub> alkylamino, -C<sub>1</sub>-C<sub>8</sub> alkylcycloalkyl, -(CH<sub>2</sub>)<sub>m</sub>C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, and (CH<sub>2</sub>)<sub>n</sub>NR<sup>6</sup>R<sup>8</sup>, wherein each R<sup>4</sup> or R<sup>5</sup> is attached to its respective ring only at carbon atoms, and wherein y is 0, 1, 2, or 3; and wherein z is 0, 1, 2, or 3;

R<sup>6</sup> and R<sup>7</sup> are each independently selected from hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, hydroxy, C<sub>1</sub>-C<sub>8</sub> alkoxy, -SO<sub>2</sub>C<sub>1</sub>-C<sub>8</sub> alkyl, SO<sub>2</sub>C<sub>1</sub>-C<sub>8</sub> alkylaryl, -SO<sub>2</sub>C<sub>1</sub>-C<sub>8</sub> alkylheterocyclic, aryl, -C<sub>1</sub>-C<sub>8</sub> alkylaryl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, -C<sub>1</sub>-C<sub>6</sub> alkylcycloalkyl, -(CH<sub>2</sub>)<sub>n</sub>C(O)R<sup>8</sup>, -(CH<sub>2</sub>)<sub>m</sub>C(O)NR<sup>8</sup>R<sup>8</sup>, and -(CH<sub>2</sub>)<sub>m</sub>NSO<sub>2</sub>R<sup>8</sup>; wherein each of the alkyl, alkenyl, and aryl groups are optionally substituted with one to five groups independently selected from C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, aryl, and C<sub>1</sub>-C<sub>8</sub> alkylaryl; and wherein R<sup>6</sup> and R<sup>7</sup> may independently combine with each other, and with the nitrogen atom to which they are attached or with 1, or 2 atoms adjacent to the nitrogen atom to form a 4, 5, 6, or 7-membered nitrogen containing heterocycle which nitrogen-containing heterocycle may optionally have substituents selected from the group consisting of oxo, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, aryl, -C<sub>1</sub>-C<sub>8</sub> alkylaryl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, -CO(O)C<sub>1</sub>-C<sub>8</sub> alkyl, hydroxy, C<sub>1</sub>-C<sub>8</sub> alkoxy, -C<sub>1</sub>-C<sub>8</sub> alkylamine, amino, halo, and haloalkyl;

R<sup>8</sup> is hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>1</sub>-C<sub>8</sub> alkylaryl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, or -C(O)OC<sub>1</sub>-C<sub>8</sub> alkyl; and wherein n is 0, 1, 2, 3 or 4 and m is 1, 2, or 3;

or a compound selected from the group consisting of:

- 6-[4-(3-Pentylamino-propyl)-phenoxy]-nicotinamide,
- 6-[4-(1-Methyl-2-pentylamino-ethyl)-phenoxy]-nicotinamide,
- 6-[2-Methyl-4-(3-methyl-butylamino-methyl)-phenoxy]nicotinamide,
- 6-[2-Fluoro-4-(3-methyl-butylamino-methyl)-phenoxy]nicotinamide,
- 6-[2-Chloro-4-(3-methyl-butylamino-methyl)-phenoxy]nicotinamide,
- 6-[2-Ethoxy-4-(3-methyl-butylamino-methyl)-phenoxy]nicotinamide,
- 6-[4-[(3,3-Dimethyl-butylamino)-methyl]-2-methyl-phenoxy]-nicotinamide,
- 6-(4-Butylaminomethyl-2-methyl-phenoxy)-nicotinamide,
- 6-(2-Methyl-4-[[methyl-(3-methyl-butyl)-amino]-methyl]-phenoxy)-nicotinamide,
- 3-Fluoro-4-{2-methyl-4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,
- 6-(4-Allylaminomethyl-phenoxy)-nicotinamide,
- 6-[4-((3,3-Dimethyl-butylamino)-methyl)-2-ethoxyphenoxy]nicotinamide,
- 6-[4-((3-Methyl-butylamino)-methyl)-2,5-dimethylphenoxy]nicotinamide,
- 6-[4-((3-Methyl-butylamino)-methyl)-2-ethoxyphenoxy]nicotinamide,
- 6-[4-((3,3-Dimethyl-butylamino)-methyl)-2-ethoxyphenoxy]nicotinamide,
- 6-[4-(Butylamino-methyl)-2-ethoxyphenoxy]nicotinamide,
- 6-[4-((3-Methyl-butylamino)-methyl)-2,5-dimethylphenoxy]nicotinonamide,
- 5-{4-[(3-Methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide, 5-{2-Methyl-4-[(3-methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide, 5-{2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide,
- 5-{2-Fluoro-4-[(3-methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide, 5-{2-Methyl-4-[(3-methylbutylamino)methyl]phenoxy}pyrazine-2-carboxamide,
- 5-(2-Fluoro-4-pentylaminomethylphenoxy)pyridine-2-carboxamide,
- 5-{2-Chloro-4-[(3-methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide,
- 5-(2-Chloro-4-(pentylaminomethyl)phenoxy)pyridine-2-carboxamide,
- 6-{2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy}nicotinamide,
- 6-(2-Methoxy-4-pentylaminomethylphenoxy)nicotinamide,
- 6-(4-Butylaminomethyl-2-methoxyphenoxy)nicotinamide,



X-15876 PCT

## REPLACEMENT CLAIMS

542

- 6-{4-[(2-Ethylbutylamino)methyl]-2-methoxyphenoxy}nicotinamide,  
6-(4-Hexylaminomethyl-2-methoxyphenoxy)nicotinamide,  
6-{2-Methoxy-4-[(4-methylpentylamino)methyl]phenoxy}nicotinamide,  
5-{4-[(3,3-Dimethylbutylamino)methyl]-2-methylphenoxy}pyrazine-2-carboxamide, 5-  
{4-[(3-Methylbutylamino)methyl]phenoxy}pyrazine-2-carboxamide,  
5-{4-[(3,3-Dimethylbutylamino)methyl]phenoxy}pyrazine-2-carboxamide,  
6-(4-Hexylaminomethyl-2-methoxyphenoxy)nicotinamide methanesulfonate, 6-{4-[(2-  
Ethylbutylamino)methyl]-2-methoxyphenoxy}nicotinamide,  
6-{4-[(3,3-Dimethylbutylamino)methyl]-2-methoxyphenoxy}nicotinamide,  
6-{2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy}nicotinamide,  
4-[5-(Isobutylamino-methyl)-pyridin-2-yloxy]-benzamide,  
4-{5-[(3,3-Dimethyl-butylamino)-methyl]-pyridin-2-yloxy}-benzamide  
4-{5-[(3-Methyl-butylamino)-methyl]-pyridin-2-yloxy}-benzamide,  
4-{5-[(3,3-Dimethyl-butylamino)-methyl]-pyridin-2-yloxy}-benzamide,  
4-{5-[(3-Methyl-butylamino)-methyl]-pyridin-2-yloxy}-benzamide,  
6-{2-Chloro-4-[(3,3-dimethylbutylamino)-methyl]-phenoxy}-nicotinamide,  
3-Bromo-4-(5-pentylaminomethyl-pyridin-2-yloxy)-benzamide,  
3-Bromo-4-{5-[(3,3-dimethyl-butylamino)-methyl]-pyridin-2-yloxy}-benzamide,  
3-Methoxy-4-(5-pentylaminomethyl-pyridin-2-yloxy)-benzamide,  
4-{5-[(3,3-Dimethyl-butylamino)-methyl]-pyridin-2-yloxy}-3-methoxy-benzamide,  
4-{2-Methyl-4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
4-{3-Chloro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide, 4-{2-Ethoxy-4-  
[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
6-{2-Methyl-4-[2-(3-methyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{2-Methyl-4-[2-(3,3-dimethyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-[2-Methyl-4-(2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
6-{3-Chloro-4-[2-(3-methyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{3-Chloro-4-[2-(3,3-dimethyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-[3-Chloro-4-(2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
6-{2,6-Difluoro-4-[2-(3-methyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3,3-Dimethyl-butylamino)-ethyl]-2,6-difluoro-phenoxy}-nicotinamide,

6-[2,6-Difluoro-4-(2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
6-{2-Methyl-4-[2-(3-methyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{2-Methyl-4-[2-(3,3-dimethyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-[2-Methyl-4-(2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
6-[3-Chloro-4-(2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
6-{2,6-Difluoro-4-[2-(3-methyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3,3-Dimethyl-butylamino)-ethyl]-2,6-difluoro-phenoxy}-nicotinamide,  
6-[2,6-Difluoro-4-(2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
6-[4-(*tert*-butylamino methyl)-2-fluoro phenoxy] nicotinonamide,  
6-(4-Ethylaminomethyl-2-fluoro-phenoxy)-nicotinamide,  
6-(2-Fluoro-4-propylaminomethyl-phenoxy)-nicotinamide,  
6-(2-Fluoro-4-hexylaminomethyl-phenoxy)-nicotinamide,  
6-[2-Fluoro-4-(isobutylamino-methyl)-phenoxy]-nicotinamide,  
6-[2-Fluoro-4-(isobutylamino-methyl)-phenoxy]-nicotinamide,  
2-Fluoro-4-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
3-Methoxy-4-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
2-Methyl-4-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
3-Methyl-4-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
3-Fluoro-4-{4-[3-methylbutylamino)-methyl]phenoxy}-benzamide,  
3-Fluoro-4-{4-[(3,3-Dimethyl-butylamino)-methy]-phenoxy}-3-fluoro-benzamide,  
3-Fluoro-4-(4-pentylaminomethyl-phenoxy)-benzamide,  
3,5-Difluoro-4-{4-[3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
3-Fluoro-4-(4-{[methyl-(3-methyl-butyl)-amino]-methyl}-phenoxy)-benzamide,  
3,5-Difluoro-4-(4-{[methyl-(3-methyl-butyl)-amino]-methyl}-phenoxy)-benzamide,  
4-{2-Chloro-4-[(3,3-dimethyl-butylamino)-methyl]-phenoxy}-benzamide,  
4-{2-Chloro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
4-(2-Chloro-4-pentylaminomethyl-phenoxy)-benzamide,  
6-[4-(2-Methylamino-ethyl)-phenoxy]-nicotinamide,  
4-{4-[(3,3-Dimethyl-butylamino)-methyl]-2-trifluoromethyl-phenoxy}-benzamide,  
3-Chloro-4-(3-methoxy-4-pentylaminomethyl-phenoxy)-benzamide,  
3-Bromo-4-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,

X-15876 PCT

## REPLACEMENT CLAIMS


544

3-Bromo-4-(3-pentylaminomethyl-phenoxy)-benzamide,  
6-(2,3-Difluoro-4-pentylaminomethyl-phenoxy)-nicotinamide,  
6-{4-[(3,3-Dimethyl-butylamino)-methyl]-2-fluoro-6-methoxy-phenoxy}-nicotinamide,  
6-{4-[(3,3-Dimethyl-butylamino)-methyl]-2,6-difluoro-phenoxy}-nicotinamide,  
6-{2,6-Difluoro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide,  
6-{2,3,6-Trifluoro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide,  
6-{3-[(2-Cyclohexyl-ethylamino)-methyl]-2-methyl-phenoxy}-nicotinamide,  
6-[2-Isopropyl-3-(2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
5-(2-Methoxy-4-pentylaminomethylphenoxy)pyrazine-2-carboxamide,  
6-{2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy}pyridazine-3-carboxamide,  
6-(2-Methoxy-4-propylaminomethylphenoxy)nicotinamide,  
6-[4-(Isobutylaminomethyl)-2-methoxyphenoxy]nicotinamide,  
6-{4-[(2,2-Dimethylpropylamino)methyl]-2-methoxyphenoxy}nicotinamide,  
5-{4-[(3,3-Dimethylbutylamino)methyl]-2-fluorophenoxy}pyrazine-2-carboxamide,  
5-{2-Fluoro-4-[(4-methylpentylamino)methyl]phenoxy}pyridine-2-carboxamide,  
5-{4-[(3,3-Dimethylbutylamino)methyl]-2-fluorophenoxy}pyridine-2-carboxamide,  
5-{2-Fluoro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-pyrazine-2-carboxamide,  
5-(2-Fluoro-4-pentylaminomethylphenoxy)pyrazine-2-carboxamide,  
5-(2-Fluoro-4-hexylaminomethylphenoxy)pyrazine-2-carboxamide,  
6-{4-[(3,3-Dimethylbutylamino)methyl]-2-methoxyphenoxy}pyridazine-3-carboxamide,  
5-{2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy}pyrazine-2-carboxamide,  
5-{2-Methoxy-4-[(4-methylpentylamino)methyl]phenoxy}pyrazine-2-carboxamide,  
5-{4-[(3,3-Dimethylbutylamino)methyl]-2-methoxyphenoxy}pyrazine-2-carboxamide,  
(6-{4-[(3-Methyl-butylamino)-methyl]-phenoxy}-pyridin-3-yl)-piperidin-1-yl-methanone,  
N-Methyl-6-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide,  
N-Ethyl-6-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide,  
N-Isopropyl-6-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide,  
5-{4-[(4,4-Dimethylpentylamino)methyl]-2-fluorophenoxy}pyridine-2-carboxamide,  
5-{4-[(3-Ethylpentylamino)methyl]-2-fluorophenoxy}pyridine-2-carboxamide,  
5-{4-[(4,4-Dimethylpentylamino)methyl]-2-fluorophenoxy}pyrazine-2-carboxamide,  
5-{4-[(3-Ethylpentylamino)methyl]-2-fluorophenoxy}pyrazine-2-carboxamide,

5-{4-[(4,4-Dimethylpentylamino)methyl]-2-methoxyphenoxy}pyrazine-2-carboxamide,  
and

5-{4-[(3-Ethylpentylamino)methyl]-2-methoxyphenoxy}pyrazine-2-carboxamide;  
or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or  
mixture of diastereomers thereof.

2. A compound of formula Ib



wherein

each X is independently C, CH, or N; provided that ring B has no more than 2 nitrogen atoms;

v is 1, 2, or 3;

R<sup>1</sup> and R<sup>2</sup> are independently selected from hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, aryl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, -C<sub>1</sub>-C<sub>10</sub> alkylaryl, heterocyclyl, -C<sub>1</sub>-C<sub>10</sub> alkylheterocyclic, -arylheterocyclyl, -C<sub>3</sub>-C<sub>8</sub> cycloalkylheterocyclyl, -C<sub>1</sub>-C<sub>8</sub> alkylC(O)C<sub>1</sub>-C<sub>8</sub> alkyl, aryl C(O)C<sub>1</sub>-C<sub>8</sub> alkyl-, C<sub>3</sub>-C<sub>8</sub> cycloalkylC(O)(CH<sub>2</sub>)<sub>n</sub>-, -C<sub>1</sub>-C<sub>8</sub> alkylC(O)heterocyclic, -C<sub>1</sub>-C<sub>8</sub> alkylC(O)aryl, aryloxyC<sub>1</sub>-C<sub>8</sub> alkyl-, benzhydryl, fused bicyclic, C<sub>1</sub>-C<sub>8</sub> alkylfused bicyclic, phenylC(O)-, phenylC(O) C<sub>1</sub>-C<sub>8</sub> alkyl-, C<sub>1</sub>-C<sub>8</sub> alkoxyC<sub>1</sub>-C<sub>8</sub> alkyl-, -CO(O)C<sub>1</sub>-C<sub>8</sub>alkyl-, -SO<sub>2</sub>C<sub>1</sub>-C<sub>8</sub>alkyl, -SO<sub>2</sub>C<sub>1</sub>-C<sub>10</sub> alkylaryl, -SO<sub>2</sub>C<sub>1</sub>-C<sub>8</sub> alkylheterocyclic, -C<sub>1</sub>-C<sub>8</sub> alkylcycloalkyl, -(CH<sub>2</sub>)<sub>n</sub>C(O)OR<sup>8</sup>, -(CH<sub>2</sub>)<sub>m</sub>C(O)NR<sup>5</sup>R<sup>8</sup>, and -(CH<sub>2</sub>)<sub>m</sub>NSO<sub>2</sub>R<sup>8</sup>; wherein each of the alkyl, alkenyl, cycloalkyl, heterocyclic, and aryl groups are optionally substituted with one to five groups independently selected from halo, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> thioalkyl, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, aryl, -C<sub>1</sub>-C<sub>8</sub> alkylaryl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, -SO<sub>2</sub>C<sub>1</sub>-C<sub>8</sub> alkyl, -SO<sub>2</sub>C<sub>1</sub>-C<sub>8</sub> alkylaryl, -SO<sub>2</sub>C<sub>1</sub>-C<sub>8</sub> alkylheterocyclic, -C<sub>1</sub>-C<sub>8</sub> alkylcycloalkyl, -(CH<sub>2</sub>)<sub>n</sub>C(O)OR<sup>8</sup>, -(CH<sub>2</sub>)<sub>n</sub>C(O)R<sup>8</sup>; and wherein R<sup>1</sup> and R<sup>2</sup> may optionally combine with each other, or with 1, or 2 atoms adjacent to the nitrogen atom to form a 4, 5, 6, or 7-membered nitrogen-containing heterocycle which nitrogen-containing

heterocycle may further have substituents selected from the group consisting of amino, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, aryl, C<sub>1</sub>-C<sub>8</sub> alkylaryl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, -CO(O)C<sub>1</sub>-C<sub>8</sub> alkyl, halo, oxo, C<sub>1</sub>-C<sub>8</sub> haloalkyl; and wherein R<sup>1</sup> and R<sup>2</sup> may independently attach to the A ring to form a 4, 5, 6, or 7-member nitrogen-containing bicyclic heterocycle which nitrogen-containing bicyclic heterocycle may further have substituents selected from the group consisting of oxo, amino, -C<sub>1</sub>-C<sub>8</sub> alkyl, -C<sub>2</sub>-C<sub>8</sub> alkenyl, -C<sub>2</sub>-C<sub>8</sub> alkynyl, aryl, -C<sub>1</sub>-C<sub>8</sub> alkylaryl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, -CO(O)C<sub>1</sub>-C<sub>8</sub> alkyl, halo, and C<sub>1</sub>-C<sub>8</sub> haloalkyl;

and wherein R<sup>1</sup> and R<sup>2</sup> are not simultaneously hydrogen; and provided that when one of R<sup>1</sup> and R<sup>2</sup> is hydrogen the other is not C<sub>1</sub>-C<sub>8</sub> alkyl; and provided that the group NR<sup>1</sup>R<sup>2</sup> is not -NHCH<sub>2</sub>Ph; and further provided that when one of R<sup>1</sup> or R<sup>2</sup> is -CH<sub>2</sub>CH<sub>2</sub>-optionally substituted phenyl or -CH<sub>2</sub>CH<sub>2</sub>-optionally substituted naphthyl, or -CH<sub>2</sub>CH<sub>2</sub>-optionally substituted 5 or 6 member monocyclic heterocyclic aromatic, and v is 1, then R<sup>6</sup> and R<sup>7</sup> are not simultaneously hydrogen;

R<sup>3</sup> and R<sup>3'</sup> are each independently selected from hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, aryl, -C<sub>1</sub>-C<sub>8</sub> alkylcycloalkyl, and -C<sub>1</sub>-C<sub>8</sub> alkylaryl;

R<sup>4</sup> and R<sup>5</sup> are each independently selected from hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, -C<sub>2</sub>-C<sub>8</sub> alkynyl, -C<sub>1</sub>-C<sub>8</sub> alkoxyalkyl, C<sub>1</sub>-C<sub>8</sub> thioalkyl, halo, C<sub>1</sub>-C<sub>8</sub> haloalkyl, -C<sub>1</sub>-C<sub>8</sub> alkoxyhaloalkyl, aryl, -C<sub>1</sub>-C<sub>8</sub> alkylaryl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, or -C(O)OC<sub>1</sub>-C<sub>8</sub> alkyl, -C<sub>1</sub>-C<sub>8</sub> alkylamino, -C<sub>1</sub>-C<sub>8</sub> alkylcycloalkyl, -(CH<sub>2</sub>)<sub>m</sub>C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, and (CH<sub>2</sub>)<sub>n</sub>NR<sup>8</sup>R<sup>8</sup>, wherein each R<sup>4</sup> or R<sup>5</sup> is attached to its respective ring only at carbon atoms, and wherein y is 0, 1, 2, or 3; and wherein z is 0, 1, 2, or 3;

R<sup>6</sup> and R<sup>7</sup> are each independently selected from hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, hydroxy, C<sub>1</sub>-C<sub>8</sub> alkoxy, -SO<sub>2</sub>C<sub>1</sub>-C<sub>8</sub> alkyl, SO<sub>2</sub>C<sub>1</sub>-C<sub>8</sub> alkylaryl, -SO<sub>2</sub>C<sub>1</sub>-C<sub>8</sub> alkylheterocyclic, aryl, -C<sub>1</sub>-C<sub>8</sub> alkylaryl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, -C<sub>1</sub>-C<sub>6</sub> alkylcycloalkyl, -(CH<sub>2</sub>)<sub>n</sub>C(O)R<sup>8</sup>, -(CH<sub>2</sub>)<sub>m</sub>C(O)NR<sup>8</sup>R<sup>8</sup>, and -(CH<sub>2</sub>)<sub>m</sub>NSO<sub>2</sub>R<sup>8</sup>; wherein each of the alkyl, alkenyl, and aryl groups are optionally substituted with one to five groups independently selected from C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, aryl, and C<sub>1</sub>-C<sub>8</sub> alkylaryl; and wherein R<sup>6</sup> and R<sup>7</sup> may independently combine with each other, and with the nitrogen atom to which they are attached or with 1, or 2 atoms adjacent to the nitrogen atom to form a 4, 5, 6, or 7-membered nitrogen containing heterocycle which nitrogen-containing heterocycle may optionally have substituents selected from the group consisting of oxo,

C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, aryl, -C<sub>1</sub>-C<sub>8</sub> alkylaryl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, -CO(O)C<sub>1</sub>-C<sub>8</sub> alkyl, hydroxy, C<sub>1</sub>-C<sub>8</sub> alkoxy, -C<sub>1</sub>-C<sub>8</sub> alkylamine, amino, halo, and haloalkyl;

R<sup>8</sup> is hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>1</sub>-C<sub>8</sub> alkylaryl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, or -C(O)OC<sub>1</sub>-C<sub>8</sub> alkyl; and wherein n is 0, 1, 2, 3 or 4 and m is 1, 2, or 3;

or a compound selected from the group consisting of:

- 6-[4-(3-Pentylamino-propyl)-phenoxy]-nicotinamide,
- 6-[4-(1-Methyl-2-pentylamino-ethyl)-phenoxy]-nicotinamide,
- 6-[2-Methyl-4-(3-methyl-butylamino-methyl)-phenoxy]nicotinamide,
- 6-[2-Fluoro-4-(3-methyl-butylamino-methyl)-phenoxy]nicotinamide,
- 6-[2-Chloro-4-(3-methyl-butylamino-methyl)-phenoxy]nicotinamide,
- 6-[2-Ethoxy-4-(3-methyl-butylamino-methyl)-phenoxy]nicotinamide,
- 6-{4-[(3,3-Dimethyl-butylamino)-methyl]-2-methyl-phenoxy}-nicotinamide,
- 6-(4-Butylaminomethyl-2-methyl-phenoxy)-nicotinamide,
- 6-(2-Methyl-4-{[methyl-(3-methyl-butyl)-amino]-methyl}-phenoxy)-nicotinamide,
- 3-Fluoro-4-{2-methyl-4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,
- 6-(4-Allylaminomethyl-phenoxy)-nicotinamide,
- 6-[4-((3,3-Dimethyl-butylamino)-methyl)-2-ethoxyphenoxy]nicotinamide,
- 6-[4-((3-Methyl-butylamino)-methyl)-2,5-dimethylphenoxy]nicotinamide,
- 6-[4-((3-Methyl-butylamino)-methyl)-2-ethoxyphenoxy]nicotinamide,
- 6-[4-((3,3-Dimethyl-butylamino)-methyl)-2-ethoxyphenoxy]nicotinamide,
- 6-[4-(Butylamino-methyl)-2-ethoxyphenoxy]nicotinamide,
- 6-[4-((3-Methyl-butylamino)-methyl)-2,5-dimethylphenoxy]nicotinonamide,
- 5-{4-[(3-Methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide, 5-{2-Methyl-4-[(3-methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide, 5-{2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide,
- 5-{2-Fluoro-4-[(3-methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide, 5-{2-Methyl-4-[(3-methylbutylamino)methyl]phenoxy}pyrazine-2-carboxamide,
- 5-(2-Fluoro-4-pentylaminomethylphenoxy)pyridine-2-carboxamide,
- 5-{2-Chloro-4-[(3-methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide,
- 5-(2-Chloro-4-(pentylaminomethyl)phenoxy)pyridine-2-carboxamide,

X-15876 PCT

## REPLACEMENT CLAIMS

548

- 6-{2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy}nicotinamide,  
6-(2-Methoxy-4-pentylaminomethylphenoxy)nicotinamide,  
6-(4-Butylaminomethyl-2-methoxyphenoxy)nicotinamide,  
6-{4-[(2-Ethylbutylamino)methyl]-2-methoxyphenoxy}nicotinamide,  
6-(4-Hexylaminomethyl-2-methoxyphenoxy)nicotinamide,  
6-{2-Methoxy-4-[(4-methylpentylamino)methyl]phenoxy}nicotinamide,  
5-{4-[(3,3-Dimethylbutylamino)methyl]-2-methylphenoxy}pyrazine-2-carboxamide, 5-  
{4-[(3-Methylbutylamino)methyl]phenoxy}pyrazine-2-carboxamide,  
5-{4-[(3,3-Dimethylbutylamino)methyl]phenoxy}pyrazine-2-carboxamide,  
6-(4-Hexylaminomethyl-2-methoxyphenoxy)nicotinamide methanesulfonate, 6-{4-[(2-  
Ethylbutylamino)methyl]-2-methoxyphenoxy}nicotinamide,  
6-{4-[(3,3-Dimethylbutylamino)methyl]-2-methoxyphenoxy}nicotinamide,  
6-{2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy}nicotinamide,  
6-{2-Chloro-4-[(3,3-dimethylbutylamino)-methyl]-phenoxy}-nicotinamide,  
4-{2-Methyl-4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
4-{3-Chloro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide, 4-{2-Ethoxy-4-  
[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
6-{2-Methyl-4-[2-(3-methyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{2-Methyl-4-[2-(3,3-dimethyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-[2-Methyl-4-(2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
6-{3-Chloro-4-[2-(3-methyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{3-Chloro-4-[2-(3,3-dimethyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-[3-Chloro-4-(2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
6-{2,6-Difluoro-4-[2-(3-methyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3,3-Dimethyl-butylamino)-ethyl]-2,6-difluoro-phenoxy}-nicotinamide,  
6-[2,6-Difluoro-4-(2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
6-{2-Methyl-4-[2-(3-methyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{2-Methyl-4-[2-(3,3-dimethyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-[2-Methyl-4-(2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
6-[3-Chloro-4-(2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
6-{2,6-Difluoro-4-[2-(3-methyl-butylamino)-ethyl]-phenoxy}-nicotinamide,

X-15876 PCT

## REPLACEMENT CLAIMS

549

6-{4-[2-(3,3-Dimethyl-butylamino)-ethyl]-2,6-difluoro-phenoxy}-nicotinamide,  
6-[2,6-Difluoro-4-(2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
6-[4-(*tert*-butylamino methyl)-2-fluoro phenoxy] nicotinonamide,  
6-(4-Ethylaminomethyl-2-fluoro-phenoxy)-nicotinamide,  
6-(2-Fluoro-4-propylaminomethyl-phenoxy)-nicotinamide,  
6-(2-Fluoro-4-hexylaminomethyl-phenoxy)-nicotinamide,  
6-[2-Fluoro-4-(isobutylamino-methyl)-phenoxy]-nicotinamide,  
6-[2-Fluoro-4-(isobutylamino-methyl)-phenoxy]-nicotinamide,  
2-Fluoro-4-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
3-Methoxy-4-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
2-Methyl-4-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
3-Methyl-4-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
3-Fluoro-4-{4-[3-methylbutylamino)-methyl]phenoxy}-benzamide,  
3-Fluoro-4-{4-[(3,3-Dimethyl-butylamino)-methy]-phenoxy}-3-fluoro-benzamide,  
3-Fluoro-4-(4-pentylaminomethyl-phenoxy)-benzamide,  
3,5-Difluoro-4-{4-[3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
3-Fluoro-4-(4-{[methyl-(3-methyl-butyl)-amino]-methyl}-phenoxy)-benzamide,  
3,5-Difluoro-4-(4-{[methyl-(3-methyl-butyl)-amino]-methyl}-phenoxy)-benzamide,  
4-{2-Chloro-4-[(3,3-dimethyl-butylamino)-methyl]-phenoxy}-benzamide,  
4-{2-Chloro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
4-(2-Chloro-4-pentylaminomethyl-phenoxy)-benzamide,  
6-[4-(2-Methylamino-ethyl)-phenoxy]-nicotinamide,  
4-{4-[(3,3-Dimethyl-butylamino)-methyl]-2-trifluoromethyl-phenoxy}-benzamide,  
3-Chloro-4-(3-methoxy-4-pentylaminomethyl-phenoxy)-benzamide,  
3-Bromo-4-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
3-Bromo-4-(3-pentylaminomethyl-phenoxy)-benzamide,  
6-(2,3-Difluoro-4-pentylaminomethyl-phenoxy)-nicotinamide,  
6-{4-[(3,3-Dimethyl-butylamino)-methyl]-2-fluoro-6-methoxy-phenoxy}-nicotinamide,  
6-{4-[(3,3-Dimethyl-butylamino)-methyl]-2,6-difluoro-phenoxy}-nicotinamide,  
6-{2,6-Difluoro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide,  
6-{2,3,6-Trifluoro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide,



6-{3-[(2-Cyclohexyl-ethylamino)-methyl]-2-methyl-phenoxy}-nicotinamide,  
6-[2-Isopropyl-3-(2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
5-(2-Methoxy-4-pentylaminomethylphenoxy)pyrazine-2-carboxamide,  
6-{2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy}pyridazine-3-carboxamide,  
6-(2-Methoxy-4-propylaminomethylphenoxy)nicotinamide,  
6-[4-(Isobutylaminomethyl)-2-methoxyphenoxy]nicotinamide,  
6-{4-[(2,2-Dimethylpropylamino)methyl]-2-methoxyphenoxy}nicotinamide,  
5-{4-[(3,3-Dimethylbutylamino)methyl]-2-fluorophenoxy}pyrazine-2-carboxamide,  
5-{2-Fluoro-4-[(4-methylpentylamino)methyl]phenoxy}pyridine-2-carboxamide,  
5-{4-[(3,3-Dimethylbutylamino)methyl]-2-fluorophenoxy}pyridine-2-carboxamide,  
5-{2-Fluoro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-pyrazine-2-carboxamide,  
5-(2-Fluoro-4-pentylaminomethylphenoxy)pyrazine-2-carboxamide,  
5-(2-Fluoro-4-hexylaminomethylphenoxy)pyrazine-2-carboxamide,  
6-{4-[(3,3-Dimethylbutylamino)methyl]-2-methoxyphenoxy}pyridazine-3-carboxamide,  
5-{2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy}pyrazine-2-carboxamide,  
5-{2-Methoxy-4-[(4-methylpentylamino)methyl]phenoxy}pyrazine-2-carboxamide,  
5-{4-[(3,3-Dimethylbutylamino)methyl]-2-methoxyphenoxy}pyrazine-2-carboxamide,  
(6-{4-[(3-Methyl-butylamino)-methyl]-phenoxy}-pyridin-3-yl)-piperidin-1-yl-  
methanone,  
N-Methyl-6-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide,  
N-Ethyl-6-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide,  
N-Isopropyl-6-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide,  
5-{4-[(4,4-Dimethylpentylamino)methyl]-2-fluorophenoxy}pyridine-2-carboxamide,  
5-{4-[(3-Ethylpentylamino)methyl]-2-fluorophenoxy}pyridine-2-carboxamide,  
5-{4-[(4,4-Dimethylpentylamino)methyl]-2-fluorophenoxy}pyrazine-2-carboxamide,  
5-{4-[(3-Ethylpentylamino)methyl]-2-fluorophenoxy}pyrazine-2-carboxamide,  
5-{4-[(4,4-Dimethylpentylamino)methyl]-2-methoxyphenoxy}pyrazine-2-carboxamide,  
and  
5-{4-[(3-Ethylpentylamino)methyl]-2-methoxyphenoxy}pyrazine-2-carboxamide;  
or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or  
mixture of diastereomers thereof.

X-15876 PCT

## REPLACEMENT CLAIMS

539

3. The compound according to claim 1 or 2 wherein the A-ring is selected from the group consisting of phenyl, pyridine, pyrimidine, pyrazine, and pyridazine.
4. A compound according to Claim 1 or 2 wherein the B-ring is selected from the group consisting of phenyl, pyridine, pyrimidine, pyrazine, and pyridazine.
5. A compound according to Claim 1 or 2 wherein the A-ring is phenyl and the B ring is pyridinyl.
6. A compound according to Claim 1 or 2 wherein the A ring is phenyl and the B ring is pyrazinyl.
7. A compound according to Claim 1 or 2 wherein the A-ring is pyridinyl and the B-ring is phenyl.
8. A compound according to Claim 1 or 2 wherein both rings A and B are pyridinyl.
9. A compound according to Claim 1 or 2 wherein both rings A and B are phenyl.
10. A compound according to any one of Claims 1 wherein E is an oxygen atom.
11. A compound according to Claim 1 wherein y is 0, 1, or 2, and R<sup>4</sup> is independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, methoxy, ethoxy, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, phenyl, and benzyl.

AMENDED SHEET


X-15876 PCT

# REPLACEMENT CLAIMS

540

12. A compound according to Claim 1 wherein  $z$  is 0, 1, or 2, and  $R^5$  is independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, methoxy, ethoxy, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, phenyl, and benzyl.

13. A compound according to Claim 1 or 2 wherein  $R^1$  and  $R^2$  are each independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, phenyl,



and wherein  $n$  is 1, 2, or 3.

14. The compound according to any one of Claims 1 to 13 wherein  $R^6$  and  $R^7$  are each independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, phenyl, provided that when one of  $R^1$  or  $R^2$  is  $-CH_2CH_2-$  optionally substituted phenyl or  $-CH_2CH_2-$  optionally substituted naphthyl, or  $-CH_2CH_2-$  optionally substituted 5 or 6 member monocyclic heterocyclic aromatic, and  $v$  is 1, then  $R^6$  and  $R^7$  are not simultaneously hydrogen.

AMENDED SHEET


X-15876 PCT

## REPLACEMENT CLAIMS


541

15. A compound according to Claim 1 wherein E is an oxygen atom, R<sup>6</sup> and R<sup>7</sup> are each hydrogen wherein R<sup>1</sup> and R<sup>2</sup> are not simultaneously hydrogen; and provided that when one of R<sup>1</sup> and R<sup>2</sup> is hydrogen the other is not C<sub>1</sub>-C<sub>6</sub> alkyl; and provided that the group -NR<sup>1</sup>R<sup>2</sup> is not -NHCH<sub>2</sub>Phenyl; and further provided that when one of R<sup>1</sup> or R<sup>2</sup> is -CH<sub>2</sub>CH<sub>2</sub>-optionally substituted phenyl or -CH<sub>2</sub>CH<sub>2</sub>-optionally substituted naphthyl, or -CH<sub>2</sub>CH<sub>2</sub>-optionally substituted 5 or 6 member monocyclic heterocyclic aromatic, v is not equal to 1.
16. A compound according to any one of Claims 1 to 13 wherein v is 1 or 2.
17. A compound according to any one of Claims 1 to 13 wherein v is 1.
18. A compound according to any one of Claims 1 to 13 wherein v is 2, m is 1, n is 1, y is 0 or 1 and z is 0 or 1.

19. A compound selected from the group consisting of:  
6-{4-[(3-Methyl-butylamino)-methyl]-phenoxy}-nicotinamide



- 5-{2-Fluoro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-pyrazine-2-carboxamide




- 5-(2-Methoxy-4-pentylaminomethyl-phenoxy)-pyrazine-2-carboxamide


X-15876 PCT

# REPLACEMENT CLAIMS


542




6-(2-Fluoro-4-{[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-nicotinamide




6-(2,3-Difluoro-4-pentylaminomethyl-phenoxy)-nicotinamide



5-{4-[2-(4-Fluoro-phenyl)-ethylamino]-methyl}-2-methoxy-phenoxy}-pyrazine-2-carboxamide



5-{4-[(4,4-Dimethyl-pentylamino)-methyl]-2-methoxy-phenoxy}-pyrazine-2-carboxamide




5-(2-Methoxy-4-{[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-pyrazine-2-carboxamide


X-15876 PCT

## REPLACEMENT CLAIMS


543




5-{4-[(3,3-Dimethyl-butylamino)-methyl]-2-fluoro-phenoxy}-pyrazine-2-carboxamide




5-(2-Fluoro-4-{[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-pyrazine-2-carboxamide



6-{2-Methyl-4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide;  
methanesulfonic acid salt



5-(2-Methyl-4-{[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-pyrazine-2-carboxamide




X-15876 PCT


# REPLACEMENT CLAIMS

544


6-{4-[(3,3-Dimethyl-butylamino)-methyl]-2-fluoro-6-methoxy-phenoxy}-nicotinamide




5-(2-Fluoro-4-pentylaminomethyl-phenoxy)-pyrazine-2-carboxamide




3-Chloro-4-{4-[(3,3-dimethyl-butylamino)-methyl]-phenoxy}-benzamide




6-{4-{[2-(Tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy}-nicotinamide



6-{4-[2-(3,3-Dimethyl-butylamino)-ethyl]-2,6-difluoro-phenoxy}-nicotinamide



6-{2-Chloro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide




X-15876 PCT


# REPLACEMENT CLAIMS

545


3,5-Difluoro-4-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide




6-{2,3,6-Trifluoro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide



6-{2,6-Difluoro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide




3-Fluoro-4-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide



and a pharmaceutically acceptable salt, or solvate thereof.

20. The compound 6-{4-[(3-Methyl-butylamino)-methyl]-phenoxy}-nicotinamide




or a pharmaceutically acceptable salt, or solvate thereof.




546

21. The hydrochloric acid salt of the compound 6-{4-[(3-Methyl-butylamino)-methyl]-phenoxy}-nicotinamide




22. The compound 5-(4-{[2-(4-Fluoro-phenyl)-ethylamino]-methyl}-2-methoxy-phenoxy)-pyrazine-2-carboxamide




or a pharmaceutically acceptable salt, or solvate thereof.

23. The compound 5-(2-Methoxy-4-pentylaminomethyl-phenoxy)-pyrazine-2-carboxylic acid amide




or a pharmaceutically acceptable salt, or solvate thereof.

24. The compound 5-(2-Methoxy-4-{[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-pyrazine-2-carboxamide




or a pharmaceutically acceptable salt, or solvate thereof.

25. The compound 6-(2-Fluoro-4-{{2-(tetrahydro-pyran-4-yl)-ethylamino}-methyl}-phenoxy)-nicotinamide; methanesulfonic acid salt



26. A compound according to any one of Claims 1 to 18 wherein the pharmaceutically acceptable salt is the hydrochloric acid salt, the methanesulfonic acid salt, hydrobromide salt, the bisulfate salt or tartaric acid salt.
27. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of Claims 1 to 24 in association with a carrier, diluent and/or excipient.
28. A method for blocking a mu, kappa, delta or receptor combination (heterodimer) thereof in mammals comprising administering to a mammal requiring blocking of a mu, kappa, delta or receptor combination (heterodimer) thereof, a receptor blocking dose of a compound according to any one of Claims 1 to 25, or a pharmaceutically acceptable salt, enantiomer, racemate, mixture of diastereomers, or solvate thereof.
29. A method of treating or preventing obesity and Related Diseases comprising administering a therapeutically effective amount of a compound of formula II wherein formula II is represented by the structure



wherein

each of  $X_1'$ ,  $X_2'$ ,  $X_3'$ ,  $X_4'$ ,  $X_5'$ ,  $X_6'$ ,  $X_7'$ ,  $X_8'$ ,  $X_9'$ , and  $X_{10}'$  is C, CH, or N; provided that each of rings A' or B' has no more than 2 nitrogen atoms;

$E'$  is O or NH;

$v$  is 0, 1, 2 or 3;

$R^{1'}$  and  $R^{2'}$  are independently selected from hydrogen,  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_8$  alkenyl,  $C_2$ - $C_8$  alkynyl, aryl,  $C_3$ - $C_8$  cycloalkyl,  $-C_1$ - $C_{10}$  alkylaryl, heterocyclyl,  $-C_1$ - $C_{10}$  alkylheterocyclic, arylheterocyclyl,  $-C_3$ - $C_8$  cycloalkylheterocyclyl,  $-C_1$ - $C_8$  alkylC(O) $C_1$ - $C_8$  alkyl, aryl C(O) $C_1$ - $C_8$  alkyl-,  $C_3$ - $C_8$  cycloalkylC(O)( $CH_2$ ) $n$ -,  $-C_1$ - $C_8$  alkylC(O)heterocyclic,  $-C_1$ - $C_8$  alkylC(O)aryl, aryloxy $C_1$ - $C_8$  alkyl-, benzhydryl, fused bicyclic,  $C_1$ - $C_8$  alkylfused bicyclic, phenylC(O)-, phenylC(O)  $C_1$ - $C_8$  alkyl-,  $C_1$ - $C_8$  alkoxy $C_1$ - $C_8$  alkyl-,  $-CO(O)C_1$ - $C_8$ alkyl,  $-SO_2C_1$ - $C_8$ alkyl,  $-SO_2C_1$ - $C_{10}$  alkylaryl,  $-SO_2C_1$ - $C_8$  alkylheterocyclic,  $-C_1$ - $C_8$  alkylcycloalkyl,  $-(CH_2)_nC(O)OR^8$ ,  $-(CH_2)_nC(O)R^8$ ,  $-(CH_2)_mC(O)NR^8R^8$ , and  $-(CH_2)_mNSO_2R^8$ ; wherein each of the alkyl, alkenyl, cycloalkyl, heterocyclic, and aryl groups are optionally substituted with one to five groups independently selected from halo,  $C_1$ - $C_8$  haloalkyl,  $C_1$ - $C_8$  thioalkyl,  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_8$  alkenyl, aryl,  $-C_1$ - $C_8$  alkylaryl,  $-C(O)C_1$ - $C_8$  alkyl,  $-CO(O)C_1$ - $C_8$  alkyl,  $-SO_2C_1$ - $C_8$  alkyl,  $-SO_2C_1$ - $C_8$  alkylaryl,  $-SO_2C_1$ - $C_8$  alkylheterocyclic,  $-C_1$ - $C_8$  alkylcycloalkyl,  $-(CH_2)_nC(O)OR^8$ ,  $-(CH_2)_nC(O)R^8$ ; and wherein  $R^{1'}$  and  $R^{2'}$  may optionally combine with each other, or with 1, or 2 atoms adjacent to the nitrogen atom to form a 4, 5, 6, or 7-membered nitrogen-containing heterocycle which nitrogen-containing heterocycle may further have substituents selected from the group consisting of amino,  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_8$

alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, aryl, C<sub>1</sub>-C<sub>8</sub> alkylaryl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, -CO(O)C<sub>1</sub>-C<sub>8</sub> alkyl, halo, oxo, C<sub>1</sub>-C<sub>8</sub> haloalkyl; and wherein R<sup>1'</sup> and R<sup>2'</sup> may independently attach to the A' ring to form a 4, 5, 6, or 7-member nitrogen-containing bicyclic heterocycle which nitrogen-containing bicyclic heterocycle may further have substituents selected from the group consisting of oxo, amino, -C<sub>1</sub>-C<sub>8</sub> alkyl, -C<sub>2</sub>-C<sub>8</sub> alkenyl, -C<sub>2</sub>-C<sub>8</sub> alkynyl, aryl, -C<sub>1</sub>-C<sub>8</sub> alkylaryl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, -CO(O)C<sub>1</sub>-C<sub>8</sub> alkyl, halo, and C<sub>1</sub>-C<sub>8</sub> haloalkyl; provided that R<sup>1'</sup> and R<sup>2'</sup> are not simultaneously hydrogen; and provided that when v is 2, and R<sup>3a</sup> and R<sup>3b</sup> are both hydrogen or CH<sub>3</sub>, and both A' and B' rings are phenyl, then the group -NR<sup>1'</sup>R<sup>2'</sup> is not -NHCH<sub>2</sub>Phenyl; and further provided that when one of R<sup>1'</sup> or R<sup>2'</sup> is -CH<sub>2</sub>CH<sub>2</sub>-optionally substituted phenyl or -CH<sub>2</sub>CH<sub>2</sub>-optionally substituted naphthyl, or -CH<sub>2</sub>CH<sub>2</sub>-optionally substituted 5 or 6 member monocyclic heterocyclic aromatic, and v is 1, then R<sup>6'</sup> and R<sup>7'</sup> are not simultaneously hydrogen;

R<sup>3a</sup> and R<sup>3b</sup> are each independently selected from hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, aryl, -C<sub>1</sub>-C<sub>8</sub> alkylcycloalkyl, aryl, and -C<sub>1</sub>-C<sub>8</sub> alkylaryl;

R<sup>4'</sup> and R<sup>5'</sup> are each independently selected from hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, -C<sub>2</sub>-C<sub>8</sub> alkynyl, -C<sub>1</sub>-C<sub>8</sub> alkoxyalkyl, C<sub>1</sub>-C<sub>8</sub> thioalkyl, halo, C<sub>1</sub>-C<sub>8</sub> haloalkyl, -C<sub>1</sub>-C<sub>8</sub> alkoxyhaloalkyl, aryl, -C<sub>1</sub>-C<sub>8</sub> alkylaryl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, or -C(O)OC<sub>1</sub>-C<sub>8</sub> alkyl, -C<sub>1</sub>-C<sub>8</sub> alkylamino, -C<sub>1</sub>-C<sub>8</sub> alkylcycloalkyl, -(CH<sub>2</sub>)<sub>m</sub>C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, and -(CH<sub>2</sub>)<sub>n</sub>NR<sup>8</sup>R<sup>8</sup>, wherein each R<sup>4'</sup> and R<sup>5'</sup> is attached to its respective ring only at carbon atoms, and wherein y is 0, 1, 2, or 3; and wherein z is 0, 1, 2, or 3;

R<sup>6'</sup> and R<sup>7'</sup> are each independently selected from hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, hydroxy, C<sub>1</sub>-C<sub>8</sub> alkoxy, -SO<sub>2</sub>C<sub>1</sub>-C<sub>8</sub> alkyl, SO<sub>2</sub>C<sub>1</sub>-C<sub>8</sub> alkylaryl, -SO<sub>2</sub>C<sub>1</sub>-C<sub>8</sub> alkylheterocyclic, aryl, -C<sub>1</sub>-C<sub>8</sub> alkylaryl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, -C<sub>1</sub>-C<sub>6</sub> alkylcycloalkyl, -(CH<sub>2</sub>)<sub>n</sub>C(O)R<sup>8</sup>, -(CH<sub>2</sub>)<sub>m</sub>C(O)NR<sup>8</sup>R<sup>8</sup>, and -(CH<sub>2</sub>)<sub>m</sub>NSO<sub>2</sub>R<sup>8</sup>; wherein each of the alkyl, alkenyl, and aryl groups are optionally substituted with one to five groups independently selected from C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, aryl, and C<sub>1</sub>-C<sub>8</sub> alkylaryl; and wherein R<sup>6'</sup> and R<sup>7'</sup> may

X-15876 PCT

## REPLACEMENT CLAIMS

550

independently combine together, and with the nitrogen atom to which they are attached or with 1, or 2 atoms adjacent to the nitrogen atom to form a 4, 5, 6, or 7-membered nitrogen containing heterocycle which nitrogen containing heterocycle may further have substituents selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, phenyl, -C<sub>1</sub>-C<sub>8</sub> alkylaryl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, -CO(O)C<sub>1</sub>-C<sub>8</sub> alkyl, hydroxy, -C<sub>1</sub>-C<sub>8</sub> alkoxy, halo, and haloalkyl; R<sup>8</sup> is hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>1</sub>-C<sub>8</sub> alkylaryl, -C(O)C<sub>1</sub>-C<sub>8</sub> alkyl, or -C(O)OC<sub>1</sub>-C<sub>8</sub> alkyl; wherein n is 0, 1, 2, 3 or 4 and wherein m is 1, 2 or 3; or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomers or mixtures thereof.

30. A method according to Claim 29 wherein the Related Diseases is selected from the group consisting of diabetes, diabetic complications, diabetic retinopathy, atherosclerosis, hyperlipidemia, hypertriglycemia, hyperglycemia, and hyperlipoproteinemia.

31. A method of treating and/or preventing diseases related to obesity including irritable bowel syndrome, nausea, vomiting, obesity-related depression, obesity-related anxiety, smoking and alcohol addiction, sexual dysfunction, substance abuse, drug overdose, addictive behavior disorders, compulsive behaviors and stroke, comprising administering a therapeutically effective amount of a compound of formula I or II.

32. Use of a compound according to any one of Claims 1 to 24 or a compound of formula II according to Claim 29 in the manufacture of a medicament for the treatment and/or amelioration of the symptoms associated with obesity and Related Diseases.

33. A method of treating and/or preventing obesity and Related Diseases comprising administering a therapeutically effective amount of a compound of formula I or II to a patient in need thereof.
34. A method of suppressing appetite in a patient in need thereof, comprising administering a therapeutically effective amount of a compound of formula I or II.
35. A method of effecting weight loss in an obese patient comprising administering an effective amount of a compound of formula I or formula II or pharmaceutically acceptable salt, solvate, racemate or enantiomer thereof.
36. Use of a compound according to Claim 19 for the treatment of obesity comprising administering an effective dose of said compound to a person in need thereof.
37. Use of a compound according to Claim 19 for the treatment of weight loss comprising administering an effective dose of said compound to a person in need thereof.
38. Use of a compound according to Claim 20 or 21 or 22 or 23 or 24 or 25 for the treatment of obesity comprising administering an effective dose of said compound to a person in need thereof.
39. A pharmaceutical composition for the treatment and/or amelioration of the symptoms associated with obesity and Related Diseases, containing as an active ingredient a compound according to any one of Claims 1 to 25 or a compound of formula II according to Claim 29.

40. A pharmaceutical composition for the treatment and/or amelioration of the symptoms associated with obesity and Related Diseases, containing as an active ingredient a compound selected from the group consisting of:
- 6-{4-[2-(Benzyl-phenethyl-amino)-ethyl]-phenoxy}-nicotinamide,
  - 6-(4-{2-[Benzyl-(3-phenyl-propyl)-amino]-ethyl}-phenoxy)-nicotinamide,
  - 6-{4-[2-(Benzyl-hexyl-amino)-ethyl]-phenoxy}-nicotinamide,
  - 6-{4-[2-(Benzyl-heptyl-amino)-ethyl]-phenoxy}-nicotinamide,
  - 6-(4-{2-[Benzyl-(5-methyl-hexyl)-amino]-ethyl}-phenoxy)-nicotinamide,
  - 6-[4-(2-{Benzyl-[2-(3-chloro-phenyl)-ethyl]-amino}-ethyl)-phenoxy]-nicotinamide,
  - 6-(4-{2-[Benzyl-(3-cyclohexyl-propyl)-amino]-ethyl}-phenoxy)-nicotinamide,
  - 6-(4-{2-[Benzyl-(3-o-tolyl-propyl)-amino]-ethyl}-phenoxy)-nicotinamide,
  - 6-(4-{2-[Benzyl-(3-thiophen-2-yl-propyl)-amino]-ethyl}-phenoxy)-nicotinamide,
  - 6-{4-[2-(Benzyl-pentyl-amino)-ethyl]-phenoxy}-nicotinamide,
  - 6-(4-{2-[Benzyl-(3-cyclopentyl-propyl)-amino]-ethyl}-phenoxy)-nicotinamide,
  - 6-[4-(2-{Benzyl-[2-(2-fluoro-phenyl)-ethyl]-amino}-ethyl)-phenoxy]-nicotinamide,
  - 6-[4-(2-Dibenzylamino-ethyl)-phenoxy]-nicotinamide,
  - 6-(4-{2-[Benzyl-(3-oxo-3-phenyl-propyl)-amino]-ethyl}-phenoxy)-nicotinamide,
  - 6-(4-{2-[Benzyl-(3-oxo-3-thiophen-2-yl-propyl)-amino]-ethyl}-phenoxy)-nicotinamide,
  - 6-(4-{2-[Benzyl-(3-cyclohexyl-3-oxo-propyl)-amino]-ethyl}-phenoxy)-nicotinamide,
  - 6-(4-{2-[Benzyl-(3-hydroxy-3-phenyl-propyl)-amino]-ethyl}-phenoxy)-nicotinamide,
  - 6-(4-{2-[Benzyl-(3-hydroxy-3-thiophen-2-yl-propyl)-amino]-ethyl}-phenoxy)-nicotinamide,
  - 6-(4-{2-[Benzyl-(3-cyclohexyl-3-hydroxy-propyl)-amino]-ethyl}-phenoxy)-nicotinamide,

- 6-{4-[2-(3-Phenyl-propylamino)-ethyl]-phenoxy}-nicotinamide,  
6-[4-(2-Phenethylamino-ethyl)-phenoxy]-nicotinamide,  
6-[4-(2-Hexylamino-ethyl)-phenoxy]-nicotinamide,  
6-[4-(2-Heptylamino-ethyl)-phenoxy]-nicotinamide,  
6-[4-(2-Pentylamino-ethyl)-phenoxy]-nicotinamide,  
6-{4-[2-(5-Methyl-hexylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-[2-(3-Chloro-phenyl)-ethylamino]-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Cyclopentyl-propylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Cyclohexyl-propylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-[2-(3-Fluoro-phenyl)-ethylamino]-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-o-Tolyl-propylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Thiophen-2-yl-propylamino)-ethyl]-phenoxy}-nicotinamide,  
6-[4-(2-Amino-ethyl)-phenoxy]-nicotinamide,  
6-{4-[2-(2-Methoxy-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Fluoro-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Chloro-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3,4-Dichloro-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Trifluoromethyl-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(4-Cyano-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(4-Fluoro-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(4-Methyl-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3,5-Bis-trifluoromethyl-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(2,6-Difluoro-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3,5-Difluoro-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(4-Acetylamino-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(2-Trifluoromethyl-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(2-Methyl-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Methoxy-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(4-Chloro-benzylamino)-ethyl]-phenoxy}-nicotinamide,



6-{4-[2-(4-Phenoxy-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(4-Methoxy-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(4-Trifluoromethyl-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Oxo-2,3-dihydro-1H-isoindol-1-ylamino)-ethyl]-phenoxy}-  
nicotinamide,  
6-{4-[2-(4-Trifluoromethoxy-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Trifluoromethoxy-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-[(Thiophen-2-ylmethyl)-amino]-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-[(Furan-2-ylmethyl)-amino]-ethyl]-phenoxy}-nicotinamide,  
6-[4-(2-Octylamino-ethyl)-phenoxy]-nicotinamide,  
6-[4-(2-Cyclohexylamino-ethyl)-phenoxy]-nicotinamide,  
6-{4-[2-(Cyclohexylmethyl)-amino]-ethyl]-phenoxy}-nicotinamide,  
6-[4-(2-Propylamino-ethyl)-phenoxy]-nicotinamide,  
6-[4-(2-Butylamino-ethyl)-phenoxy]-nicotinamide,  
6-[4-(2-Isopropylamino-ethyl)-phenoxy]-nicotinamide,  
6-[4-(2-Isobutylamino-ethyl)-phenoxy]-nicotinamide,  
6-{4-[2-(3-Methyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-[(Pyridin-4-ylmethyl)-amino]-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-[(Pyridin-2-ylmethyl)-amino]-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-[(5-Methyl-furan-2-ylmethyl)-amino]-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-[(3-Methyl-thiophen-2-ylmethyl)-amino]-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-[(5-Methyl-thiophen-2-ylmethyl)-amino]-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-[(Thiophen-3-ylmethyl)-amino]-ethyl]-phenoxy}-nicotinamide,  
6-[4-(2-Ethylamino-ethyl)-phenoxy]-nicotinamide,  
6-{4-[2-(4-Hydroxy-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Hydroxy-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Phenyl-prop-2-ynylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-[(Furan-3-ylmethyl)-amino]-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-[(Benzofuran-2-ylmethyl)-amino]-ethyl]-phenoxy}-nicotinamide,

X-15876 PCT

## REPLACEMENT CLAIMS

555

- 6-(4-{2-[(5-Ethyl-furan-2-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-(4-{2-[(5-Chloro-thiophen-2-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-(4-{2-[(4,5-Dimethyl-furan-2-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-(4-{2-[(4-Chloro-1-methyl-1H-pyrazol-3-ylmethyl)-amino]-ethyl}-phenoxy)-  
nicotinamide,  
6-(4-{2-[(Thiazol-2-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-(4-{2-[(2-Methyl-1H-imidazol-4-ylmethyl)-amino]-ethyl}-phenoxy)-  
nicotinamide,  
6-{4-[2-(3,5-Di-tert-butyl-4-hydroxy-benzylamino)-ethyl]-phenoxy}-  
nicotinamide,  
6-{4-[2-(2-Fluoro-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Phenoxy-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(2-Chloro-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Cyano-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Methyl-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-(4-{2-[(1H-Imidazol-4-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-(4-{2-[(Pyridin-3-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-{4-[2-(2-Phenoxy-ethylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Fluoro-4-hydroxy-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-(4-{2-[(2-Butyl-1H-imidazol-4-ylmethyl)-amino]-ethyl}-phenoxy)-  
nicotinamide,  
6-(4-{2-[(Benzo[b]thiophen-3-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-(4-{2-[(3-Phenyl-1H-pyrazol-4-ylmethyl)-amino]-ethyl}-phenoxy)-  
nicotinamide,  
6-[4-(2-Allylamino-ethyl)-phenoxy]-nicotinamide,  
6-{4-[2-(4-Imidazol-1-yl-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-(4-{2-[(3-Methyl-benzo[b]thiophen-2-ylmethyl)-amino]-ethyl}-phenoxy)-  
nicotinamide,  
6-{4-[2-(4-Methyl-pent-2-enylamino)-ethyl]-phenoxy}-nicotinamide,

X-15876 PCT

## REPLACEMENT CLAIMS

556

6-{4-[2-(2-Trifluoromethoxy-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-(4-{2-[(2-Piperidin-1-yl-thiazol-5-ylmethyl)-amino]-ethyl}-phenoxy)-  
nicotinamide,  
6-{4-[2-(4-Cyclohexyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(2-Cyclohexyl-ethylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(2-Chloro-6-fluoro-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(Cyclopropylmethyl-amino)-ethyl]-phenoxy}-nicotinamide,  
6-(4-{2-[(Naphthalen-1-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-(4-{2-[(Bicyclo[2.2.1]hept-5-en-2-ylmethyl)-amino]-ethyl}-phenoxy)-  
nicotinamide,  
6-(4-{2-[(Naphthalen-2-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-(4-{2-[(Quinolin-4-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-{4-[2-(2,6-Dichloro-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(Indan-1-ylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(2-Hydroxy-5-methoxy-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Bromo-4-fluoro-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(4-Fluoro-2-trifluoromethyl-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Chloro-4-fluoro-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-[4-(2-Cyclooctylamino-ethyl)-phenoxy]-nicotinamide,  
6-{4-[2-(2-Phenoxy-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(Cyclobutylmethyl-amino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(Cycloheptylmethyl-amino)-ethyl]-phenoxy}-nicotinamide,  
6-(4-{2-[(2-Morpholin-4-yl-thiazol-5-ylmethyl)-amino]-ethyl}-phenoxy)-  
nicotinamide,  
6-(4-{2-[(2,4-Dichloro-thiazol-5-ylmethyl)-amino]-ethyl}-phenoxy)-  
nicotinamide,  
6-(4-{2-[(2-Chloro-thiazol-5-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-{4-[2-(Cyclopentylmethyl-amino)-ethyl]-phenoxy}-nicotinamide,

AMENDED SHEET

X-15876 PCT

## REPLACEMENT CLAIMS

557

- 6-(4-{2-[(3,5-Dimethyl-isoxazol-4-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,
- 6-(4-{2-[(5-Methyl-isoxazol-3-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,
- 6-(4-{2-[(3-Phenyl-isoxazol-5-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,
- 6-[4-(2-{[3-(4-Chloro-phenyl)-[1,2,4]oxadiazol-5-ylmethyl]-amino}-ethyl)-phenoxy]-nicotinamide,
- 6-(4-{2-[(5-p-Tolyl-[1,3,4]oxadiazol-2-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,
- 6-{4-[2-(1-Phenyl-ethylamino)-ethyl]-phenoxy}-nicotinamide,
- 6-[4-(3-Benzylamino-propyl)-phenoxy]-nicotinamide,
- 6-{4-[3-(Benzyl-pentyl-amino)-propyl]-phenoxy}-nicotinamide,
- 6-{4-[3-(Benzyl-phenethyl-amino)-propyl]-phenoxy}-nicotinamide,
- 6-(4-{3-[Benzyl-(3-cyclopentyl-propyl)-amino]-propyl}-phenoxy)-nicotinamide,
- 6-[4-(3-{Benzyl-[2-(3-fluoro-phenyl)-ethyl]-amino}-propyl)-phenoxy]-nicotinamide,
- 6-[4-(3-Pentylamino-propyl)-phenoxy]-nicotinamide,
- 6-[4-(3-Phenethylamino-propyl)-phenoxy]-nicotinamide,
- 6-{4-[3-(3-Cyclopentyl-propylamino)-propyl]-phenoxy}-nicotinamide,
- 6-(4-{3-[2-(3-Fluoro-phenyl)-ethylamino]-propyl}-phenoxy)-nicotinamide,
- (R)-6-[4-(2-Benzylamino-propyl)-phenoxy]-nicotinamide,
- (R)-6-[4-(2-Dibenzylamino-propyl)-phenoxy]-nicotinamide,
- 6-[4-(2-Benzylamino-2-methyl-propyl)-phenoxy]-nicotinamide,
- 6-[4-(2-Methyl-2-pentylamino-propyl)-phenoxy]-nicotinamide,
- 6-[4-(2-Methyl-2-phenethylamino-propyl)-phenoxy]-nicotinamide,
- 6-(4-{2-[2-(3-Fluoro-phenyl)-ethylamino]-2-methyl-propyl}-phenoxy)-nicotinamide,
- 6-{4-[2-(3-Cyclopentyl-propylamino)-2-methyl-propyl]-phenoxy}-nicotinamide,
- 6-[4-(3-Benzylamino-butyl)-phenoxy]-nicotinamide,
- 6-[4-(3-Pentylamino-butyl)-phenoxy]-nicotinamide,

X-15876 PCT

## REPLACEMENT CLAIMS

558

6-[4-(3-Propylamino-butyl)-phenoxy]-nicotinamide,  
6-[4-(3-Methylamino-butyl)-phenoxy]-nicotinamide,  
6-[4-(3-Phenethylamino-butyl)-phenoxy]-nicotinamide,  
6-[4-{3-[2-(3-Fluoro-phenyl)-ethylamino]-butyl}-phenoxy]-nicotinamide,  
6-[4-{3-[2-(3-Chloro-phenyl)-ethylamino]-butyl}-phenoxy]-nicotinamide,  
6-[4-{3-[(Furan-2-ylmethyl)-amino]-butyl}-phenoxy]-nicotinamide,  
6-[4-{3-[2-(Thiophen-2-yl)-ethylamino]-butyl}-phenoxy]-nicotinamide,  
6-[4-{3-(Cyclopropylmethyl-amino)-butyl}-phenoxy]-nicotinamide,  
6-[4-{3-(3-Trifluoromethyl-benzylamino)-butyl}-phenoxy]-nicotinamide,  
6-[4-{3-(4-Fluoro-benzylamino)-butyl}-phenoxy]-nicotinamide,  
6-[4-{3-(3-Fluoro-benzylamino)-butyl}-phenoxy]-nicotinamide,  
6-[4-(3-Allylamino-butyl)-phenoxy]-nicotinamide,  
6-[4-{3-(4-Chloro-benzylamino)-butyl}-phenoxy]-nicotinamide,  
6-[4-{3-(4-Methoxy-benzylamino)-butyl}-phenoxy]-nicotinamide,  
6-[4-{3-(4-Trifluoromethyl-benzylamino)-butyl}-phenoxy]-nicotinamide,  
6-[4-{3-(4-Trifluoromethoxy-benzylamino)-butyl}-phenoxy]-nicotinamide,  
6-[4-{3-(3-Trifluoromethoxy-benzylamino)-butyl}-phenoxy]-nicotinamide,  
(1R)-6-[4-{3-(1-Phenyl-ethylamino)-butyl}-phenoxy]-nicotinamide,  
(1S)-6-[4-{3-(1-Phenyl-ethylamino)-butyl}-phenoxy]-nicotinamide,  
6-[4-(2-Benzylamino-propyl)-phenoxy]-nicotinamide,  
6-[4-(2-Pentylamino-propyl)-phenoxy]-nicotinamide,  
6-[4-(2-Propylamino-propyl)-phenoxy]-nicotinamide,  
6-[4-(2-Methylamino-propyl)-phenoxy]-nicotinamide,  
6-[4-(2-Phenethylamino-propyl)-phenoxy]-nicotinamide,  
6-[4-{2-[2-(3-Fluoro-phenyl)-ethylamino]-propyl}-phenoxy]-nicotinamide,  
6-[4-{2-[2-(3-Chloro-phenyl)-ethylamino]-propyl}-phenoxy]-nicotinamide,  
6-[4-{2-[(Furan-2-ylmethyl)-amino]-propyl}-phenoxy]-nicotinamide,  
6-[4-{2-[2-(Thiophen-2-yl)-ethylamino]-propyl}-phenoxy]-nicotinamide,  
6-[4-{2-(Cyclopropylmethyl-amino)-propyl}-phenoxy]-nicotinamide,

AMENDED SHEET

6-{4-[2-(3-Trifluoromethyl-benzylamino)-propyl]-phenoxy}-nicotinamide,  
6-{4-[2-(4-Fluoro-benzylamino)-propyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Fluoro-benzylamino)-propyl]-phenoxy}-nicotinamide,  
6-[4-(2-Allylamino-propyl)-phenoxy]-nicotinamide,  
6-{4-[2-(4-Chloro-benzylamino)-propyl]-phenoxy}-nicotinamide,  
6-{4-[2-(4-Trifluoromethyl-benzylamino)-propyl]-phenoxy}-nicotinamide,  
6-{4-[2-(4-Methoxy-benzylamino)-propyl]-phenoxy}-nicotinamide,  
6-{4-[2-(4-Trifluoromethoxy-benzylamino)-propyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Trifluoromethoxy-benzylamino)-propyl]-phenoxy}-nicotinamide,  
(1S)-6-{4-[2-(1-Phenyl-ethylamino)-propyl]-phenoxy}-nicotinamide,  
(1R)-6-{4-[2-(1-Phenyl-ethylamino)-propyl]-phenoxy}-nicotinamide,  
6-[4-(2-Benzylamino-1-methyl-ethyl)-phenoxy]-nicotinamide,  
6-{4-[2-(Benzyl-pentyl-amino)-1-methyl-ethyl]-phenoxy}-nicotinamide,  
6-[4-(1-Methyl-2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
6-[4-(2-Benzylamino-1,1-dimethyl-ethyl)-phenoxy]-nicotinamide,  
6-{4-[2-(Cyclohexylmethyl-amino)-1,1-dimethyl-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(2-Chloro-benzylamino)-1,1-dimethyl-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Fluoro-benzylamino)-1,1-dimethyl-ethyl]-phenoxy}-nicotinamide,  
6-[4-(3-Phenylamino-propyl)-phenoxy]-nicotinamide,  
6-[4-(2-Dimethylamino-ethyl)-phenoxy]-nicotinamide,  
6-[4-(2-Piperidin-1-yl-ethyl)-phenoxy]-nicotinamide,  
6-[4-(2-Morpholin-1-yl-ethyl)-phenoxy]-nicotinamide,  
6-{4-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(4-Benzoyl-piperidin-1-yl)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Methyl-piperidin-1-yl)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3,5-Dimethyl-piperidin-1-yl)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(4-Benzhydryl-piperidin-1-yl)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(4-Phenyl-piperidin-1-yl)-ethyl]-phenoxy}-nicotinamide,  
6-(4-{2-[3-Fluoro-phenyl]-piperidin-1-yl}-ethyl)-phenoxy}-nicotinamide,

6-[4-(2-Azepan-1-yl-ethyl)-phenoxy]-nicotinamide,  
6-{4-[2-(Benzyl-methyl-amino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(Benzyl-ethyl-amino)-ethyl]-phenoxy}-nicotinamide,  
6-[4-[2-(Benzyl-propyl-amino)-ethyl]-phenoxy]-nicotinamide,  
6-{4-[2-(Benzyl-butyl-amino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(Benzyl-cyclopropylmethylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(Benzyl-isobutyl-amino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(Benzyl-(3-methyl-butyl)-amino)-ethyl]-phenoxy}-nicotinamide,  
6-[4-(2-Benzoylamino-ethyl)-phenoxy]-nicotinamide,  
4-[4-(2-Benzylamino-ethyl)-phenoxy]-2-fluoro-benzamide,  
2-[4-(2-Benzylamino-ethyl)-phenoxy]-4-fluoro-benzamide,  
4-[4-(2-Benzylamino-ethyl)-phenoxy]-2-chloro-benzamide,  
6-[4-(2-Benzylamino-ethyl)-2-methyl-phenoxy]-nicotinamide,  
6-[2-Methyl-4-(phenethylamino-methyl)-phenoxy]nicotinamide,  
6-[2-Fluoro-4-(phenethylamino-methyl)-phenoxy]nicotinamide,  
6-[2-Ethoxy-4-(phenethylamino-methyl)-phenoxy]nicotinamide,  
6-[2-Chloro-4-(phenethylamino-methyl)-phenoxy]nicotinamide,  
6-[3-Chloro-4-(phenethylamino-methyl)-phenoxy]nicotinamide,  
6-[2-Methyl-4-(3-methyl-butylamino-methyl)-phenoxy]nicotinamide,  
6-[2-Fluoro-4-(3-methyl-butylamino-methyl)-phenoxy]nicotinamide,  
6-[2-Chloro-4-(3-methyl-butylamino-methyl)-phenoxy]nicotinamide,  
6-[2-Ethoxy-4-(3-methyl-butylamino-methyl)-phenoxy]nicotinamide,  
6-{4-[2-Cyclopentyl-ethylamino)-methyl]-2-methyl-phenoxy}-nicotinamide,  
6-{4-[2-Cyclopentyl-ethylamino)-methyl]-2-fluoro-phenoxy}-nicotinamide,  
6-{2-Chloro-4-[2-Cyclopentyl-ethylamino)-methyl]-phenoxy}-nicotinamide,  
6-{4-[2-Cyclopentyl-ethylamino)-methyl]-2-ethoxy-phenoxy}-nicotinamide,  
6-{2-Methyl-4-[2-thiophen-2-yl-ethylamino)-methyl]-phenoxy}-nicotinamide,

- 6-(4-{[2-(3-Fluoro-phenyl)-ethylamino]-methyl}-2-methyl-phenoxy)-nicotinamide,
- 6-{2-Methyl-4-[(2-o-tolyl-ethylamino)-methyl]-phenoxy}-nicotinamide,
- 6-{4-[(3,3-Dimethyl-butylamino)-methyl]-2-methyl-phenoxy}-nicotinamide,
- 6-(4-{[2-(3-Chloro-phenyl)-ethylamino]-methyl}-2-methyl-phenoxy)-nicotinamide,
- 6-(4-Butylaminomethyl-2-methyl-phenoxy)-nicotinamide,
- 6-(2-Methyl-4-{[methyl-(3-methyl-butyl)-amino]-methyl}-phenoxy)-nicotinamide,
- 6-{2-Methyl-4-[(methyl-phenethyl-amino)-methyl]-phenoxy}-nicotinamide,
- 3-Fluoro-4-[4-(phenethylamino-methyl)-phenoxy]-benzamide,
- 3-Chloro-4-[4-(phenethylamino-methyl)-phenoxy]-benzamide,
- 2-Chloro-4-[4-(phenethylamino-methyl)-phenoxy]-benzamide,
- 3-Fluoro-4-{2-methyl-4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,
- 4-(4-Benzylamino-phenoxy)-benzamide,
- 4-(4-Phenethylamino-phenoxy)-benzamide,
- 6-[4-(Benzylamino-methyl)-phenoxy]-nicotinamide,
- 6-(4-Allylaminomethyl-phenoxy)-nicotinamide,
- 6-{4-[(4-Methoxy-benzylamino)-methyl]-phenoxy}-nicotinamide,
- 6-{4-[(3-Trifluoromethyl-benzylamino)-methyl]-phenoxy}-nicotinamide,
- 6-{4-[(2-Thiophen-2-yl-ethylamino)-methyl]-phenoxy}-nicotinamide,
- 6-{4-[(3-Fluoro-benzylamino)-methyl]-phenoxy}-nicotinamide,
- 6-(4-{[(Furan-2-ylmethyl)-amino]-methyl}-phenoxy)-nicotinamide,
- 6-(4-{[2-(3-Fluoro-phenyl)-ethylamino]-methyl}-phenoxy)-nicotinamide,
- 6-{4-[(4-Trifluoromethoxy-benzylamino)-methyl]-phenoxy}-nicotinamide,
- 6-[4-(Phenethylamino-methyl)-phenoxy]-nicotinamide,
- 6-(4-{[2-(3-Chloro-phenyl)-ethylamino]-methyl}-phenoxy)-nicotinamide,
- 6-(4-{[2-(4-Sulfamoyl-phenyl)-ethylamino]-methyl}-phenoxy)-nicotinamide,



- 6-{4-[(3-Phenyl-propylamino)-methyl]-phenoxy}-nicotinamide,  
6-{4-[(3,3-Diphenyl-propylamino)-methyl]-phenoxy}-nicotinamide,  
6-{4-[(3,3-Dimethyl-butylamino)-methyl]-phenoxy}-nicotinamide,  
6-{4-[(2-(2-Methoxy-phenyl)-ethylamino)-methyl]-phenoxy}-nicotinamide,  
6-{4-[(2-Phenylamino-ethylamino)-methyl]-phenoxy}-nicotinamide,  
6-{4-[(2-Phenyl-propylamino)-methyl]-phenoxy}-nicotinamide,  
6-{4-[(2-Pyridin-2-yl-ethylamino)-methyl]-phenoxy}-nicotinamide,  
6-{4-[(2-(2-Chloro-phenyl)-ethylamino)-methyl]-phenoxy}-nicotinamide,  
6-{4-[(2-Pyridin-3-yl-ethylamino)-methyl]-phenoxy}-nicotinamide,  
6-{4-[(2,2-Diphenyl-ethylamino)-methyl]-phenoxy}-nicotinamide,  
6-{4-[(3-Methyl-butylamino)-methyl]-phenoxy}-nicotinamide,  
6-{4-[(2-Cyclohexyl-ethylamino)-methyl]-phenoxy}-nicotinamide,  
6-{4-[(2-Methylsulfanyl-ethylamino)-methyl]-phenoxy}-nicotinamide,  
6-{4-[(6-Hydroxy-hexylamino)-methyl]-phenoxy}-nicotinamide,  
6-{4-[(2-Dimethylamino-ethylamino)-methyl]-phenoxy}-nicotinamide,  
6-{4-Decylaminomethyl-phenoxy}-nicotinamide,  
6-{4-[(2-Ethyl-hexylamino)-methyl]-phenoxy}-nicotinamide,  
6-{4-[(Tetrahydro-furan-2-ylmethyl)-amino]-methyl}-phenoxy}-nicotinamide,  
6-{4-[(2-Pyrrolidin-1-yl-ethylamino)-methyl]-phenoxy}-nicotinamide,  
6-{4-[(2-(1-Methyl-pyrrolidin-2-yl)-ethylamino)-methyl]-phenoxy}-nicotinamide,  
6-{4-[(2-(1H-Imidazol-4-yl)-ethylamino)-methyl]-phenoxy}-nicotinamide,  
6-{4-[(3-(2-Methyl-piperidin-1-yl)-propylamino)-methyl]-phenoxy}-  
nicotinamide,  
6-{4-[(2-Diisopropylamino-ethylamino)-methyl]-phenoxy}-nicotinamide,  
6-{4-[(2-Cyclohex-1-enyl-ethylamino)-methyl]-phenoxy}-nicotinamide,  
6-{4-Pentylaminomethyl-phenoxy}-nicotinamide,  
4-{4-[(4-Trifluoromethoxy-benzylamino)-methyl]-phenoxy}-benzamide,  
4-{4-[(2-(3-Chloro-phenyl)-ethylamino)-methyl]-phenoxy}-benzamide,  
4-{4-[(4-Trifluoromethyl-benzylamino)-methyl]-phenoxy}-benzamide,

- 4-{4-[(4-Fluoro-benzylamino)-methyl]-phenoxy}-benzamide,  
4-(4-Pentylaminomethyl-phenoxy)-benzamide,  
4-{4-[(2-Phenyl-propylamino)-methyl]-phenoxy}-benzamide,  
4-(4-{[2-(2-Chloro-phenyl)-ethylamino]-methyl}-phenoxy)-benzamide,  
4-(4-{[2-(2,4-Dichloro-phenyl)-ethylamino]-methyl}-phenoxy)-benzamide,  
4-(4-{[2-(4-Fluoro-phenyl)-ethylamino]-methyl}-phenoxy)-benzamide,  
4-(4-{[2-(3-Fluoro-phenyl)-ethylamino]-methyl}-phenoxy)-benzamide,  
4-(4-{[2-(2-Fluoro-phenyl)-ethylamino]-methyl}-phenoxy)-benzamide,  
4-(4-{[2-(2,5-Dimethoxy-phenyl)-ethylamino]-methyl}-phenoxy)-benzamide,  
4-(4-{[2-(2,6-Dichloro-phenyl)-ethylamino]-methyl}-phenoxy)-benzamide,  
4-{4-[(2-o-Tolyl-ethylamino)-methyl]-phenoxy}-benzamide,  
4-{4-[(2,2-Diphenyl-ethylamino)-methyl]-phenoxy}-benzamide,  
4-[4-(3-Phenyl-propylamino)-phenoxy]-benzamide,  
4-{4-[(2-Cyclopentyl-ethylamino)-methyl]-phenoxy}-benzamide,  
4-{4-[(2,6-Dichloro-benzylamino)-methyl]-phenoxy}-benzamide,  
4-(4-{[(Furan-2-ylmethyl)-amino]-methyl}-phenoxy)-benzamide,  
6-(4-{[2-(3,4-Dichloro-phenyl)-ethylamino]-methyl}-phenoxy)-nicotinamide,  
6-(4-{[2-(2-Ethoxy-phenyl)-ethylamino]-methyl}-phenoxy)-nicotinamide,  
6-{4-[(2-o-Tolyl-ethylamino)-methyl]-phenoxy}-nicotinamide,  
6-(4-{[2-(2-Phenoxy-phenyl)-ethylamino]-methyl}-phenoxy)-nicotinamide,

6-[4-((2-Thiophenyl-ethylamino)-methyl)-2-ethoxy phenoxy] nicotinamide,  
6-[4-((3-Methyl-butylamino)-methyl)-2-ethoxy phenoxy] nicotinamide  
methanesulfonate salt,  
6-[4-((3-Dimethyl-butylamino)-methyl)-2-ethoxy phenoxy] nicotinamide,  
6-[4-(Butylamino-methyl)-2-ethoxy phenoxy] nicotinamide,  
6-[4-((2-Phenyl-ethylamino)-methyl)-2,5-dimethyl phenoxy] nicotinamide,  
6-[4-((2-Cyclopentyl-ethylamino)-methyl)-2-ethoxy phenoxy] nicotinamide  
metanesulfonate salt,  
6-[4-((3-Methyl-butylamino)-methyl)-2,5-dimethyl phenoxy] nicotinamide  
6-(4-Iodo-phenoxy)-nicotinamide,  
(±)-6-(4-Piperidin-3-yl-phenoxy)-nicotinamide,  
(±)-6-[4-(1-Benzyl-piperidin-3-yl)-phenoxy]-nicotinamide,  
(±)-6-[4-(1-Cyclohexylmethyl-piperidin-3-yl)-phenoxy]-nicotinamide,  
(±)-6-[4-(1-Methyl-piperidin-3-yl)-phenoxy]-nicotinamide,  
(±)-6-[4-(1-(3-Fluoro-benzyl)-piperidin-3-yl)-phenoxy]-nicotinamide,  
(±)-6-[4-(1-(2-Fluoro-benzyl)-piperidin-3-yl)-phenoxy]-nicotinamide,  
(±)-6-[4-(1-Hexyl-piperidin-3-yl)-phenoxy]-nicotinamide,  
(±)-6-{4-[1-(3-Methyl-butyl)-piperidin-3-yl]-phenoxy}-nicotinamide,  
(±)-6-[4-(1-Phenethyl-piperidin-3-yl)-phenoxy]-nicotinamide,  
(±)-6-{4-[1-(2-Cyclohexyl-ethyl)-piperidin-3-yl]-phenoxy}-nicotinamide,  
6-[4-(4-Benzyl-piperazin-1-ylmethyl)-phenoxy]-nicotinamide,  
6-[4-(4-Phenethyl-piperazin-1-ylmethyl)-phenoxy]-nicotinamide,  
6-[4-(4-Cyclopentyl-piperazin-1-ylmethyl)-phenoxy]-nicotinamide,  
(±)-6-{4-[4-(1-Phenyl-ethyl)-piperazin-1-ylmethyl]-phenoxy}-nicotinamide,  
6-[4-(4-Benzhydryl-piperazin-1-ylmethyl)-phenoxy]-nicotinamide,  
6-{4-[4-(4-Fluoro-phenyl)-piperazin-1-ylmethyl]-phenoxy}-nicotinamide,  
6-[4-(4-Phenyl-piperazin-1-ylmethyl)-phenoxy]-nicotinamide,  
6-[4-(4-Cyclohexyl-piperazin-1-ylmethyl)-phenoxy]-nicotinamide,

X-15876 PCT

# REPLACEMENT CLAIMS

565

6-[4-(4-Isopropyl-piperazin-1-ylmethyl)-phenoxy]-nicotinamide,  
 (3R)-6-{4-[(1-Benzyl-pyrrolidin-3-ylamino)-methyl]-phenoxy}-nicotinamide,  
 (3S)-6-{4-[(1-Benzyl-pyrrolidin-3-ylamino)-methyl]-phenoxy}-nicotinamide,  
 (±)-6-[4-(2-Phenyl-piperidin-1-ylmethyl)-phenoxy]-nicotinamide,  
 (±)-6-[4-(2-Phenyl-pyrrolidin-1-ylmethyl)-phenoxy]-nicotinamide, hydrochloric acid salt,  
 (±)-6-[4-(3-Phenyl-pyrrolidin-1-ylmethyl)-phenoxy]-nicotinamide,  
 6-[4-(4-Phenyl-piperidin-1-ylmethyl)-phenoxy]-nicotinamide,  
 (±)-6-[4-(3-Phenyl-azepan-1-ylmethyl)-phenoxy]-nicotinamide,  
 (±)-6-[4-(4-Phenyl-azepan-1-ylmethyl)-phenoxy]-nicotinamide,  
 6-[4-(4,4-Diphenyl-piperidin-1-ylmethyl)-phenoxy]-nicotinamide,  
 6-[4-(3,3-Diphenyl-pyrrolidin-1-ylmethyl)-phenoxy]-nicotinamide,  
 6-[4-(2,2-Diphenyl-pyrrolidin-1-ylmethyl)-phenoxy]-nicotinamide,  
 6-(4-Piperidin-1-ylmethyl)-phenoxy]-nicotinamide,  
 (±)-6-[4-(1,2,4,4a,9,9a-Hexahydro-3-aza-fluoren-3-ylmethyl)-phenoxy]-nicotinamide,  
 (±)-6-{4-[3-(2-Chloro-phenyl)-piperidin-1-ylmethyl]-phenoxy}-nicotinamide,  
 (±)-6-{4-[3-(3-Chloro-phenyl)-piperidin-1-ylmethyl]-phenoxy}-nicotinamide,  
 (±)-6-{4-[3-(3-Trifluoromethyl-phenyl)-piperidin-1-ylmethyl]-phenoxy}-nicotinamide,  
 (±)-6-[4-(3-Methyl-piperidin-1-ylmethyl)-phenoxy]-nicotinamide,  
 (±)-6-[4-(3-Phenethyl-piperidin-1-ylmethyl)-phenoxy]-nicotinamide,  
 (±)-6-[4-(3-Phenpropyl-piperidin-1-ylmethyl)-phenoxy]-nicotinamide,  
 (±)-6-[4-(3-Benzyl-piperidin-1-ylmethyl)-phenoxy]-nicotinamide,  
 (±)-6-[4-(3-Phenyl-piperidin-1-ylmethyl)-phenoxy]-nicotinamide,  
 (±)-6-{4-[3-(4-Fluoro-phenyl)-piperidin-1-ylmethyl]-phenoxy}-nicotinamide, hydrochloric acid salt,

X-15876 PCT

## REPLACEMENT CLAIMS

566

- (±)-6-{4-[3-(2-Fluoro-phenyl)-piperidin-1-ylmethyl]-phenoxy}-nicotinamide, hydrochloric acid salt,
- (±)-6-[4-(3-Cyclohexyl-piperidin-1-ylmethyl)-phenoxy]-nicotinamide, hydrochloric acid salt,
- (±)-6-[2-Methyl-4-(3-phenyl-piperidin-1-ylmethyl)-phenoxy]-nicotinamide, hydrochloric acid salt,
- (±)-6-[2-Methyl-4-(3-phenyl-azepan-1-ylmethyl)-phenoxy]-nicotinamide, hydrochloric acid salt,
- (±)-6-[2-Methyl-4-(4-phenyl-azepan-1-ylmethyl)-phenoxy]-nicotinamide,
- (±)-1-{6-[2-Methyl-4-(3-phenyl-pyrrolidin-1-ylmethyl)-phenoxy]-pyridin-3-yl}-ethanone,
- (±)-5-(1,1-Difluoro-ethyl)-2-[2-methyl-4-(3-phenyl-pyrrolidin-1-ylmethyl)-phenoxy]-pyridine hydrochloric acid salt,
- (±)-6-[2-Fluoro-4-(3-phenyl-pyrrolidin-1-ylmethyl)-phenoxy]-nicotinamide,
- (±)-6-[2-Ethoxy-4-(3-phenyl-pyrrolidin-1-ylmethyl)-phenoxy]-nicotinamide,
- (±)-6-[2-Chloro-4-(3-phenyl-pyrrolidin-1-ylmethyl)-phenoxy]-nicotinamide,
- 6-(3-Phenethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)nicotinamide,
- 6-(3-Benzyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)-nicotinamide,
- 6-[4-(Phenethylaminomethyl)phenoxy]nicotinamide,
- {2-[4-(5-Aminomethylpyridin-2-yloxy)phenyl]ethyl} benzylamine,
- 5-[4-(Phenethylaminomethyl)phenoxy]pyridine-2-carboxamide,
- 2-[4-(2-Benzylaminoethyl)phenoxy]nicotinamide,
- 6-[4-(2-Benzylaminoethyl)phenoxy]pyridine-2-carboxamide,
- 2-[4-(2-Benzylaminoethyl)phenoxy]isonicotinamide,
- N-Methyl-{6-[4-(phenethylaminomethyl)phenoxy]nicotinamide,
- 5-[4-(Phenethylaminomethyl)phenoxy]pyrazine-2-carboxamide,
- 5-(4-{[2-(4-Fluorophenyl)ethylamino]methyl}phenoxy)pyridine-2-carboxamide,

- 5-{4-[(3-Methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide  
methanesulfonate,
- 5-{2-Methyl-4-[(3-methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide  
methanesulfonate,
- 5-{2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide  
methanesulfonate,
- 5-(4-{[2-(3-Trifluoromethylphenyl)ethylamino]methyl}phenoxy)pyridine-2-  
carboxamide methanesulfonate,
- 5-{4-[(2-Thiophen-2-ylethylamino)methyl]phenoxy}pyridine-2-carboxamide  
methanesulfonate,
- 5-{2-Methyl-4-[(2-thiophen-2-ylethylamino)methyl]phenoxy}pyridine-2-  
carboxamide methanesulfonate,
- 5-{2-Methoxy-4-[(2-thiophen-2-ylethylamino)methyl]phenoxy}pyridine-2-  
carboxamide methanesulfonate,
- 5-{4-[(2-Cyclopentylethylamino)methyl]phenoxy}pyridine-2-carboxamide  
methanesulfonate,
- 5-{4-[(2-Cyclopentylethylamino)methyl]-2-methylphenoxy}pyridine-2-  
carboxamide methanesulfonate,
- 5-{4-[(2-Cyclopentylethylamino)methyl]-2-methoxyphenoxy}pyridine-2-  
carboxamide methanesulfonate,
- 5-(4-{[(Benzo[b]thiophen-3-ylmethyl)amino]methyl}phenoxy)pyridine-2-  
carboxamide methanesulfonate,
- 5-(4-{[2-(4-Methoxyphenyl)ethylamino]methyl}phenoxy)pyridine-2-  
carboxamide methanesulfonate,
- 5-(4-{[2-(3-Fluorophenyl)ethylamino]methyl}phenoxy)pyridine-2-carboxamide  
methanesulfonate,
- 5-(4-{[2-(2-Fluorophenyl)ethylamino]methyl}phenoxy)pyridine-2-carboxamide  
methanesulfonate,

X-15876 PCT

## REPLACEMENT CLAIMS

568

- 5-{2-Fluoro-4-[(3-methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide  
methanesulfonate,
- 5-{2-Methyl-4-[(3-methylbutylamino)methyl]phenoxy}pyrazine-2-carboxamide  
methanesulfonate,
- 5-(2-Fluoro-4-pentylaminomethylphenoxy)pyridine-2-carboxamide
- 5-{2-Fluoro-4-[(2-thiophen-2-ylethylamino)methyl]phenoxy} pyridine-2-  
carboxamide,
- 5-{2-Fluoro-4-[(2-pyridin-3-ylethylamino)methyl]phenoxy} pyridine-2-  
carboxamide,
- 5-{2-Fluoro-4-[(2-*m*-tolylethylamino)methyl]phenoxy}pyridine-2-carboxamide,
- 5-(2-Fluoro-4-{[2-(4-fluorophenyl)ethylamino]methyl}phenoxy)pyridine-2-  
carboxamide,
- 5-{2-Chloro-4-[(3-methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide,
- 5-(2-Chloro-4-(pentylaminomethyl)phenoxy)pyridine-2-carboxamide,
- 5-{2-Chloro-4-[(2-thiophen-2-ylethylamino)methyl]phenoxy}pyridine-2-  
carboxamide,
- 5-{2-Chloro-4-[(2-pyridin-3-ylethylamino)methyl]phenoxy}pyridine-2-  
carboxamide,
- 6-{2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy}nicotinamide,
- 5-(2-Fluoro-4-{[2-(tetrahydropyran-4-yl)ethylamino]methyl}phenoxy)pyridine-2-  
carboxamide,
- 5-{2-Fluoro-4-[(2-*o*-tolylethylamino)methyl]phenoxy}pyridine-2-carboxamide,
- 5-{4-[(2-Naphthalen-2-ylethylamino)methyl]phenoxy}pyridine-2-carboxamide,
- 5-{4-[(2-Naphthalen-1-ylethylamino)methyl]phenoxy}pyridine-2-carboxamide,
- 5-{4-[(2-Benzo[*b*]thiophen-3-ylethylamino)methyl]phenoxy}pyridine-2-  
carboxamide,
- 6-(2-Methoxy-4-pentylaminomethylphenoxy)nicotinamide,
- 6-{2-Methoxy-4-[(2-thiophen-2-ylethylamino)methyl]phenoxy}nicotinamide,
- 6-{2-Methoxy-4-[(2-*o*-tolylethylamino)methyl]phenoxy}nicotinamide,

6-{2-Methoxy-4-[(2-*m*-tolylethylamino)methyl]phenoxy}nicotinamide,  
6-{4-[(3,3-Dimethylbutylamino)methyl]-2-methoxyphenoxy}nicotinamide,  
6-{2-Methoxy-4-[(2-pyridin-3-ylethylamino)methyl]phenoxy}nicotinamide,  
6-(4-Butylaminomethyl-2-methoxyphenoxy)nicotinamide,  
6-(2-Methoxy-4-{[2-(tetrahydropyran-4-yl)ethylamino]methyl}phenoxy)nicotinamide,  
6-{2-Methoxy-4-[(2-morpholin-4-ylethylamino)methyl]phenoxy}nicotinamide,  
6-{4-[(2-Ethylbutylamino)methyl]-2-methoxyphenoxy}nicotinamide,  
6-(4-{[2-(4-Fluorophenyl)ethylamino]methyl}-2-methoxyphenoxy)nicotinamide,  
6-(4-{[2-(2-Fluorophenyl)ethylamino]methyl}-2-methoxyphenoxy)nicotinamide,  
6-(4-Hexylaminomethyl-2-methoxyphenoxy)nicotinamide,  
6-{2-Methoxy-4-[(4-methylpentylamino)methyl]phenoxy}nicotinamide  
methanesulfonate,  
6-{2-Methoxy-4-[(2-*p*-tolylethylamino)methyl]phenoxy}nicotinamide  
methanesulfonate,  
5-(2-Methyl-4-{[2-(tetrahydropyran-4-yl)ethylamino]methyl}phenoxy)pyrazine-  
2-carboxamide,  
5-{4-[(3,3-Dimethylbutylamino)methyl]-2-methylphenoxy}pyrazine-2-  
carboxamide,  
5-{4-[(3-Methylbutylamino)methyl]phenoxy}pyrazine-2-carboxamide,  
5-(4-{[2-(Tetrahydropyran-4-yl)ethylamino]methyl}phenoxy)pyrazine-2-  
carboxamide;  
5-{4-[(3,3-Dimethylbutylamino)methyl]phenoxy}pyrazine-2-carboxamide,  
6-(2-Methoxy-4-{[2-(tetrahydropyran-4-yl)ethylamino]methyl}phenoxy)nicotinamide methanesulfonate,  
6-(4-Hexylaminomethyl-2-methoxyphenoxy)nicotinamide methanesulfonate,  
6-(2-Methoxy-4-pentylaminomethylphenoxy)nicotinamide methanesulfonate,  
6-(4-Butylaminomethyl-2-methoxyphenoxy)nicotinamide methanesulfonate,



- 6-{2-Methoxy-4-[(2-pyridin-3-ylethylamino)methyl]phenoxy}nicotinamide methanesulfonate,
- 6-{4-[(2-Ethylbutylamino)methyl]-2-methoxyphenoxy}nicotinamide methanesulfonate,
- 6-{4-[(3,3-Dimethylbutylamino)methyl]-2-methoxyphenoxy}nicotinamide methanesulfonate,
- 6-{2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy}nicotinamide methanesulfonate,
- 6-(2-Phenethyl-2,3,4,5-tetrahydro-1*H*-benzo[*c*]azepin-7-yloxy)nicotinamide,
- 6-[2-(3-Methylbutyl)-2,3,4,5-tetrahydro-1*H*-benzo[*c*]azepin-7-yloxy]nicotinamide,
- 6-[2-(3-Methylpentyl)-2,3,4,5-tetrahydro-1*H*-benzo[*c*]azepin-7-yloxy]nicotinamide,
- (±)-6-{4-[2-(2-Hydroxycyclohexylamino)ethyl]phenoxy}nicotinamide,
- (±)-(cis)-6-{4-[2-(3-Hydroxycyclohexylamino)ethyl]phenoxy}nicotinamide,
- (±)-(trans)-6-{4-[2-(3-Hydroxycyclohexylamino)ethyl]phenoxy}nicotinamide,
- (±)-6-{4-[2-((trans)-4-Hydroxycyclohexylamino)ethyl]phenoxy}nicotinamide,
- (±)-6-{4-[2-((trans)-2-Hydroxycyclopentylamino)ethyl]phenoxy}nicotinamide,
- 4-[5-(Phenethylamino-methyl)-pyridin-2-yloxy]-benzamide dihydrochloride 4-{5-[(3-Trifluoromethyl-benzylamino)-methyl]-pyridin-2-yloxy}-benzamide 4-{5-[(3-Phenyl-propylamino)-methyl]-pyridin-2-yloxy}-benzamide.
- 4-{5-[(4-Fluoro-benzylamino)-methyl]-pyridin-2-yloxy}-benzamide 4-[5-(Isobutylamino-methyl)-pyridin-2-yloxy]-benzamide 4-{5-[(2-Thiophen-2-ylethylamino)-methyl]-pyridin-2-yloxy}-benzamide
- 4-(5-{[2-(3-Fluoro-phenyl)-ethylamino]-methyl}-pyridin-2-yloxy)-benzamide
- 4-(5-{[2-(2-Methoxy-phenyl)-ethylamino]-methyl}-pyridin-2-yloxy)-benzamide
- 4-(5-{[2-(2-Chloro-phenyl)-ethylamino]-methyl}-pyridin-2-yloxy)-benzamide 4-[5-(3-Phenyl-pyrrolidin-1-ylmethyl)-pyridin-2-yloxy]-benzamide 4-{5-[(3,3-

X-15876 PCT

## REPLACEMENT CLAIMS

571

Dimethyl-butylamino)-methyl]-pyridin-2-yloxy}-benzamide 4-{5-[(3-Methyl-butylamino)-methyl]-pyridin-2-yloxy}-benzamide

4-{3-Chloro-5-[(2-thiophen-2-yl-ethylamino)-methyl]-pyridin-2-yloxy}-benzamide

4-(3-Chloro-5-{[2-(3-chloro-phenyl)-ethylamino]-methyl}-pyridin-2-yloxy)-benzamide

and pharmaceutically acceptable salts, solvates, enantiomers, and mixtures of diastereomers thereof.

41. Use of a compound selected from the group consisting of:

6-{4-[2-(Benzyl-phenethyl-amino)-ethyl]-phenoxy}-nicotinamide,

6-(4-{2-[Benzyl-(3-phenyl-propyl)-amino]-ethyl}-phenoxy)-nicotinamide,

6-{4-[2-(Benzyl-hexyl-amino)-ethyl]-phenoxy}-nicotinamide,

6-{4-[2-(Benzyl-heptyl-amino)-ethyl]-phenoxy}-nicotinamide,

6-(4-{2-[Benzyl-(5-methyl-hexyl)-amino]-ethyl}-phenoxy)-nicotinamide,

6-[4-(2-{Benzyl-[2-(3-chloro-phenyl)-ethyl]-amino}-ethyl)-phenoxy]-nicotinamide,

6-(4-{2-[Benzyl-(3-cyclohexyl-propyl)-amino]-ethyl}-phenoxy)-nicotinamide,

6-(4-{2-[Benzyl-(3-o-tolyl-propyl)-amino]-ethyl}-phenoxy)-nicotinamide,

6-(4-{2-[Benzyl-(3-thiophen-2-yl-propyl)-amino]-ethyl}-phenoxy)-nicotinamide,

6-{4-[2-(Benzyl-pentyl-amino)-ethyl]-phenoxy}-nicotinamide,

6-(4-{2-[Benzyl-(3-cyclopentyl-propyl)-amino]-ethyl}-phenoxy)-nicotinamide,

6-[4-(2-{Benzyl-[2-(2-fluoro-phenyl)-ethyl]-amino}-ethyl)-phenoxy]-nicotinamide,

6-[4-(2-Dibenzylamino-ethyl)-phenoxy]-nicotinamide,

6-(4-{2-[Benzyl-(3-oxo-3-phenyl-propyl)-amino]-ethyl}-phenoxy)-nicotinamide,

6-(4-{2-[Benzyl-(3-oxo-3-thiophen-2-yl-propyl)-amino]-ethyl}-phenoxy)-nicotinamide,

- 6-(4-{2-[Benzyl-(3-cyclohexyl-3-oxo-propyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-(4-{2-[Benzyl-(3-hydroxy-3-phenyl-propyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-(4-{2-[Benzyl-(3-hydroxy-3-thiophen-2-yl-propyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-(4-{2-[Benzyl-(3-cyclohexyl-3-hydroxy-propyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-{4-[2-(3-Phenyl-propylamino)-ethyl]-phenoxy}-nicotinamide,  
6-[4-(2-Phenethylamino-ethyl)-phenoxy]-nicotinamide,  
6-[4-(2-Hexylamino-ethyl)-phenoxy]-nicotinamide,  
6-[4-(2-Heptylamino-ethyl)-phenoxy]-nicotinamide,  
6-[4-(2-Pentylamino-ethyl)-phenoxy]-nicotinamide,  
6-{4-[2-(5-Methyl-hexylamino)-ethyl]-phenoxy}-nicotinamide,  
6-(4-{2-[2-(3-Chloro-phenyl)-ethylamino]-ethyl}-phenoxy)-nicotinamide,  
6-{4-[2-(3-Cyclopentyl-propylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Cyclohexyl-propylamino)-ethyl]-phenoxy}-nicotinamide,  
6-(4-{2-[2-(3-Fluoro-phenyl)-ethylamino]-ethyl}-phenoxy)-nicotinamide,  
6-{4-[2-(3-o-Tolyl-propylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Thiophen-2-yl-propylamino)-ethyl]-phenoxy}-nicotinamide,  
6-[4-(2-Amino-ethyl)-phenoxy]-nicotinamide,  
6-{4-[2-(2-Methoxy-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Fluoro-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Chloro-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3,4-Dichloro-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Trifluoromethyl-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(4-Cyano-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(4-Fluoro-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(4-Methyl-benzylamino)-ethyl]-phenoxy}-nicotinamide,

X-15876 PCT

## REPLACEMENT CLAIMS

573

6-{4-[2-(3,5-Bis-trifluoromethyl-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(2,6-Difluoro-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3,5-Difluoro-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(4-Acetylamino-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(2-Trifluoromethyl-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(2-Methyl-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Methoxy-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(4-Chloro-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(4-Phenoxy-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(4-Methoxy-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(4-Trifluoromethyl-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Oxo-2,3-dihydro-1H-isoindol-1-ylamino)-ethyl]-phenoxy}-  
nicotinamide,  
6-{4-[2-(4-Trifluoromethoxy-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Trifluoromethoxy-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-(4-{2-[(Thiophen-2-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-(4-{2-[(Furan-2-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-[4-(2-Octylamino-ethyl)-phenoxy]-nicotinamide,  
6-[4-(2-Cyclohexylamino-ethyl)-phenoxy]-nicotinamide,  
6-{4-[2-(Cyclohexylmethyl-amino)-ethyl]-phenoxy}-nicotinamide,  
6-[4-(2-Propylamino-ethyl)-phenoxy]-nicotinamide,  
6-[4-(2-Butylamino-ethyl)-phenoxy]-nicotinamide,  
6-[4-(2-Isopropylamino-ethyl)-phenoxy]-nicotinamide,  
6-[4-(2-Isobutylamino-ethyl)-phenoxy]-nicotinamide,  
6-{4-[2-(3-Methyl-butylamino)-ethyl]-phenoxy}-nicotinamide,  
6-(4-{2-[(Pyridin-4-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-(4-{2-[(Pyridin-2-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-(4-{2-[(5-Methyl-furan-2-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-(4-{2-[(3-Methyl-thiophen-2-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,

6-(4-{2-[(5-Methyl-thiophen-2-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-(4-{2-[(Thiophen-3-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-[4-(2-Ethylamino-ethyl)-phenoxy]-nicotinamide,  
6-{4-[2-(4-Hydroxy-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Hydroxy-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Phenyl-prop-2-ynylamino)-ethyl]-phenoxy}-nicotinamide,  
6-(4-{2-[(Furan-3-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-(4-{2-[(Benzofuran-2-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-(4-{2-[(5-Ethyl-furan-2-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-(4-{2-[(5-Chloro-thiophen-2-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-(4-{2-[(4,5-Dimethyl-furan-2-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-(4-{2-[(4-Chloro-1-methyl-1H-pyrazol-3-ylmethyl)-amino]-ethyl}-phenoxy)-  
nicotinamide,  
6-(4-{2-[(Thiazol-2-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-(4-{2-[(2-Methyl-1H-imidazol-4-ylmethyl)-amino]-ethyl}-phenoxy)-  
nicotinamide,  
6-{4-[2-(3,5-Di-tert-butyl-4-hydroxy-benzylamino)-ethyl]-phenoxy}-  
nicotinamide,  
6-{4-[2-(2-Fluoro-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Phenoxy-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(2-Chloro-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Cyano-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Methyl-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-(4-{2-[(1H-Imidazol-4-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-(4-{2-[(Pyridin-3-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-{4-[2-(2-Phenoxy-ethylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Fluoro-4-hydroxy-benzylamino)-ethyl]-phenoxy}-nicotinamide,  
6-(4-{2-[(2-Butyl-1H-imidazol-4-ylmethyl)-amino]-ethyl}-phenoxy)-  
nicotinamide,

X-15876 PCT

# REPLACEMENT CLAIMS

575

- 6-(4-{2-[(Benzo[b]thiophen-3-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,
- 6-(4-{2-[(3-Phenyl-1H-pyrazol-4-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,
- 6-[4-(2-Allylamino-ethyl)-phenoxy]-nicotinamide,
- 6-{4-[2-(4-Imidazol-1-yl-benzylamino)-ethyl]-phenoxy}-nicotinamide,
- 6-(4-{2-[(3-Methyl-benzo[b]thiophen-2-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,
- 6-{4-[2-(4-Methyl-pent-2-enylamino)-ethyl]-phenoxy}-nicotinamide,
- 6-{4-[2-(2-Trifluoromethoxy-benzylamino)-ethyl]-phenoxy}-nicotinamide,
- 6-(4-{2-[(2-Piperidin-1-yl-thiazol-5-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,
- 6-{4-[2-(4-Cyclohexyl-butylamino)-ethyl]-phenoxy}-nicotinamide,
- 6-{4-[2-(2-Cyclohexyl-ethylamino)-ethyl]-phenoxy}-nicotinamide,
- 6-{4-[2-(2-Chloro-6-fluoro-benzylamino)-ethyl]-phenoxy}-nicotinamide,
- 6-{4-[2-(Cyclopropylmethyl-amino)-ethyl]-phenoxy}-nicotinamide,
- 6-(4-{2-[(Naphthalen-1-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,
- 6-(4-{2-[(Bicyclo[2.2.1]hept-5-en-2-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,
- 6-(4-{2-[(Naphthalen-2-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,
- 6-(4-{2-[(Quinolin-4-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,
- 6-{4-[2-(2,6-Dichloro-benzylamino)-ethyl]-phenoxy}-nicotinamide,
- 6-{4-[2-(Indan-1-ylamino)-ethyl]-phenoxy}-nicotinamide,
- 6-{4-[2-(2-Hydroxy-5-methoxy-benzylamino)-ethyl]-phenoxy}-nicotinamide,
- 6-{4-[2-(3-Bromo-4-fluoro-benzylamino)-ethyl]-phenoxy}-nicotinamide,
- 6-{4-[2-(4-Fluoro-2-trifluoromethyl-benzylamino)-ethyl]-phenoxy}-nicotinamide,
- 6-{4-[2-(3-Chloro-4-fluoro-benzylamino)-ethyl]-phenoxy}-nicotinamide,
- 6-[4-(2-Cyclooctylamino-ethyl)-phenoxy]-nicotinamide,
- 6-{4-[2-(2-Phenoxy-benzylamino)-ethyl]-phenoxy}-nicotinamide,
- 6-{4-[2-(Cyclobutylmethyl-amino)-ethyl]-phenoxy}-nicotinamide,

- 6-{4-[2-(Cycloheptylmethyl-amino)-ethyl]-phenoxy}-nicotinamide,  
6-(4-{2-[(2-Morpholin-4-yl-thiazol-5-ylmethyl)-amino]-ethyl}-phenoxy)-  
nicotinamide,  
6-(4-{2-[(2,4-Dichloro-thiazol-5-ylmethyl)-amino]-ethyl}-phenoxy)-  
nicotinamide,  
6-(4-{2-[(2-Chloro-thiazol-5-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-{4-[2-(Cyclopentylmethyl-amino)-ethyl]-phenoxy}-nicotinamide,  
6-(4-{2-[(3,5-Dimethyl-isoxazol-4-ylmethyl)-amino]-ethyl}-phenoxy)-  
nicotinamide,  
6-(4-{2-[(5-Methyl-isoxazol-3-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-(4-{2-[(3-Phenyl-isoxazol-5-ylmethyl)-amino]-ethyl}-phenoxy)-nicotinamide,  
6-[4-(2-{[3-(4-Chloro-phenyl)-[1,2,4]oxadiazol-5-ylmethyl]-amino}-ethyl)-  
phenoxy]-nicotinamide,  
6-(4-{2-[(5-p-Tolyl-[1,3,4]oxadiazol-2-ylmethyl)-amino]-ethyl}-phenoxy)-  
nicotinamide,  
6-{4-[2-(1-Phenyl-ethylamino)-ethyl]-phenoxy}-nicotinamide,  
6-[4-(3-Benzylamino-propyl)-phenoxy]-nicotinamide,  
6-{4-[3-(Benzyl-pentyl-amino)-propyl]-phenoxy}-nicotinamide,  
6-{4-[3-(Benzyl-phenethyl-amino)-propyl]-phenoxy}-nicotinamide,  
6-(4-{3-[Benzyl-(3-cyclopentyl-propyl)-amino]-propyl}-phenoxy)-nicotinamide,  
6-[4-(3-{Benzyl-[2-(3-fluoro-phenyl)-ethyl]-amino}-propyl)-phenoxy]-  
nicotinamide,  
6-[4-(3-Pentylamino-propyl)-phenoxy]-nicotinamide,  
6-[4-(3-Phenethylamino-propyl)-phenoxy]-nicotinamide,  
6-{4-[3-(3-Cyclopentyl-propylamino)-propyl]-phenoxy}-nicotinamide,  
6-(4-{3-[2-(3-Fluoro-phenyl)-ethylamino]-propyl}-phenoxy)-nicotinamide,  
(R)-6-[4-(2-Benzylamino-propyl)-phenoxy]-nicotinamide,  
(R)-6-[4-(2-Dibenzylamino-propyl)-phenoxy]-nicotinamide,  
6-[4-(2-Benzylamino-2-methyl-propyl)-phenoxy]-nicotinamide,

6-[4-(2-Methyl-2-pentylamino-propyl)-phenoxy]-nicotinamide,  
6-[4-(2-Methyl-2-phenethylamino-propyl)-phenoxy]-nicotinamide,  
6-(4-{2-[2-(3-Fluoro-phenyl)-ethylamino]-2-methyl-propyl}-phenoxy)-  
nicotinamide,  
6-{4-[2-(3'-Cyclopentyl-propylamino)-2-methyl-propyl]-phenoxy}-nicotinamide,  
6-[4-(3-Benzylamino-butyl)-phenoxy]-nicotinamide,  
6-[4-(3-Pentylamino-butyl)-phenoxy]-nicotinamide,  
6-[4-(3-Propylamino-butyl)-phenoxy]-nicotinamide,  
6-[4-(3-Methylamino-butyl)-phenoxy]-nicotinamide,  
6-[4-(3-Phenethylamino-butyl)-phenoxy]-nicotinamide,  
6-(4-{3-[2-(3-Fluoro-phenyl)-ethylamino]-butyl}-phenoxy)-nicotinamide,  
6-(4-{3-[2-(3-Chloro-phenyl)-ethylamino]-butyl}-phenoxy)-nicotinamide,  
6-(4-{3-[(Furan-2-yl)methyl]-amino}-butyl)-phenoxy)-nicotinamide,  
6-{4-[3-(2-Thiophen-2-yl-ethylamino)-butyl]-phenoxy}-nicotinamide,  
6-{4-[3-(Cyclopropylmethyl-amino)-butyl]-phenoxy}-nicotinamide,  
6-{4-[3-(3-Trifluoromethyl-benzylamino)-butyl]-phenoxy}-nicotinamide,  
6-{4-[3-(4-Fluoro-benzylamino)-butyl]-phenoxy}-nicotinamide,  
6-{4-[3-(3-Fluoro-benzylamino)-butyl]-phenoxy}-nicotinamide,  
6-[4-(3-Allylamino-butyl)-phenoxy]-nicotinamide,  
6-{4-[3-(4-Chloro-benzylamino)-butyl]-phenoxy}-nicotinamide,  
6-{4-[3-(4-Methoxy-benzylamino)-butyl]-phenoxy}-nicotinamide,  
6-{4-[3-(4-Trifluoromethyl-benzylamino)-butyl]-phenoxy}-nicotinamide,  
6-{4-[3-(4-Trifluoromethoxy-benzylamino)-butyl]-phenoxy}-nicotinamide,  
6-{4-[3-(3-Trifluoromethoxy-benzylamino)-butyl]-phenoxy}-nicotinamide;  
(1R)-6-{4-[3-(1-Phenyl-ethylamino)-butyl]-phenoxy}-nicotinamide,  
(1S)-6-{4-[3-(1-Phenyl-ethylamino)-butyl]-phenoxy}-nicotinamide,  
6-[4-(2-Benzylamino-propyl)-phenoxy]-nicotinamide,  
6-[4-(2-Pentylamino-propyl)-phenoxy]-nicotinamide,  
6-[4-(2-Propylamino-propyl)-phenoxy]-nicotinamide,



- 6-[4-(2-Methylamino-propyl)-phenoxy]-nicotinamide,  
6-[4-(2-Phenethylamino-propyl)-phenoxy]-nicotinamide,  
6-[4-{2-[2-(3-Fluoro-phenyl)-ethylamino]-propyl}-phenoxy]-nicotinamide,  
6-[4-{2-[2-(3-Chloro-phenyl)-ethylamino]-propyl}-phenoxy]-nicotinamide,  
6-[4-{2-[(Furan-2-ylmethyl)-amino]-propyl}-phenoxy]-nicotinamide,  
6-[4-[2-(2-Thiophen-2-yl-ethylamino)-propyl]-phenoxy]-nicotinamide,  
6-[4-[2-(Cyclopropylmethyl-amino)-propyl]-phenoxy]-nicotinamide,  
6-[4-[2-(3-Trifluoromethyl-benzylamino)-propyl]-phenoxy]-nicotinamide,  
6-[4-[2-(4-Fluoro-benzylamino)-propyl]-phenoxy]-nicotinamide,  
6-[4-[2-(3-Fluoro-benzylamino)-propyl]-phenoxy]-nicotinamide,  
6-[4-(2-Allylamino-propyl)-phenoxy]-nicotinamide,  
6-[4-[2-(4-Chloro-benzylamino)-propyl]-phenoxy]-nicotinamide,  
6-[4-[2-(4-Trifluoromethyl-benzylamino)-propyl]-phenoxy]-nicotinamide,  
6-[4-[2-(4-Methoxy-benzylamino)-propyl]-phenoxy]-nicotinamide,  
6-[4-[2-(4-Trifluoromethoxy-benzylamino)-propyl]-phenoxy]-nicotinamide,  
6-[4-[2-(3-Trifluoromethoxy-benzylamino)-propyl]-phenoxy]-nicotinamide,  
(1S)-6-[4-[2-(1-Phenyl-ethylamino)-propyl]-phenoxy]-nicotinamide,  
(1R)-6-[4-[2-(1-Phenyl-ethylamino)-propyl]-phenoxy]-nicotinamide,  
6-[4-(2-Benzylamino-1-methyl-ethyl)-phenoxy]-nicotinamide,  
6-[4-[2-(Benzyl-pentyl-amino)-1-methyl-ethyl]-phenoxy]-nicotinamide,  
6-[4-(1-Methyl-2-pentylamino-ethyl)-phenoxy]-nicotinamide,  
6-[4-(2-Benzylamino-1,1-dimethyl-ethyl)-phenoxy]-nicotinamide,  
6-[4-[2-(Cyclohexylmethyl-amino)-1,1-dimethyl-ethyl]-phenoxy]-nicotinamide,  
6-[4-[2-(2-Chloro-benzylamino)-1,1-dimethyl-ethyl]-phenoxy]-nicotinamide,  
6-[4-[2-(3-Fluoro-benzylamino)-1,1-dimethyl-ethyl]-phenoxy]-nicotinamide,  
6-[4-(3-Phenylamino-propyl)-phenoxy]-nicotinamide,  
6-[4-(2-Dimethylamino-ethyl)-phenoxy]-nicotinamide,  
6-[4-(2-Piperidin-1-yl-ethyl)-phenoxy]-nicotinamide,  
6-[4-(2-Morpholin-1-yl-ethyl)-phenoxy]-nicotinamide,

6-{4-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(4-Benzoyl-piperidin-1-yl)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Methyl-piperidin-1-yl)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3,5-Dimethyl-piperidin-1-yl)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(4-Benzhydryl-piperidin-1-yl)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(4-Phenyl-piperidin-1-yl)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(3-Fluoro-phenyl)-piperidin-1-yl]-ethyl}-phenoxy}-nicotinamide,  
6-[4-(2-Azepan-1-yl-ethyl)-phenoxy]-nicotinamide,  
6-{4-[2-(Benzyl-methyl-amino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(Benzyl-ethyl-amino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(Benzyl-propyl-amino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(Benzyl-butyl-amino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(Benzyl-cyclopropylmethylamino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(Benzyl-isobutyl-amino)-ethyl]-phenoxy}-nicotinamide,  
6-{4-[2-(Benzyl-(3-methyl-butyl)-amino)-ethyl]-phenoxy}-nicotinamide,  
6-[4-(2-Benzoylamino-ethyl)-phenoxy]-nicotinamide,  
4-[4-(2-Benzylamino-ethyl)-phenoxy]-2-fluoro-benzamide,  
2-[4-(2-Benzylamino-ethyl)-phenoxy]-4-fluoro-benzamide,  
4-[4-(2-Benzylamino-ethyl)-phenoxy]-2-chloro-benzamide,  
6-[4-(2-Benzylamino-ethyl)-2-methyl-phenoxy]-nicotinamide,  
6-[2-Methyl-4-(phenethylamino-methyl)-phenoxy]nicotinamide,  
6-[2-Fluoro-4-(phenethylamino-methyl)-phenoxy]nicotinamide,  
6-[2-Ethoxy-4-(phenethylamino-methyl)-phenoxy]nicotinamide,  
6-[2-Chloro-4-(phenethylamino-methyl)-phenoxy]nicotinamide,

6-[3-Chloro-4-(phenethylamino-methyl)-phenoxy]nicotinamide,  
6-[2-Methyl-4-(3-methyl-butylamino-methyl)-phenoxy]nicotinamide,  
6-[2-Fluoro-4-(3-methyl-butylamino-methyl)-phenoxy]nicotinamide,  
6-[2-Chloro-4-(3-methyl-butylamino-methyl)-phenoxy]nicotinamide,  
6-[2-Ethoxy-4-(3-methyl-butylamino-methyl)-phenoxy]nicotinamide,  
6-{4-[2-Cyclopentyl-ethylamino)-methyl]-2-methyl-phenoxy}-nicotinamide,  
6-{4-[2-Cyclopentyl-ethylamino)-methyl]-2-fluoro-phenoxy}-nicotinamide,  
6-{2-Chloro-4-[2-Cyclopentyl-ethylamino)-methyl]-phenoxy}-nicotinamide,  
6-{4-[2-Cyclopentyl-ethylamino)-methyl]-2-ethoxy-phenoxy}-nicotinamide,  
6-{2-Methyl-4-[2-thiophen-2-yl-ethylamino)-methyl]-phenoxy}-nicotinamide,  
6-(4-{[2-(3-Fluoro-phenyl)-ethylamino]-methyl}-2-methyl-phenoxy)-  
nicotinamide,  
6-{2-Methyl-4-[(2-o-tolyl-ethylamino)-methyl]-phenoxy}-nicotinamide,  
6-{4-[(3,3-Dimethyl-butylamino)-methyl]-2-methyl-phenoxy}-nicotinamide,  
6-(4-{[2-(3-Chloro-phenyl)-ethylamino]-methyl}-2-methyl-phenoxy)-  
nicotinamide,  
6-(4-Butylaminomethyl-2-methyl-phenoxy)-nicotinamide,  
6-(2-Methyl-4-[[methyl-(3-methyl-butyl)-amino]-methyl]-phenoxy)-  
nicotinamide,  
6-{2-Methyl-4-[(methyl-phenethyl-amino)-methyl]-phenoxy}-nicotinamide,  
3-Fluoro-4-[4-(phenethylamino-methyl)-phenoxy]-benzamide,  
3-Chloro-4-[4-(phenethylamino-methyl)-phenoxy]-benzamide,  
2-Chloro-4-[4-(phenethylamino-methyl)-phenoxy]-benzamide,  
3-Fluoro-4-{2-methyl-4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide,  
4-(4-Benzylamino-phenoxy)-benzamide,  
4-(4-Phenethylamino-phenoxy)-benzamide,  
6-[4-(Benzylamino-methyl)-phenoxy]-nicotinamide,  
6-(4-Allylaminomethyl-phenoxy)-nicotinamide,

X-15876 PCT

# REPLACEMENT CLAIMS

581

- 6-{4-[(4-Methoxy-benzylamino)-methyl]-phenoxy}-nicotinamide,
- 6-{4-[(3-Trifluoromethyl-benzylamino)-methyl]-phenoxy}-nicotinamide,
- 6-{4-[(2-Thiophen-2-yl-ethylamino)-methyl]-phenoxy}-nicotinamide,
- 6-{4-[(3-Fluoro-benzylamino)-methyl]-phenoxy}-nicotinamide,
- 6-{4-[(Furan-2-ylmethyl)-amino]-methyl}-phenoxy}-nicotinamide,
- 6-{4-[(2-(3-Fluoro-phenyl)-ethylamino)-methyl]-phenoxy}-nicotinamide,
- 6-{4-[(4-Trifluoromethoxy-benzylamino)-methyl]-phenoxy}-nicotinamide,
- 6-{4-(Phenethylamino-methyl)-phenoxy}-nicotinamide,
- 6-{4-[(2-(3-Chloro-phenyl)-ethylamino)-methyl]-phenoxy}-nicotinamide,
- 6-{4-[(2-(4-Sulfamoyl-phenyl)-ethylamino)-methyl]-phenoxy}-nicotinamide,
- 6-{4-[(3-Phenyl-propylamino)-methyl]-phenoxy}-nicotinamide,
- 6-{4-[(3,3-Diphenyl-propylamino)-methyl]-phenoxy}-nicotinamide,
- 6-{4-[(3,3-Dimethyl-butylamino)-methyl]-phenoxy}-nicotinamide,
- 6-{4-[(2-(2-Methoxy-phenyl)-ethylamino)-methyl]-phenoxy}-nicotinamide,
- 6-{4-[(2-Phenylamino-ethylamino)-methyl]-phenoxy}-nicotinamide,
- 6-{4-[(2-Phenyl-propylamino)-methyl]-phenoxy}-nicotinamide,
- 6-{4-[(2-Pyridin-2-yl-ethylamino)-methyl]-phenoxy}-nicotinamide,
- 6-{4-[(2-(2-Chloro-phenyl)-ethylamino)-methyl]-phenoxy}-nicotinamide,
- 6-{4-[(2-Pyridin-3-yl-ethylamino)-methyl]-phenoxy}-nicotinamide,
- 6-{4-[(2,2-Diphenyl-ethylamino)-methyl]-phenoxy}-nicotinamide,
- 6-{4-[(3-Methyl-butylamino)-methyl]-phenoxy}-nicotinamide,
- 6-{4-[(2-Cyclohexyl-ethylamino)-methyl]-phenoxy}-nicotinamide,
- 6-{4-[(2-Methylsulfanyl-ethylamino)-methyl]-phenoxy}-nicotinamide,
- 6-{4-[(6-Hydroxy-hexylamino)-methyl]-phenoxy}-nicotinamide,
- 6-{4-[(2-Dimethylamino-ethylamino)-methyl]-phenoxy}-nicotinamide,
- 6-(4-Decylaminomethyl)-phenoxy}-nicotinamide,
- 6-{4-[(2-Ethyl-hexylamino)-methyl]-phenoxy}-nicotinamide,
- 6-{4-[(Tetrahydro-furan-2-ylmethyl)-amino]-methyl}-phenoxy}-nicotinamide,
- 6-{4-[(2-Pyrrolidin-1-yl-ethylamino)-methyl]-phenoxy}-nicotinamide,

X-15876 PCT

## REPLACEMENT CLAIMS

582

6-(4-{[2-(1-Methyl-pyrrolidin-2-yl)-ethylamino]-methyl}-phenoxy)-nicotinamide,  
6-(4-{[2-(1H-Imidazol-4-yl)-ethylamino]-methyl}-phenoxy)-nicotinamide,  
6-(4-{[3-(2-Methyl-piperidin-1-yl)-propylamino]-methyl}-phenoxy)-  
nicotinamide,  
6-{4-[(2-Diisopropylamino-ethylamino)-methyl]-phenoxy}-nicotinamide,  
6-{4-[(2-Cyclohex-1-enyl-ethylamino)-methyl]-phenoxy}-nicotinamide,  
6-(4-Pentylaminomethyl-phenoxy)-nicotinamide,  
4-{4-[(4-Trifluoromethoxy-benzylamino)-methyl]-phenoxy}-benzamide,  
4-(4-{[2-(3-Chloro-phenyl)-ethylamino]-methyl}-phenoxy)-benzamide,  
4-{4-[(4-Trifluoromethyl-benzylamino)-methyl]-phenoxy}-benzamide,  
4-{4-[(4-Fluoro-benzylamino)-methyl]-phenoxy}-benzamide,  
4-(4-Pentylaminomethyl-phenoxy)-benzamide,  
4-{4-[(2-Phenyl-propylamino)-methyl]-phenoxy}-benzamide,  
4-(4-{[2-(2-Chloro-phenyl)-ethylamino]-methyl}-phenoxy)-benzamide,  
4-(4-{[2-(2,4-Dichloro-phenyl)-ethylamino]-methyl}-phenoxy)-benzamide,  
4-(4-{[2-(4-Fluoro-phenyl)-ethylamino]-methyl}-phenoxy)-benzamide,  
4-(4-{[2-(3-Fluoro-phenyl)-ethylamino]-methyl}-phenoxy)-benzamide,  
4-(4-{[2-(2-Fluoro-phenyl)-ethylamino]-methyl}-phenoxy)-benzamide,  
4-(4-{[2-(2,5-Dimethoxy-phenyl)-ethylamino]-methyl}-phenoxy)-benzamide,  
4-(4-{[2-(2,6-Dichloro-phenyl)-ethylamino]-methyl}-phenoxy)-benzamide,  
4-{4-[(2-o-Tolyl-ethylamino)-methyl]-phenoxy}-benzamide,  
4-{4-[(2,2-Diphenyl-ethylamino)-methyl]-phenoxy}-benzamide,  
4-[4-(3-Phenyl-propylamino)-phenoxy]-benzamide,  
4-{4-[(2-Cyclopentyl-ethylamino)-methyl]-phenoxy}-benzamide,  
4-{4-[(2,6-Dichloro-benzylamino)-methyl]-phenoxy}-benzamide,  
4-(4-{[(Furan-2-ylmethyl)-amino]-methyl}-phenoxy)-benzamide,  
6-(4-{[2-(3,4-Dichloro-phenyl)-ethylamino]-methyl}-phenoxy)-nicotinamide,  
6-(4-{[2-(2-Ethoxy-phenyl)-ethylamino]-methyl}-phenoxy)-nicotinamide,  
6-{4-[(2-o-Tolyl-ethylamino)-methyl]-phenoxy}-nicotinamide,

AMENDED SHEET

X-15876 PCT

## REPLACEMENT CLAIMS

583

6-(4-{[2-(2-Phenoxy-phenyl)-ethylamino]-methyl}-phenoxy)-nicotinamide,  
6-[4-((2-Thiophenyl-ethylamino)-methyl)-2-ethoxy phenoxy] nicotinamide,  
6-[4-((3-Methyl-butylamino)-methyl)-2-ethoxy phenoxy] nicotinamide  
methanesulfonate salt,  
6-[4-((3-Dimethyl-butylamino)-methyl)-2-ethoxy phenoxy] nicotinamide,  
6-[4-(Butylamino-methyl)-2-ethoxy phenoxy] nicotinamide,  
6-[4-((2-Phenyl-ethylamino)-methyl)-2,5-dimethyl phenoxy] nicotinamide,  
6-[4-((2-Cyclopentyl-ethylamino)-methyl)-2-ethoxy phenoxy] nicotinamide  
metanosulfonate salt,  
6-[4-((3-Methyl-butylamino)-methyl)-2,5-dimethyl phenoxy] nicotinamide  
6-(4-Iodo-phenoxy)-nicotinamide,  
(±)-6-(4-Piperidin-3-yl-phenoxy)-nicotinamide,  
(±)-6-[4-(1-Benzyl-piperidin-3-yl)-phenoxy]-nicotinamide,  
(±)-6-[4-(1-Cyclohexylmethyl-piperidin-3-yl)-phenoxy]-nicotinamide,  
(±)-6-[4-(1-Methyl-piperidin-3-yl)-phenoxy]-nicotinamide,  
(±)-6-[4-(1-(3-Fluoro-benzyl)-piperidin-3-yl)-phenoxy]-nicotinamide,  
(±)-6-[4-(1-(2-Fluoro-benzyl)-piperidin-3-yl)-phenoxy]-nicotinamide,  
(±)-6-[4-(1-Hexyl-piperidin-3-yl)-phenoxy]-nicotinamide,  
(±)-6-{4-[1-(3-Methyl-butyl)-piperidin-3-yl]-phenoxy}-nicotinamide,  
(±)-6-[4-(1-Phenethyl-piperidin-3-yl)-phenoxy]-nicotinamide,  
(±)-6-{4-[1-(2-Cyclohexyl-ethyl)-piperidin-3-yl]-phenoxy}-nicotinamide,  
6-[4-(4-Benzyl-piperazin-1-ylmethyl)-phenoxy]-nicotinamide,  
6-[4-(4-Phenethyl-piperazin-1-ylmethyl)-phenoxy]-nicotinamide,  
6-[4-(4-Cyclopentyl-piperazin-1-ylmethyl)-phenoxy]-nicotinamide,  
(±)-6-{4-[4-(1-Phenyl-ethyl)-piperazin-1-ylmethyl]-phenoxy}-nicotinamide,  
6-[4-(4-Benzhydryl-piperazin-1-ylmethyl)-phenoxy]-nicotinamide,  
6-{4-[4-(4-Fluoro-phenyl)-piperazin-1-ylmethyl]-phenoxy}-nicotinamide,  
6-[4-(4-Phenyl-piperazin-1-ylmethyl)-phenoxy]-nicotinamide,

X-15876 PCT

## REPLACEMENT CLAIMS

584

6-[4-(4-Cyclohexyl-piperazin-1-ylmethyl)-phenoxy]-nicotinamide,  
6-[4-(4-Isopropyl-piperazin-1-ylmethyl)-phenoxy]-nicotinamide,  
(3R)-6-{4-[(1-Benzyl-pyrrolidin-3-ylamino)-methyl]-phenoxy}-nicotinamide,  
(3S)-6-{4-[(1-Benzyl-pyrrolidin-3-ylamino)-methyl]-phenoxy}-nicotinamide,  
(±)-6-[4-(2-Phenyl-piperidin-1-ylmethyl)-phenoxy]-nicotinamide,  
(±)-6-[4-(2-Phenyl-pyrrolidin-1-ylmethyl)-phenoxy]-nicotinamide, hydrochloric acid salt,  
(±)-6-[4-(3-Phenyl-pyrrolidin-1-ylmethyl)-phenoxy]-nicotinamide,  
6-[4-(4-Phenyl-piperidin-1-ylmethyl)-phenoxy]-nicotinamide,  
(±)-6-[4-(3-Phenyl-azepan-1-ylmethyl)-phenoxy]-nicotinamide,  
(±)-6-[4-(4-Phenyl-azepan-1-ylmethyl)-phenoxy]-nicotinamide,  
6-[4-(4,4-Diphenyl-piperidin-1-ylmethyl)-phenoxy]-nicotinamide,  
6-[4-(3,3-Diphenyl-pyrrolidin-1-ylmethyl)-phenoxy]-nicotinamide,  
6-[4-(2,2-Diphenyl-pyrrolidin-1-ylmethyl)-phenoxy]-nicotinamide,  
6-(4-Piperidin-1-ylmethyl)-phenoxy)-nicotinamide,  
(±)-6-[4-(1,2,4,4a,9,9a-Hexahydro-3-aza-fluoren-3-ylmethyl)-phenoxy]-nicotinamide,  
(±)-6-{4-[3-(2-Chloro-phenyl)-piperidin-1-ylmethyl]-phenoxy}-nicotinamide,  
(±)-6-{4-[3-(3-Chloro-phenyl)-piperidin-1-ylmethyl]-phenoxy}-nicotinamide,  
(±)-6-{4-[3-(3-Trifluoromethyl-phenyl)-piperidin-1-ylmethyl]-phenoxy}-nicotinamide,  
(±)-6-[4-(3-Methyl-piperidin-1-ylmethyl)-phenoxy]-nicotinamide,  
(±)-6-[4-(3-Phenethyl-piperidin-1-ylmethyl)-phenoxy]-nicotinamide,  
(±)-6-[4-(3-Phenpropyl-piperidin-1-ylmethyl)-phenoxy]-nicotinamide,  
(±)-6-[4-(3-Benzyl-piperidin-1-ylmethyl)-phenoxy]-nicotinamide,  
(±)-6-[4-(3-Phenyl-piperidin-1-ylmethyl)-phenoxy]-nicotinamide,  
(±)-6-{4-[3-(4-Fluoro-phenyl)-piperidin-1-ylmethyl]-phenoxy}-nicotinamide hydrochloric acid salt,

X-15876 PCT

## REPLACEMENT CLAIMS

585

(±)-6-{4-[3-(2-Fluoro-phenyl)-piperidin-1-ylmethyl]-phenoxy}-nicotinamide hydrochloric acid salt,  
(±)-6-[4-(3-Cyclohexyl-piperidin-1-ylmethyl)-phenoxy]-nicotinamide hydrochloric acid salt,  
(±)-6-[2-Methyl-4-(3-phenyl-piperidin-1-ylmethyl)-phenoxy]-nicotinamide hydrochloric acid salt,  
(±)-6-[2-Methyl-4-(3-phenyl-azepan-1-ylmethyl)-phenoxy]-nicotinamide hydrochloric acid salt,  
(±)-6-[2-Methyl-4-(4-phenyl-azepan-1-ylmethyl)-phenoxy]-nicotinamide,  
(±)-1-{6-[2-Methyl-4-(3-phenyl-pyrrolidin-1-ylmethyl)-phenoxy]-pyridin-3-yl}-ethanone,  
(±)-5-(1,1-Difluoro-ethyl)-2-[2-methyl-4-(3-phenyl-pyrrolidin-1-ylmethyl)-phenoxy]-pyridine hydrochloric acid salt,  
(±)-6-[2-Fluoro-4-(3-phenyl-pyrrolidin-1-ylmethyl)-phenoxy]-nicotinamide,  
(±)-6-[2-Ethoxy-4-(3-phenyl-pyrrolidin-1-ylmethyl)-phenoxy]-nicotinamide,  
(±)-6-[2-Chloro-4-(3-phenyl-pyrrolidin-1-ylmethyl)-phenoxy]-nicotinamide,  
6-(3-Phenethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)nicotinamide,  
6-(3-Benzyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)-nicotinamide,  
6-[4-(Phenethylaminomethyl)phenoxy]nicotinamidine,  
{2-[4-(5-Aminomethylpyridin-2-yloxy)phenyl]ethyl}benzylamine,  
5-[4-(Phenethylaminomethyl)phenoxy]pyridine-2-carboxamide,  
2-[4-(2-Benzylaminoethyl)phenoxy]nicotinamide,  
6-[4-(2-Benzylaminoethyl)phenoxy]pyridine-2-carboxamide,  
2-[4-(2-Benzylaminoethyl)phenoxy]isonicotinamide,  
N-Methyl-6-[4-(phenethylaminomethyl)phenoxy]nicotinamidine,  
5-[4-(Phenethylaminomethyl)phenoxy]pyrazine-2-carboxamide,  
5-(4-{[2-(4-Fluorophenyl)ethylamino]methyl}phenoxy)pyridine-2-carboxamide,



X-15876 PCT

## REPLACEMENT CLAIMS

586

- 5-{4-[(3-Methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide  
methanesulfonate,
- 5-{2-Methyl-4-[(3-methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide  
methanesulfonate,
- 5-{2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide  
methanesulfonate,
- 5-(4-{[2-(3-Trifluoromethylphenyl)ethylamino]methyl}phenoxy)pyridine-2-  
carboxamide methanesulfonate,
- 5-{4-[(2-Thiophen-2-ylethylamino)methyl]phenoxy}pyridine-2-carboxamide  
methanesulfonate,
- 5-{2-Methyl-4-[(2-thiophen-2-ylethylamino)methyl]phenoxy}pyridine-2-  
carboxamide methanesulfonate,
- 5-{2-Methoxy-4-[(2-thiophen-2-ylethylamino)methyl]phenoxy}pyridine-2-  
carboxamide methanesulfonate,
- 5-{4-[(2-Cyclopentylethylamino)methyl]phenoxy}pyridine-2-carboxamide  
methanesulfonate,
- 5-{4-[(2-Cyclopentylethylamino)methyl]-2-methylphenoxy}pyridine-2-  
carboxamide methanesulfonate,
- 5-{4-[(2-Cyclopentylethylamino)methyl]-2-methoxyphenoxy}pyridine-2-  
carboxamide methanesulfonate,
- 5-(4-{[(Benzo[b]thiophen-3-ylmethyl)amino]methyl}phenoxy)pyridine-2-  
carboxamide methanesulfonate,
- 5-(4-{[2-(4-Methoxyphenyl)ethylamino]methyl}phenoxy)pyridine-2-  
carboxamide methanesulfonate,
- 5-(4-{[2-(3-Fluorophenyl)ethylamino]methyl}phenoxy)pyridine-2-carboxamide  
methanesulfonate,
- 5-(4-{[2-(2-Fluorophenyl)ethylamino]methyl}phenoxy)pyridine-2-carboxamide  
methanesulfonate,

X-15876 PCT

## REPLACEMENT CLAIMS

587

- 5-{2-Fluoro-4-[(3-methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide methanesulfonate,
- 5-{2-Methyl-4-[(3-methylbutylamino)methyl]phenoxy}pyrazine-2-carboxamide methanesulfonate,
- 5-(2-Fluoro-4-pentylaminomethylphenoxy)pyridine-2-carboxamide,
- 5-{2-Fluoro-4-[(2-thiophen-2-ylethylamino)methyl]phenoxy}pyridine-2-carboxamide,
- 5-{2-Fluoro-4-[(2-pyridin-3-ylethylamino)methyl]phenoxy}pyridine-2-carboxamide,
- 5-{2-Fluoro-4-[(2-*m*-tolylethylamino)methyl]phenoxy}pyridine-2-carboxamide,
- 5-(2-Fluoro-4-{[2-(4-fluorophenyl)ethylamino]methyl}phenoxy)pyridine-2-carboxamide,
- 5-{2-Chloro-4-[(3-methylbutylamino)methyl]phenoxy}pyridine-2-carboxamide,
- 5-(2-Chloro-4-(pentylaminomethyl)phenoxy)pyridine-2-carboxamide,
- 5-{2-Chloro-4-[(2-thiophen-2-ylethylamino)methyl]phenoxy}pyridine-2-carboxamide,
- 5-{2-Chloro-4-[(2-pyridin-3-ylethylamino)methyl]phenoxy}pyridine-2-carboxamide,
- 6-{2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy}nicotinamide,
- 5-(2-Fluoro-4-{[2-(tetrahydropyran-4-yl)ethylamino]methyl}phenoxy)pyridine-2-carboxamide,
- 5-{2-Fluoro-4-[(2-*o*-tolylethylamino)methyl]phenoxy}pyridine-2-carboxamide,
- 5-{4-[(2-Naphthalen-2-ylethylamino)methyl]phenoxy}pyridine-2-carboxamide,
- 5-{4-[(2-Naphthalen-1-ylethylamino)methyl]phenoxy}pyridine-2-carboxamide,
- 5-{4-[(2-Benzo[*b*]thiophen-3-ylethylamino)methyl]phenoxy}pyridine-2-carboxamide,
- 6-(2-Methoxy-4-pentylaminomethylphenoxy)nicotinamide,
- 6-{2-Methoxy-4-[(2-thiophen-2-ylethylamino)methyl]phenoxy}nicotinamide,
- 6-{2-Methoxy-4-[(2-*o*-tolylethylamino)methyl]phenoxy}nicotinamide,

AMENDED SHEET

X-15876 PCT

## REPLACEMENT CLAIMS

588

6-{2-Methoxy-4-[(2-*m*-tolylethylamino)methyl]phenoxy}nicotinamide,  
6-{4-[(3,3-Dimethylbutylamino)methyl]-2-methoxyphenoxy}nicotinamide,  
6-{2-Methoxy-4-[(2-pyridin-3-ylethylamino)methyl]phenoxy}nicotinamide,  
6-(4-Butylaminomethyl-2-methoxyphenoxy)nicotinamide,  
6-(2-Methoxy-4-{[2-(tetrahydropyran-4-yl)ethylamino]methyl}phenoxy)nicotinamide,  
6-{2-Methoxy-4-[(2-morpholin-4-ylethylamino)methyl]phenoxy}nicotinamide,  
6-{4-[(2-Ethylbutylamino)methyl]-2-methoxyphenoxy}nicotinamide,  
6-(4-{[2-(4-Fluorophenyl)ethylamino]methyl}-2-methoxyphenoxy)nicotinamide,  
6-(4-{[2-(2-Fluorophenyl)ethylamino]methyl}-2-methoxyphenoxy)nicotinamide,  
6-(4-Hexylaminomethyl-2-methoxyphenoxy)nicotinamide,  
6-{2-Methoxy-4-[(4-methylpentylamino)methyl]phenoxy}nicotinamide  
methanesulfonate,  
6-{2-Methoxy-4-[(2-*p*-tolylethylamino)methyl]phenoxy}nicotinamide  
methanesulfonate,  
5-(2-Methyl-4-{[2-(tetrahydropyran-4-yl)ethylamino]methyl}phenoxy)pyrazine-  
2-carboxamide,  
5-{4-[(3,3-Dimethylbutylamino)methyl]-2-methylphenoxy}pyrazine-2-  
carboxamide,  
5-{4-[(3-Methylbutylamino)methyl]phenoxy}pyrazine-2-carboxamide,  
5-(4-{[2-(Tetrahydropyran-4-yl)ethylamino]methyl}phenoxy)pyrazine-2-  
carboxamide,  
5-{4-[(3,3-Dimethylbutylamino)methyl]phenoxy}pyrazine-2-carboxamide,  
6-(2-Methoxy-4-{[2-(tetrahydropyran-4-yl)ethylamino]methyl}phenoxy)nicotinamide methanesulfonate,  
6-(4-Hexylaminomethyl-2-methoxyphenoxy)nicotinamide methanesulfonate,  
6-(2-Methoxy-4-pentylaminomethylphenoxy)nicotinamide methanesulfonate,  
6-(4-Butylaminomethyl-2-methoxyphenoxy)nicotinamide methanesulfonate,

AMENDED SHEET

X-15876 PCT

## REPLACEMENT CLAIMS

589

6-{2-Methoxy-4-[(2-pyridin-3-ylethylamino)methyl]phenoxy}nicotinamide  
methanesulfonate,

6-{4-[(2-Ethylbutylamino)methyl]-2-methoxyphenoxy}nicotinamide  
methanesulfonate,

6-{4-[(3,3-Dimethylbutylamino)methyl]-2-methoxyphenoxy}nicotinamide  
methanesulfonate,

6-{2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy}nicotinamide  
methanesulfonate,

6-(2-Phenethyl-2,3,4,5-tetrahydro-1*H*-benzo[*c*]azepin-7-yloxy)nicotinamide,

6-[2-(3-Methylbutyl)-2,3,4,5-tetrahydro-1*H*-benzo[*c*]azepin-7-  
yloxy]nicotinamide,

6-[2-(3-Methylpentyl)-2,3,4,5-tetrahydro-1*H*-benzo[*c*]azepin-7-  
yloxy]nicotinamide,

(±)-6-{4-[2-(2-Hydroxycyclohexylamino)ethyl]phenoxy}nicotinamide,

(±)-(cis)-6-{4-[2-(3-Hydroxycyclohexylamino)ethyl]phenoxy}nicotinamide,

(±)-(trans)-6-{4-[2-(3-Hydroxycyclohexylamino)ethyl]phenoxy}nicotinamide,

(±)-6-{4-[2-((trans)-4-Hydroxycyclohexylamino)ethyl]phenoxy}nicotinamide,

(±)-6-{4-[2-((trans)-2-Hydroxycyclopentylamino)ethyl]phenoxy}nicotinamide,

4-[5-(Phenethylamino-methyl)-pyridin-2-yloxy]-benzamide dihydrochloride 4-{5-  
[(3-Trifluoromethyl-benzylamino)-methyl]-pyridin-2-yloxy}-benzamide 4-{5-[(3-  
Phenyl-propylamino)-methyl]-pyridin-2-yloxy}-benzamide

4-{5-[(4-Fluoro-benzylamino)-methyl]-pyridin-2-yloxy}-benzamide 4-[5-  
(Isobutylamino-methyl)-pyridin-2-yloxy]-benzamide 4-{5-[(2-Thiophen-2-yl-  
ethylamino)-methyl]-pyridin-2-yloxy}-benzamide

4-(5-{[2-(3-Fluoro-phenyl)-ethylamino]-methyl}-pyridin-2-yloxy)-benzamide

4-(5-{[2-(2-Methoxy-phenyl)-ethylamino]-methyl}-pyridin-2-yloxy)-benzamide

4-(5-{[2-(2-Chloro-phenyl)-ethylamino]-methyl}-pyridin-2-yloxy)-benzamide 4-

[5-(3-Phenyl-pyrrolidin-1-ylmethyl)-pyridin-2-yloxy]-benzamide 4-{5-[(3,3-

X-15876 PCT

## REPLACEMENT CLAIMS

590

Dimethyl-butylamino)-methyl]-pyridin-2-yloxy}-benzamide 4-{5-[(3-Methyl-butylamino)-methyl]-pyridin-2-yloxy}-benzamide

4-{3-Chloro-5-[(2-thiophen-2-yl-ethylamino)-methyl]-pyridin-2-yloxy}-benzamide

4-(3-Chloro-5-{[2-(3-chloro-phenyl)-ethylamino]-methyl}-pyridin-2-yloxy)-benzamide.

and pharmaceutically acceptable salts, solvates, enantiomers, and mixtures of diastereomers thereof in the manufacture of a medicament for the treatment of obesity, and related diseases.

AMENDED SHEET